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Part I: 
 Fungi serve as a rich source of prenylated indole alkaloids, which exhibit 
important biological activities including antiproliferative, antibiotic, and 
antihelminthic properties. Their promise as therapeutics, coupled with their diverse 
and complex molecular architectures, have made prenylated indole alkaloids 
popular targets for synthetic chemists in order to probe their activities and develop 
new synthetic methods. Herein, we describe the first total synthesis of aspeverin, a 
unique bridged carbamate-containing prenylated indole alkaloid isolated from 
Aspergillus versicolor. We also describe the synthesis of a closely related congener, 
penicimutamide A, isolated from a mutant strain of Penicillium purpurogenum. 
These molecules belong to a recently described subclass of prenylated indoles 
thought to be degradation products of parent bicyclo[2.2.2]diazaoctane congeners. 
 In this research, we showcase a highly diastereoselective Diels−Alder 
cycloaddition, followed by an electrophilic Rawal arylation – reductive indolization 
to forge the pentacyclic scaffold of these natural products. A novel sequence for 
installation of a geminal dimethyl group was also developed. This involved a 
carefully devised transannular carbamate cyclization followed by a ring-opening / 
 alkylation sequence. Finally, the bridging carbamate common to both of these 
natural products was forged using a hypervalent iodine(III)-mediated oxidative 
cyclization.  
Part II: 
 The KRas protein is a small GTP-binding protein important in cellular 
signaling, involved in growth, differentiation, motility, and survival. Oncogenic 
mutated Ras is involved in approximately 30% of all cancers. Despite the 
identification of this target in human cancers over 30 years ago, no small molecules 
targeting KRas have been successful in the clinic, and this target has long been 
considered “undruggable.” In an effort to develop novel therapeutics, this project 
seeks to complete a total synthesis of an all-D amino acid variant of the KRas 
protein. This synthetic protein enantiomer will be used as a tool for mirror-image 
yeast surface display studies to identify all-D residue peptide ligands for KRas. In 
this section, the synthesis of biotinylated variants of KRas(G12V) consisting of all-L 
and all-D amino acid residues is described. Moreover, we demonstrate that this 
enantiomeric pair of 166-residue proteins bind to nucleotide substrates as well as 
Ras-binding peptides with enantiospecificity. 
 During our studies on the total synthesis of KRas, we further demonstrate 
the utility of isonitrile-mediated activation of C-terminal thiocarboxylic acids for 
peptide ligation. This method is advantageous, in that it does not rely on a cysteine 
disconnection and takes place under mild conditions in polar aprotic organic 
solvents. Beyond a synthesis of KRas, we also demonstrate that isonitrile-mediated 
 ligation and native chemical ligation strategies can be combined and applied toward 
a novel synthesis of HIV-1 protease I66A. 
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Penicimutamide A 
 
 
Motivation for the study of Natural Products Total Synthesis 
 
 Natural products represent an important class of molecules rich in biological 
activities and functions that serve as vital inspiration for drug discovery.1 These 
secondary metabolites derive from plants, fungi, microbes, and higher-order life 
forms and often play critical biological or survival roles for the organisms from 
which they are biosynthesized.2 Prior to the age of modern medicine, plants and 
extracts containing these naturally-derived molecules were widely used for their 
medicinal value, with the earliest accounts of their use dating back to 2600 BC.3 
Today, many natural products are counted among the most valuable and historically 
utilized therapeutics, with broad representation in the categories of antineoplastic 
agents, antibiotics, antivirals, antihelminthics, immunomodulators, CNS-
modulators, and cardiovascular agents, among others. Notable examples of such 
molecules are highlighted in Figure 1.  
Owing to their high density in sp3 hybridized centers and diverse functional 
patterns, natural products often display high target specificity and biological 
functions, and often serve as exceptions to Lipinski’s rule of five governing the 
“druggability” of a given molecule.4 These anticipated properties inspire the 
generation of “natural product-like” molecular libraries in drug discovery; a lofty 
ongoing goal, which is realized to some extent with advances in synthetic strategies 
such as diversity-oriented synthesis (DOS).5 Advances in biological strategies such 
as combinatorial biosynthesis, metagenomic analysis, and synthetic biology have 
1
also aided in the discovery of new “unnatural products” or previously unattainable 
natural products.6,7,8 According to a 2016 analysis of all small-molecule drugs 
approved by the United States FDA between 1981-2014, 65% of these 1211 
chemical entities are either natural products themselves, derived synthetically from 
natural products, or were inspired by natural product pharmacophores.9  
 
Figure 1: Representative natural products with important medicinal value 
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 Modern organic synthesis has endowed chemists with the tools to achieve 
total syntheses of such important molecules—many densely functionalized, 
challenging targets—starting from simpler stock chemicals. Complex target-
oriented studies, although narrowly focused, open the door for the exploration of the 
biology of simplified pharmacophores or diversified analogs with preferable 
metabolic and toxicological profiles. This process, previously termed by our 
laboratory as diverted total synthesis (DTS), allows for systematic structure-activity-
relationship (SAR) evaluation of complex natural products.10 In this way, accessible 
synthetic core structures can be edited, simplified and evaluated at will. The logic of 
DTS empowers the chemist with full control of every atom within a target of 
interest – an ultimate goal in drug discovery that cannot be fully realized through 
reliance on biosynthetic machinery or semisynthetic approaches (Figure 2). Shown 
in Figure 3 is a notable example benefited by this logic which was devised in our 
laboratory. Epothilone B (EpoB, 1) is a highly cytotoxic polyketide macrocyclic 
natural product, which interferes with tubulin similar to Taxol, and exhibits potent 
cytotoxicity to multidrug resistant (MDR) cell lines.11 Our laboratory completed the 
total syntheses of epothilones A and B in 1996 and 1997, in which EpoB was found 
to be extremely toxic at low doses in mouse models, precluding its utility as a drug 
candidate.12,13,14 However, the development of a de novo synthesis from simple 
building blocks enabled the identification of a reactive epoxide moiety responsible 
for this toxicity. Synthetic editing of this functionality to a simple olefin, or to the 
corresponding trifluoromethyl olefin (3) significantly reduces this broad toxicity, 
while maintaining its potent antitumor effects.15,16 
3
 Figure 2: Concept of diverted total synthesis (DTS) 
 
 
Figure 3: Application of DTS logic to the discovery of fludelone (2) 
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quantities of natural or non-natural analogous compounds for biological study. Due 
to their complexity, natural products present a formidable synthetic challenge, 
which challenges the capabilities of modern synthetic organic chemistry.17 
Historically, the challenges associated with synthesizing such molecules have 
served as inspiration for the development of new, generally-applicable methods in 
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steroid and alkaloid chemistry inspired our current understanding of synthesis logic 
for generating carbon-carbon bonds and our knowledge of heterocyclic chemistry, 
respectively. For example, research on the targeted synthesis of β-lactam antibiotics 
inspired the development of ubiquitous amide bond synthesis methods centered on 
carbodiimide-based reagents – methods which have broader impact beyond these 
individual targets – especially in the context of peptide and protein chemical 
synthesis.18 In the modern age, natural products continue to inspire the development 
of stereo- and enantioselective synthetic methods, as well as the discovery of new 
catalytic methods. 
 
Aspeverin (3) : A Prenylated Indole with Unique Synthetic Challenges 
 Aspeverin (3, Figure 4) is an indole alkaloid isolated by Ji and co-workers 
from an endophytic species of Aspergillus versicolor found in a Codium fragile 
species of marine green algae in China.19 After 30 days of fermentation (15L 
fermentation broth), extraction afforded 29.6 g of ethyl acetate-soluble organic 
material, from which 8.6 mg (0.029% yield) of pure 3 was ultimately isolated. In 
particular, the molecule contains distinctive functionality among alkaloids isolated 
from similar fungal species. The bridging carbamate, linking the indole C-3 carbon 
(position 14 within the natural product numbering) with an angular amine is 
particularly unique to this natural product; an oxidative linkage which has not been 
previously observed. Additionally, the α-cyanoamine functionality is a rarely 
observed moiety in alkaloid natural products. 
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The isolation chemists reported preliminary biological data for this 
molecule, which includes antibiotic activity as well as inhibitory properties of 
phytoplankton and marine zooplankton growth (Table 1). Aspeverin (3) displays 
moderate inhibitory activity against the plankton species A. salina and H. akashiwo. 
Of significance, Aspeverin (3) also displayed antibiotic activity against Gram-
negative species P. mirabilis, E. cloacae, as well as Gram-positive B. cereus.  
 
Figure 4: Structure of aspeverin 3. 
 
Table 1: Preliminary inhibition of phyto- and zooplankton growth and antibiotic 
activity displayed by 3 (adapted from Ref. 19) 
 
The structurally related natural products pertinent to the subject of this thesis 
are fungal-derived prenylated indole dipeptide alkaloids. Aspergillus and 
Penicillium fungi, in particular, serve as a rich source of prenylated indole 
alkaloids.20,21,22 Biosynthetically, these dipeptidyl alkaloids are derived from L-
tryptophan and one or more amino acids (commonly cyclic amino acids such as 
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proline or pipecolic acid, although not limited to these) by means of non-ribosomal 
peptide synthetases (NRPS’s). Dipeptide indole alkaloids biosynthesized through 
this process generally contain a characteristic 2,5-diketopiperazine (DKP) ring 
formed from cyclization of a free amine onto an aminoacyl thioester intermediate 
(Scheme 1).23 Due to the modular reactivity of the indole heterocycle within 
tryptophan, relatively simple common dipeptide intermediates are rapidly 
diversified through oxidation and prenylation with variable stereo- and 
regiochemistries, forging progeny with complex and distinct molecular 
architectures. To highlight one such example, Scheme 1 outlines the biosynthetic 
pathway leading to brevianamides A and B (4 and 5).24 Brevianamide F (6) serves 
as a precursor to many natural products, bearing the signature DKP ring 
(highlighted in blue) formed between L-Trp and L-Pro. Prenylation can occur under 
a variety of modes with one or multiple units of dimethylallyl pyrophosphate 
(DMAPP); one example being the conversion of 6 to deoxybrevianamide E (7) by 
means of a reverse prenyl transferase. Oxidation of the indole ring system leads to 
hydroxyindole 8, which subsequently can undergo nucleophilic addition to afford 
brevianamide E (9), or alternatively can undergo rearrangement to afford a spiro-
indoxyl ring. Upon further oxidation, 10 is poised to undergo an intramolecular 
Diels-Alder reaction (IMDA), forging the diastereomeric bicyclo[2.2.2]diazaoctane-
containing natural products brevianamide A and B (4 and 5, ring system highlighted 
in red). Deoxybrevianamide E (7) itself is also capable of undergoing an oxidative 
Diels-Alder reaction to generate a bicyclo[2.2.2]diazaoctane skeleton without prior 
indole rearrangement, giving rise to non-rearranged indolic structures such as the 
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malbranchiamide natural product class (not shown).25 Not only rich in structural 
diversity, these metabolites exhibit a spectrum of biological activity, including 
potent antiproliferative, antibiotic, and antihelminthic activity. Such structural 
complexity and biological activities have historically prompted a great deal of 
interest from synthetic chemists in this area of natural products, including several 
successful efforts from our own lab.26-29 In addition to brevianamides A and B, 
Figure 5A highlights several other example classes of bicyclo[2.2.2]diazaoctanes 
found in Nature.  
 
Scheme 1: Representative biosynthesis of diverse prenylated indole dipeptide 
alkaloids of the brevianamide family, derived from L-Trp, L-Pro, and DMAPP. 
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 Figure 5: (A) Bicyclo[2.2.2]diazaoctane-containing prenylated indole dipeptide 
natural products. (B) Structurally related prenylated indoles lacking the 
bicyclo[2.2.2]diazaoctane ring system. 
 
In recent years, a number of structurally similar fungal natural products 
lacking this bicyclo[2.2.2]diazaoctane ring system have been identified (Figure 5B). 
These molecules are structurally comprised of the same biosynthetic precursors, but 
appear to be degradation products of parent bicyclo[2.2.2]diazaoctane congeners. 
Structurally, aspeverin (3) belongs within this category of natural products, although 
its speculative biosynthesis is not confirmed. Likely components that can be 
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structurally recognized include Trp, Pro, and one unit of DMAPP. The α-
cyanoamine moiety is unique, and may arise from a partial reduction at the 
highlighted carbon atom (C-11, as outlined in Figure 4); a position which is 
commonly oxidized as the lactam or reduced to a methylene in similar congeners. In 
fact, during the course of writing this thesis (July 2016), Li and co-workers reported 
the isolation of penicimutamides A-C (19-21) from a mutated strain of Penicillium 
purpurogenum, which differ from 3 only at C-11 with varying oxidation states.30 
These researchers suggest a similar biosynthetic pathway as postulated here, and 
also suggest that the absolute stereochemistry of aspeverin was likely assigned 
incorrectly. Such examples of other hypothesized related molecules are highlighted, 
and include citrinadin B (16), citrinalin B (17), and PF1270A (18). In 2005, 
Mugishima and co-workers proposed that citrinadin B (16) may arise from lactam 
ring-opening of bicyclo[2.2.2]diazaoctane-containing hypothetical precursor 23, 
with loss of a carbonyl in the form of carbon dioxide to obtain the observed ring-
opened scaffold observed in the natural product (Figure 6).31 In 2014, a largely 
collaborative isolation, total synthesis, and biosynthesis study similarly conjectured 
the existence of citrinalin C (25) as a hypothetical bicyclo[2.2.2]diazaoctane-
containing precursor to known metabolites citrinalins A and B (24 and 17).32 This 
hypothetical precursor was ultimately isolated as a minor metabolite from P. 
citrinum F53, lending credence for their assumption, as well as indirect support for 
the existence of bicyclo[2.2.2]diazaoctane-containing precursors to molecules such 
as 3 and 16-22. 
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 Figure 6: Biosynthetic hypotheses for arisal of bicyclo[2.2.2]diazaoctane-deficient 
natural products. 
 
Despite myriad total synthesis studies revolved around prenylated indole 
alkaloids, the highlighted unique ring-opened natural products present novel 
challenges for stereoselective synthesis strategies. Arguably, to approach the 
synthesis of these molecules from higher-order bicyclo[2.2.2]diazaoctane precursors 
would be quite difficult, and previously described methods for the synthesis of 
DKP-containing indole alkaloids may not be readily applicable to the synthesis of 
this class of molecules. A number of groups, including efforts by the Wood, Martin, 
Sarpong, and Sorensen groups, either achieved or aimed at syntheses of citrinadin A 
(not shown) and citrinadin B (16).33-37 
Due to the structural similarities of their targets and differences in synthetic 
challenges associated with the target of this study (3), it is instructive to describe the 
key elements of Sarpong’s unified strategy toward the synthesis of citrinalin family 
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members as well as their connection with bicyclo[2.2.2]diazaoctane-containing 
congeners.38 Highlighted in Scheme 2 is their general strategy, which begins with a 
highly diastereoselective Diels-Alder reaction between indolizidine 26 and diene 27 
to afford a single diastereomer 28. Conversion of the angular cyano group to the 
corresponding amide, followed by oxidative Hoffmann rearrangement mediated by 
[Bis(trifluoroacetoxy)iodo]benzene (PIFA) affords carbamate 29 as a key 
intermediate. This intermediate was further elaborated to obtain 17-
hydroxycitrinalin B (30), bearing an angular nitro group and rearranged spiro-
oxindole ring. Alternatively, 29 could be elaborated to phenyl carbamate 31, which 
underwent base-catalyzed enolization and isocyanate-capture, ultimately yielding 
the bicyclo[2.2.2]diazaoctane scaffold related to the natural products (+)-stephacidin 
A (ent-12) and (+)-notoamide I (not shown). 
 
Scheme 2: Sarpong’s unified approach toward prenylated indole alkaloids 
 
 A close comparative analysis of various related prenylated indole dipeptide 
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highlighted in Scheme 2 and the subject of this study (3). Analysis of relative 
stereochemical relationships in Figure 7 reveals the distinguishing syn relationship 
at the C:D ring junction within the targets found in Sarpong’s work, as well as the 
anti relationship between the distal angular hydrogen atoms (17 as one example). 
Aspeverin (3) as well as penicimutamides A-C (19-21), on the other hand bear an 
anti- C:D ring junction and a syn relationship between the highlighted angular 
hydrogen atoms. A similar relationship is echoed in related natural products such as 
PF1270A (18).39 This anti relationship at the C:D ring junction is quite rare within 
the bicyclo[2.2.2]diazaoctane natural products, only observed in the case of the 
brevianamides (4, 5), versicolamide B (13), and chrysogenamide A (not shown). 
The majority of bicyclo[2.2.2]diazaoctane natural products instead bear a cis ring 
junction, as highlighted for the case of VM55599 (15). These differences, especially 
with respect to the stereochemistry of the C:D ring juncture are critical to the 
approaches necessary for their total synthesis. For example, the Diels-Alder reaction 
between 26 and 27 incorporates the distinctive geminal dimethyl group and gives 
rise to the cis C:D ring juncture in a straightforward manner. Moreover, the trans-
relationship between angular hydrogen atoms sets the stage to attain molecules such 
as citrinalin B (17) and stephacidin A (12). This direct approach would be difficult 
to apply to members with a trans C:D ring juncture such as aspeverin (3) or 
PF1270A (18). 
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 Figure 7: Comparative stereochemical analysis of structurally similar indole 
alkaloids 
 
Proposed Synthetic Access to Aspeverin (3) 
 Retrosynthetically, our approach toward the synthesis of aspeverin relied on 
a late-stage construction of the unique cyclic carbamate linking the indole C3-
carbon to the angular nitrogen atom (Figure 8). Although one could envision the 
synthesis of this cyclic carbamate via the linking of a C3-hydroxyindole with a free 
angular amine using a phosgene-like reagent, such a disconnection could be 
complicated by a lack of stereocontrol in the indole oxidation, possibly giving rise 
to diastereomers. Additionally, hydroxyindoles are known to be susceptible to 
rearrangement, either to form spiroindoxyl or spiro-oxindole products depending on 
the electronic nature of the adjoined aryl ring. Therefore, our disconnection relied 
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directly cyclize onto the indole core structure, negating any potential issues in 
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in an umpolung fashion. This is in contrast to the generally understood nucleophilic 
character of indoles. This direct intramolecular cyclization of a carbamate onto the 
C3-position of indole simplifies the target and is supported by literature precedent 
with regard to the electrophilic reactivity of indoles. However, the exact 
transformation is unknown, and our proposal served as motivation to develop this 
new bond-forming reaction. 
 Further disconnection of 3 by partial lactam reduction and stereoselective 
cyanation leads back to compound 34. The proposed cyanation of an intermediate 
hemiaminal derived from reduction of the parent lactam was predicted to proceed 
with a high level of stereoselectivity arising from trans-diaxial attack of cyanide 
onto the iminium intermediate.40 Installation of the angular carbamate was 
hypothesized as arising through a stereospecific Curtius-type reaction of the 
corresponding acyl azide, or alternatively through Hoffmann reaction of the 
corresponding amide at that position. This simplification brought us to core scaffold 
35. Taking advantage of the angular electron-withdrawing carboxylic acid 
derivative, 35 was ultimately traced back to 36, arising from a Diels-Alder reaction 
between 37 and 38. This disconnection was advantageous because of the facile entry 
it would allow toward the core CDE ring system of aspeverin (3). However 
simplifying, a Diels-Alder approach would also create challenges in the synthetic 
route. Most obviously, the highlighted stereocenter of 36 (highlighted in blue) 
would require inversion from a cis ring junction to the desired trans relationship 
(highlighted in red for 35). A geminal dimethyl group would require later 
installation in order to accommodate this stereochemical inversion. Further 
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discussion of our plans for these necessary transformations will follow later in this 
chapter.  
 
Figure 8: Retrosynthetic disconnections for aspeverin (3) 
 
 
 
Umpolung Indole Reactivity: Precedent for the Oxidative Carbamate 
Cyclization 
 
Explicit examples of umpolung indole reactivity are highlighted in Figures 9 
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the hypervalent iodine reagent. More complex instances of this reactivity have been 
N
N
CN
H H
O NH
O
aspeverin (3)
oxidative cyclization
reductive
cyanation
N
N
H H
O NH
OR
O
34
N
H H
O
35
Curtius
rearrangement
Indolization
R O
epimerization
R R
N
H H
O
36
R3SiO
OHO
ORO
Diels-Alder
N
O
RO2C
RO
+
3738
C D E
16
demonstrated since this initial discovery. Treatment of indole 42 with PhI(OAc)2 
initiates intramolecular cyclization of a tethered dihydrooxazole to ultimately give 
rise to a pair of diastereomeric bis-annulation products 44 and 45.42 
Substoichiometric amounts of oxidant in a non-nucleophilic solvent can produce 
indole dimerization products in a variety of modes, whereby half of the indolic 
material undergoes oxidation, and a second equivalent of indole acts as an 
intermolecular nucleophile. One such example is the dimerization of 1,2,3,4-
tetrahydrocarbazole (46) initiated by PhI(OAc)2 (0.5 equiv.) to produce indolenine 
dimer 48 as an equal mixture of diastereomers.43  
Although mechanistically dissimilar from the previously described 
examples, Feldman and co-workers have extensively investigated the vinylogous 
Pummerer-like reactivity of 2-thiophenylindoles to incorporate nucleophiles at the 
indolic 3-position.44 This process is initiated either through traditional Pummerer-
rearrangement conditions (i.e. activation of a sulfoxide with TFAA or Tf2O) or more 
efficiently through direct engagement of the sulfide with hypervalent iodine(III) 
reagents. Compound 49 reacts with Stang’s reagent, PhI(CN)OTf, to promote 
intermolecular cyclization of a tethered tert-butyloxycarbamate, yielding 51 in 74% 
yield.44,45  
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 Figure 9: Hypervalent-iodine mediated oxidation of indoles to promote nucleophilic 
capture at the C3 position. 
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fragmentation, to yield 3-functionalized indolenines.46 This is observed in the C-3 
acetoxylation of yohimbine-derivative 52 to yield 54. Using alternative conditions, 
N-hydroxyindole 55 can be activated by para-toluenesulfonyl chloride to enable 
nucleophilic attack by enamine 56, affording 57.47 Nucleophilic capture can also be 
achieved through the intermediacy of 3-chloroindolenines, such as the conversion of 
58 to 60.48 Büchi and co-workers reported an interesting oxidative lactonization of 
N-phthalimido-L-tryptophan (61) utilizing DMSO-based oxidants during studies 
culminating in a total synthesis of tryptoquivaline G (not shown).49 Similar 
oxidative spirolactonizations have also been effected using excess N-
bromosuccinimide, with concurrent halogenation of the indole C5 position (not 
shown).50  
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 Figure 10: Additional methods to generate electrophilic indole intermediates for C-
3 functionalization 
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the C:D ring system of the natural product. Depicted in Scheme 3 are two 
hypothesized synthetic routes of how 36, arising from a Diels-Alder cycloaddition 
could be converted into core structure 64 with the correct stereochemical 
configuration. In one possible pathway (Path A), the isomerization of enol ethers 
within a cis-decalin framework could be exploited. Based on previous literature and 
studies in our own laboratory, the silyl enol ether of 36 may undergo isomerization 
to produce a thermodynamically-favored enol ether regioisomer.51,52,53 This would 
set the stage for regioselective oxidation of the enol ether to produce enone 63, with 
selective eradication of the stereocenter at position-4 (highlighted in red). 
Subsequent stereoselective reduction of the resulting enone and further 
functionalization may lead to an intermediate such as 64. 
 Alternatively, it was hypothesized that the correct stereochemical 
configuration could be attained through epimerization of the highlighted 
stereocenter via an enol/enolate intermediate (Path B). This could be achieved by 
initial installation of an indole within the tricyclic system, producing linear 
pentacycle 65. Subsequent benzylic oxidation, using one of several known 
regioselective methods, would afford ketone 66. This ketone could then be utilized 
for simple acid or base-mediated epimerization to produce 67. The ketone would 
also serve as a functional handle for synthesis of the necessary geminal dimethyl 
group within 64. 
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 Scheme 3: Alternative proposed sequences for conversion of 36 to key intermediate 
64 
 
 One can qualitatively rationalize the comparative thermodynamic stability of 
olefins within fused ring systems by understanding their distortional impact on 
dihedral angles about the C-C bond at the ring junction. Introduction of an olefin 
within one ring of the decalin system affects the dihedral angles of the fused rings, 
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increasing the dihedral angle for the A-ring, has an equal and opposite effect on the 
dihedral angle for the B-ring, effectively flattening the B-ring.  
In the case of a cis-ring junction, placement of unsaturation between the C2-
C3 bond of ring-A (70) increases the dihedral angles for both A- and B-rings about 
the central bond, thereby pushing the two rings in closer proximity. This increases 
the steric strain between the C4 methylene with the axial substituents at C6 and C8. 
Alternatively, if unsaturation is placed between the C3- C4 bond (71), this creates 
two stabilizing interactions. First, the olefin causes a decrease in the dihedral angles 
for both ring-A and ring-B, thereby decreasing the concavity of the system (and 
decreasing steric interactions between axial substituents). Second, elimination of the 
axial hydrogen at C4 further reduces the steric interaction with C6 and C8.  
The explanation for difference in olefin stability in the case of a trans-
decalin system with unsaturation is more subtle than the cis-decalin case. In this 
instance, the difference in olefin stability between C2-C3 versus C3-C4 is almost 
negligible if the substituent at C9 is hydrogen. However, if there is a larger 
substituent at C9, then unsaturation between C3-C4 (74) will distort the junction 
dihedral angles to shorten the distance between the C9 substituent and axial 
substituents at C5 and C7, thereby increasing A1,3 steric interactions. Therefore, 
unsaturation is thermodynamically favored between C2-C3 instead of C3-C4; 
contrary to the observed favorability in the cis-decalin case. 
23
 Figure 11: (A) Effect of dihedral angle distortion for cis and trans-fused decalin 
ring systems (B) Effect of unsaturation within cis fused ring systems (C) Effect of 
unsaturation within trans fused ring systems. 
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intermediate between C2-C3 for 81 (in the case of trans). The reactivity of these 
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simple decalin systems is mirrored by the more complex case of the Fischer indole 
synthesis between phenylhydrazine with 5β-cholestan-3-one versus 5α-cholestan-3-
one, which also display high regioselectivity based on the ring fusion 
stereochemistry (not shown).57 It should be noted that this reactivity trend, although 
reliable especially in the case of rigid steroidal structures, is not always general for 
less rigid decalone structures.54,58 A notable exception to this selectivity is the 
Fischer indolization of 82 as described by Stork en route toward aspidospermine, 
with both the cis and trans ring configurations giving rise to the same observed 
regiochemistry (83).59 
 
 
Figure 12: (A) Christoffers’ study of regiodivergent Fischer indole syntheses in cis- 
versus trans-fused ring systems. (B) Fischer indolization en route toward 
aspidospermine. 
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  Our laboratory has exploited this difference in olefin stability in the context 
of total synthesis and in the synthesis of complex enone systems, which would be 
arguably difficult to attain through other means. During the course of studies on the 
total synthesis of peribysin E (not shown), an interesting olefin isomerization during 
the key Diels-Alder reaction step was disovered.51,52 The Diels-Alder reaction 
between silyloxy diene 84 and (S)-Carvone (85) followed by treatment with silica 
gel afforded thermodynamically-favored enol ether 86 in an 11:1 isomerized:non-
isomerized product ratio in 70% overall yield. Subsequent Saegusa oxidation with 
stoichiometric Pd(OAc)2 afforded enone 87. The realization of this reaction 
sequence has far-reaching synthetic value, as 87 appears to be the product of a 
classical Robinson annulation. However, it is noteworthy that the stereochemical 
relationship between the angular methyl and the distal propenyl group in 87 is the 
opposite configuration to be expected from a Robinson annulation approach. 
Conversely, the hypothetical Robinson annulation between an enone of type 89 with 
methyl vinyl ketone (88) would be 90, with an anti stereochemical configuration as 
highlighted, arising from the initially favored axial attack during the Michael 
Addition step of the annulation.60,61 Therefore, we have termed enone derivatives of 
this general sequence to be “iso-Robinson annulation” products; this overall 
approach is complementary to that of the Robinson annulation. 
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 Figure 13: Diels-Alder/Isomerization/Oxidation sequence provides controlled 
access to stereoisomeric products from that predicted by a classical Robinson 
annulation approach. 
 
Conclusion: 
This chapter seeks to explain our motivation for the study of natural products total 
synthesis in general, and our specific motivation for the study of aspeverin (3). This 
chapter has also served as an introduction to structurally related natural products and 
the synthetic challenges these molecules pose, as well as the unique synthetic 
challenges associated with achieving a total synthesis of aspeverin (3). Furthermore, 
this chapter highlights the literature precedent for the challenging synthetic steps 
proposed for the synthesis of this target. The following chapter will serve to outline 
how we ultimately achieved a total synthesis of aspeverin by using our proposed 
strategies. 
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Chapter 2: Total Synthesis of Aspeverin and Penicimutamide A 
 
Part of this chapter is adapted with permission from: Levinson, A. M. Org. Lett. 
2014, 16, 4904-4907. Copyright 2014 American Chemical Society. 
 
 The previous chapter serves as an introduction to explain our motive and 
strategies for accessing aspeverin (1, Figure 1) through chemical synthesis. Herein, 
we describe how retrosynthetic disconnections were realized to achieve a total 
synthesis of aspeverin 1. Key to our synthesis is a diastereoselective Diels−Alder 
cycloaddition to set two of three stereocenters with proper relative configuration. 
The necessary dienophile could be accessed in two steps from known indolizidine 
10 (Scheme 1).1 Starting with N-(tert-butyloxycarbonyl)-2-pyrrolidinone 5, 
reduction with diisobutylaluminum hydride yielded a hemiaminal, which underwent 
allylation with allyltrimethylsilane to produce a mixture of 6 and 7 in 88% 
combined overall yield. Both of these products react productively in the subsequent 
steps. Acid deprotection of the Boc group, followed by acylation with acryloyl 
chloride generates 8 in 74% overall yield. The resultant diene efficiently underwent 
olefin metathesis with Grubbs’ second generation catalyst (9) at room temperature 
to afford known indolizidine 10. Iodination of this compound under modified 
conditions reported by Johnson and co-workers afforded 11.2 This iodide was 
subjected to Pd-catalyzed carbonylation to yield 12. As anticipated, 12 underwent a 
Diels−Alder reaction with silyloxydiene 13 using ZnCl2 as a Lewis acid, affording 
14 in 91% yield. Facial selectivity here is guided by the distal stereocenter within 
12, giving rise to a single diastereomer as anticipated, with correct stereochemistry 
at positions 6 and 12 (according to the natural product numbering described in 
33
Figure 1).3 Notably, the stereochemistry at position 4 is incorrect, but was resolved 
in a later sequence. 
 
Figure 1: Structures of carbamate-containing indole alkaloids aspeverin (1) and 
penicimutamides A-C (2-4) 
 
 
Scheme 1: Synthesis of the C:D:E ring system of aspeverin via a diastereoselective 
Diels−Alder reaction between 12 and 13. 
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amido ester, which could foreseeably undergo undesired decarboxylation upon 
conversion to the carboxylic acid. Scheme 2 shows our model to install the angular 
carbamate. Fortunately, even without optimization, no apparent decarboxylation 
was observed upon saponification of 15 at room temperature. This crude acid was 
converted to acyl azide 16 in 54% yield upon treatment with diphenylphosphoryl 
azide (DPPA).4 Remarkably, this intermediate was stable likely due to steric 
hindrance, and could be conveniently isolated and characterized following 
purification by silica gel chromatography. Thermolysis at 85 oC fully converted 16 
to the corresponding isocyanate, at which point para-methoxybenzyl alcohol was 
added to generate carbamate 17 in 86% yield. Installation of the carbamate was 
ultimately planned to take place later in the synthesis, although these preliminary 
experiments established the feasibility of the desired transformation. 
 
Scheme 2: Successful Curtius Rearrangement sequence starting from 15. 
 Moving forward, we sought to access the correct stereochemical 
configuration at position 4. In one strategy, we were able to isomerize enol ether 14 
using a method previously reported by our lab (Scheme 3).5 Prolonged heating of 
the compound in the presence of silica gel, with reaction monitoring by 1H NMR, 
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furnished desired olefin regioisomer 18 in 67% isolated yield with a favorable 10:1 
selectivity (shown isomer). Subsequent phenylselenation followed by elimination of 
the corresponding in situ generated selenoxide afforded enone 19 in 51% overall 
yield. Notably, this compound contains the opposite stereochemical configuration 
one would expect to arise from a Robinson annulation strategy. Preliminary 
attempts to reduce this “iso-Robinson annulation” product via hydrogenation using 
various solvents generally resulted in low diastereoselectivity. Moreover, initial 
attempts at dissolving metal reduction or γ-enolate alkylation of this enone provided 
complex mixtures. Although the conditions attempted to functionalize or reduce this 
enone were not exhaustive, we explored an alternatively described synthetic route 
(Scheme 4) and diverted attention upon promising initial success. We therefore 
focused our efforts toward the natural product through this alternative sequence. In 
this route, we hoped to install the indole ring prior to epimerization of the C:D ring 
junction. Additionally, we would use the inherent reactivity of the indole 
heterocycle to functionalize benzylic position 3. 
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Scheme 3: Synthesis of enone 19, and X-ray structure confirming relative 
stereochemistry 
 
 
Scheme 4: An alternative synthetic route to 22. 
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indolization of ketone 17 again afforded a single indole product, with isolation of 
only the undesired regioisomer 25, albeit in low yield. These results are unsurprising 
in retrospect, given the favored regiochemistry of Fischer indolization within cis-
fused decalin systems as discussed in the previous chapter.  
 
Scheme 5: Fischer indolization of 15 and 17 with incorrect regioselectivity. 
 
Fortunately, we found that regioselective installation of the desired indole 
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reduced N-hydroxyindole derivative. Ultimately, it was found that 27 could be 
exclusively converted to the N-hydroxyindole either upon treatment with SnCl2 or 
upon reduction by H2 and Pd/C in the presence of Pd(PPh3)4 as described by Belley 
and co-workers.8,9 The N-hydroxyindole itself was not isolated; rather it was directly 
alkylated upon treatment with NaH and benzyl bromide. The latter described 
hydrogenation method was found to be higher yielding, without generation of tin 
byproducts, and afforded N-benzyloxyindole 28 in 94% overall yield. According to 
Belley and co-workers, Pd(PPh3)4 serves to poison the hydrogenation catalyst, such 
that cyclization of the nitroso intermediate is faster than further reduction. Notably, 
this N-benzyloxyindole was carried forward with the thought that the higher 
oxidation state could actually simplify later steps, wherein the angular carbamate 
would directly cyclize onto the indole core in a fashion similar to that described by 
Somei and co-workers for N-hydroxyindoles.10 
 
Scheme 6: Regioselective electrophilic arylation using NPIF (26) and reductive 
cyclization to N-benzyloxyindole 28. 
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benzyloxyindole 28 underwent highly efficient α-acetoxylation upon treatment with 
lead (IV) acetate in acetic acid according to the procedure of Kametani and co-
worker (Scheme 7).14 The resultant crude acetate was subjected to 
transesterification with K2CO3 in MeOH to efficiently yield alcohol 29 in 73% 
overall yield as a single, unassigned diastereomer. Further oxidation upon treatment 
with excess MnO2 afforded the desired ketone in 85% yield. As anticipated, 
epimerization of the α-stereocenter was accomplished under basic conditions. Brief 
exposure to K2CO3 in methanol yielded a 1:1 diastereomeric ratio of separable 
epimers, with isolation of 32 in 38% yield. Fortunately, enolization of 31 with 
KHMDS at low temperature and quenching at −70 oC with aqueous NH4Cl afforded 
32 in a satisfactory 9.5:1 dr and 80% isolated yield. 
 
 
Scheme 7: Benzylic oxidation and successful epimerization to yield 32 
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scaffold. We turned our attention toward methods to convert: 1) the ketone 
functionality into the requisite geminal dimethyl group, and 2) the angular ester into 
the requisite carbamate via Curtius rearrangement. Due to the potential of 
epimerization at the α-stereocenter under basic conditions, we opted to functionalize 
the ketone prior to ester saponification. We found that this ketone could be 
conveniently functionalized as an olefin upon treatment with the Tebbe reagent (33) 
to afford methylidene 34 (Scheme 8).15 Subsequent ester hydrolysis afforded the 
desired acid, which was subjected Curtius rearrangement conditions. Formation of 
the acyl azide with diphenylphosphoryl azide, followed by thermolysis in the 
presence of 2-trimethylsilylethanol afforded the desired carbamate 35. At this point, 
we were posed with two main challenges to tackle: 1) cyclization of the formed 
carbamate onto the C-3 carbon of the indole ring, and 2) conversion of the exocyclic 
olefin to a geminal dimethyl group. Notably, despite literature precedent for 
strategies to accomplish the latter goal, this still remained a non-obvious task.16,17 
Perhaps somewhat naïvely, it was envisioned that acid treatment of 35 could render 
the indole core susceptible toward nucleophilic attack. In this way, the carbamate 
may cyclize onto the indole ring with loss of benzyl alcohol to produce 37. 
Alternatively, protonation of the exocyclic olefin would generate a resonance-
stabilized tertiary carbocation 38, with two potential electrophilic sites (highlighted 
with asterisks within intermediate 38). Although the anticipated transformation did 
not occur, it was found that upon exposure of this compound to a slight excess of 
trifluoroacetic acid, the carbamate readily adds across the olefin, cleanly affording 
cyclic carbamate 40 in 80% isolated yield.18 The structure of this molecule was 
41
further confirmed with a preliminary single molecule X-ray crystal structure 
(Figure 2). It is noteworthy that this molecule is isomeric to the bridging carbamate 
found within the natural product. This further corroborates the projected 
nucleophilic capacity of the carbamate functionality and the possibility to generate 
such constrained, yet stable molecular architectures. 
 
 
Scheme 8: Ketone olefination and Curtius rearrangement 
 
 
Scheme 9: Acid-mediated carbamate cyclization to generate 40 
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 Figure 2: ORTEP rendering of the X-ray crystal structure for 40 
 
 Fortuitously, identification of structure 40 inspired a solution to the synthetic 
challenge of installing a geminal dimethyl group at position 3. With a single methyl 
group installed and a leaving group in place (i.e. benzylic carbamate), it was 
hypothesized that activation of cyclic carbamate 40 with a Lewis acid may serve to 
once again generate an intermediary stabilized tertiary carbocation. Moreover, if the 
carbocation was formed in the presence of a methyl nucleophile source, the desired 
geminal dimethyl group could be installed. This strategy was deemed successful, 
with trimethylaluminum filling both of these criteria. Indeed, upon exposure of 40 to 
excess Me3Al, the desired geminal dimethyl group was formed and primary amine 
42 was isolated (Scheme 10). This reaction is presumed to occur via the resonance-
stabilized carbocation intermediate 40. Although this compound could be purified 
for characterization, it was carried forward crude in a second step involving 
ORTEP rendering of 40
(enantiomeric to chemical structure depicted)
N
O
HH
NH
N
O
O
BnO
40
N
HH
N
O NH
O
O
O
40
43
treatment with di-tert-butyl dicarbonate (Boc2O), which generated stable isocyanate 
43 rather than the expected tert-butyloxycarbamate in 34% yield over two steps. Di-
tert-butyl dicarbonate has been previously reported as a reagent for the synthesis of 
isocyanates, especially from aromatic and hindered amine substrates.19 Nonetheless, 
heating this isocyanate 43 in methanol generated methyl carbamate 44. Moreover, 
although methanolysis is relatively fast (within approximately 1 hour), it was noted 
that an inseparable side-product formed under these reaction conditions 
corresponding to the reduced indolic form. Prolonged heating (ca. 13 hours) fully 
converted 43 to free indole 44 with liberation of benzaldehyde, based on 1H NMR 
analysis of the crude reaction mixture. This process is mechanistically unclear, but 
literature precedent suggests that similar N-benzyloxy derivatives undergo 
disproportionation either via heterolytic N-O bond cleavage or retro-ene type 
mechanisms (Figure 3).20,21,22 Similarly, Wu and co-workers demonstrated that 
pyridine N-oxide (53) can displace benzylic halides to produce intermediates of type 
54, which undergo disproportionation via a mechanism similar to the Kornblum 
oxidation.23,24 
44
 Scheme 10: Installation of a geminal dimethyl group and synthesis of 44. 
 
Figure 3: Literature precedent for observed disproportionation of 43 upon thermal 
methanolysis (A) disproportionation of N-benzyloxypyridone 45 (B) retro-ene 
reaction of N-benzyloxyenamine 49 (C) pyridine N-oxide oxidation of benzylic 
halides 
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With a functionalized scaffold of aspeverin (except for the α-cyanoamine) in 
hand, attempts at oxidative carbamate cyclization were undertaken. Surprisingly, 
this oxidative cyclization was realized rather quickly upon screening of a few 
reaction conditions. It was envisaged that development of this transformation would 
be rather arduous. Nonetheless, a previously reported protocol effected the desired 
reactivity.25,26 Indeed, treatment of 44 with PhI(OAc)2 in 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) produced indolenine 56 in 55% isolated yield 
(Scheme 11). Interestingly, the methylimidate proved stable to these conditions, but 
could be subsequently dealkylated with sodium 2-methyl-2-propanethiolate in DMF 
to afford 2. Moreover, during the course of writing this thesis, Li and co-workers 
isolated 2 from a mutant strain of Penicillium purpurogenum G59, and named this 
molecule penicimutamide A.27 Our 1H and 13C spectral data in retrospect were in 
full agreement with that reported. The penultimate functionalization required was to 
install the α-cyanoamine, which was envisioned to arise from reduction of 44 to 
afford an intermediate hemiaminal (57) that should undergo a thermodynamic 
exchange upon workup with cyanide. Treatment with DIBAL-H followed by 
workup with aqueous potassium cyanide afforded α-cyanoamine 58 in 47% yield as 
a single stereoisomer (64% based on recovered starting material).28 Subsequent 
treatment with PhI(OAc)2 as described before afforded the cyclic methyl 
carboximidate in 71% yield, which similarly underwent nucleophilic demethylation 
with sodium 2-methyl-2-propanethiolate to afford aspeverin 1 in 76% yield. 
Spectroscopic data was in agreement with that reported by Ji and co-workers for the 
isolated natural product.29 
46
 Scheme 11: Oxidative carbamate cyclization and completion of aspeverin (1) and 
penicimutamide A (2) 
 
Conclusions and Future Projections: 
 The chemistry described in this chapter delineates the first and only total 
syntheses of aspeverin (1) and penicimutamide A (2) to date.30 Our synthetic route 
toward this molecule features several unique synthetic transformations, which 
should have further utility in the synthesis of other complex natural products. We 
were able to construct the core scaffold via a highly regio- and diastereoselective 
Diels−Alder reaction. We further demonstrated that an incorrectly set stereocenter 
could be inverted with a high level of diastereoselectivity via base-mediated 
epimerization of an intermediary ketone. Notably, this ketone later served as a 
functional handle for geminal dimethylation via carefully devised synthetic 
manipulations that hinge upon the exploitation of a presumed tertiary carbocation. 
An olefin hydration − ring opening − alkylation sequence ultimately proved 
successful in providing the desired geminal dimethyl group. Finally, we 
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demonstrated that the bridging carbamate unique to this natural product could be 
forged via an iodine(III)-mediated oxidative cyclization of the pendant carbamate as 
was initially planned in our retrosynthetic proposal. With several established 
strategies to access the functionalized core of aspeverin, it could be beneficial to 
explore a diversification platform to provide access to structurally related 
molecules.  
 
Future Projections: 
 
We hope our synthetic route can provide insight toward the synthesis of 
related indolic natural products. One set of fungal indolic alkaloids in particular, 
PF1270A-C (59-61) isolated from Penicillium waksmanii, shares many of the 
unique architectural features of aspeverin, but with added synthetic challenges 
(Figure 4).31 PF1270A (59) is redrawn as its enantiomer for clarity and to exemplify 
its structural similarities with aspeverin (1). Notably, these three molecules possess 
high affinity for human histamine H3 receptors (H3Rs) (Ki = 0.047, 0.12, and 0.22 
µM respectively) and act as potent agonists for these receptors. H3Rs have been 
implicated as targets in a variety of disease types, which include obesity and 
diabetes, and several central nervous system (CNS) diseases including sleeping 
disorders, schizophrenia, movement disorders, and attention deficit hyperactivity 
disorder (ADHD).32  
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 Figure 4: Structures of PF1270A-C (59-61) 
 Despite their isolation in 2007, the synthesis of these molecules has not been 
achieved. Retrosynthetically, we hypothesize that these natural products could be 
accessed using chemistry developed for the synthesis of aspeverin (1). Spirocyclic 
pentacycle ent-PF1270A (ent-59, drawn herein as its enantiomer for clarity) could 
be traced back via oxidative indole rearrangement to parent indole 62 (Figure 5). 
The prenyl epoxide moiety could be installed via metal-catalyzed cross-coupling of 
an indolic halide, as has previously been described by the Martin group for the 
synthesis of related alkaloids, citrinadins A and B.33 In this case, one unique 
synthetic challenge would be installation of the quaternary stereocenter at position 3 
with correct stereochemical configuration of the aldehyde and the methyl group. In 
the case of aspeverin, this quaternary carbon center was degenerate and took the 
form of a geminal dimethyl group. Presuming that our Me3Al-mediated ring-
opening/methylation sequence mechanistically delivers the methyl group from the 
top face of the molecule (see proposed intermediate 41, Scheme 10), one could 
envision selective installation of this methyl group via ring opening of a similar 
compound such as 63. Further disconnections involve installation of the carbamate 
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via Curtius rearrangement and a Diels−Alder/epimerization sequence, leading back 
to projected starting diene 65 and dienophile 66.  
 
Figure 5: Retrosynthetic disconnections to access the PF1270 molecules (59-61) 
using chemistry developed for the synthesis of aspeverin (1). 
 
 
Scheme 12: divergent intramolecular cyclizations of carbamate 35 to access 
scaffolds similar to proposed intermediate 63. 
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iodocyclization of the carbamate to obtain exocyclic iodomethylene 68 in 50% 
isolated yield. Preliminary attempts at Me3Al-mediated methylation using either of 
these compounds under similarly described conditions failed. The inductively 
electron withdrawing nature of the exocyclic heteroatoms (−OH or –I) may 
destabilize the presumed tertiary carbocation that was successfully ulitized in our 
synthesis of aspeverin. Alternatively, these heteroatoms may competitively 
coordinate to the Lewis acid used in this transformation. However, experimental 
efforts at this stage are not exhaustive. An in-depth analysis varying the nature of 
this exocyclic heteroatom or protection schemes of the hydroxymethylene as well as 
the nature of the Lewis acid and methyl nucleophile source may facilitate this 
desired transformation and open the door to the synthesis of related fungal natural 
products. 
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EXPERIMENTAL SECTION 
 
General Information. All commercial reagents (Aldrich, Alfa-Aesar, Acros 
Organics, Fluka) were used without further purification. All solvents were reagent 
or HPLC grade (Fisher). Anhydrous solvents were purchased from Sigma-Aldrich 
and used without further purification. All reactions were carried out in flame-dried 
glassware under an argon or nitrogen atmosphere unless otherwise noted. Analytical 
TLC was performed on E. Merck silica gel 60 F254 plates and visualized by UV 
fluorescence quenching and KMnO4 staining. Preparative thin-layer 
chromatography (PTLC) separations were performed on E. Merck silica gel 60 F254 
plates (1 mm). Flash column chromatography was performed on Silicycle SiliaFlash 
F60 (40-63 µm). Yields refer to chromatographically and spectroscopically pure 
compounds. 1H NMR and 13C NMR spectra were recorded on a Bruker Avance 
DRX-500 MHz or DRX-600 MHz at ambient temperature unless otherwise stated. 
Chemical shifts are reported in parts per million relative to residual solvent CDCl3 
(1H, 7.26 ppm, 13C, 77.16 ppm), MeOH-d4 (1H, 3.31 ppm, 13C, 49.0 ppm) or 
DMSO-d6 (1H, 2.50 ppm, 13C, 39.52) ppm. Multiplicities are reported as follows: s 
= singlet, d = doublet, dd = doublet of doublets, t = triplet, td = triplet of doublets, tt 
= triplet of triplets, m = multiplet, q = quartet, app. = apparent, br. s = broad singlet. 
Diastereomeric ratio (dr) was determined by 1H NMR analysis. High-resolution 
mass spectral analyses were performed by the MSKCC core facility staff.  		
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To a -78 oC solution of tert-butyl 2-oxopyrrolidine-1-carboxylate (5) (46.90 g, 253.2 
mmol) in anhydrous Et2O (135 mL) was added DIBAL-H (1.56 M in anhydrous 
PhMe, 187 mL, 291 mmol) by cannula over a period of ~30 minutes. The reaction 
was stirred for 3 hours at -78 oC, then 4 hours at room temperature. The reaction 
was recooled to -78 oC, and acidic MeOH (350 mg pTSA dissolved in 350 mL) was 
carefully added. The resulting mixture was stirred at room temperature overnight 
and concentrated. Saturated aq. sodium/potassium tartrate (400 mL) was added, and 
stirred for 3 hours until the mixture became turbid. The aqueous phase was extracted 
with ether (3 x 250 mL), the combined organic layers washed with brine (300 mL), 
dried over MgSO4 and concentrated. The resulting crude hemiaminal was dissolved 
in CH2Cl2 (900 mL) and cooled in an ice bath. Allyltrimethylsilane (65 mL, 409 
mmol) was added followed by BF3.Et2O (28 mL, 227 mmol) dropwise over 10 
minutes. The reaction was stirred a further 15 minutes at 0 oC and 10 minutes at 
room temperature. Aqueous K2CO3 (600 mL) was added, and the organic layer was 
separated. The aqueous phase was further extracted with CH2Cl2 (2 x 300 mL), the 
combined organic layers washed with brine (500 mL), dried over MgSO4 and 
concentrated. Purification by silica gel chromatography (10:1 Hexane/EtOAc ! 1:1 
Hexane/EtOAc! 100% EtOAc) afforded 6 (30.0 g, 142 mmol, 56% yield) as a 
colorless oil and 7 (18.29 g, 32% yield, 1.2:1 dr) as a low-melting solid. Both 6 and 
7 react productively in the next steps. 
N N
OO
TMS
+
6 7
Boc
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 6 was in spectroscopic agreement as reported in the literature.27 
1H NMR (500 MHz, CDCl3) mixture of rotamers δ 5.74 (m, 1 H), 5.04 (m, 2 H), 
3.76-3.85 (m, 1 H), 3.31-3.38 (m, 2 H), 2.42-2.54 (m, 1 H), 2.11 (m, 1 H), 1.70-1.87 
(m, 4 H), 1.46 (s, 9 H). 
 
7: Rf=0.05 (silica gel, 2:1 Hexane/EtOAc). 1H NMR (600 MHz, CDCl3) δ 5.02 – 
4.22 (m, 2H), 3.75 – 3.35 (m, 6H), 2.32 – 1.92 (m, 5H), 1.85– 1.69 (m, 3H), 1.54 – 
1.27 (m, 4H), 1.27 – 1.10 (m, 2H), 0.95-0.80 (m, 2H), 0.08 (s, 18H). 13C NMR (150 
MHz, CDCl3) δ 153.5, 152.9, 76.3, 74.9, 56.8, 52.4, 46.7, 46.5, 36.8, 33.8, 33.5, 
33.4, 24.6, 23.1, 23.0, 22.9, -0.7, -0.9. IR (film): cm-1 2948, 2894, 1688, 1251, 843. 
HRMS (ESI, m/z) calcd for C11H22NO2Si [M+H]+ 228.1420, found 228.1411. 
 
 
To a 0 oC solution of 6 (23.21 g, 109.8 mmol) in CH2Cl2 (75 mL) was added Et3SiH 
(18 mL, 113 mmol) followed by careful addition of TFA (75 mL, 980 mmol) in 
small portions. The reaction was stirred for 1.5 hours, and concentrated to yield the 
corresponding amine TFA salt. The crude salt was then dissolved in CH2Cl2 (211 
mL) and cooled to 0 oC. NEt3 (60 mL, 430 mmol) was carefully added followed by 
4-dimethylaminopyridine (670 mg, 5.5 mmol). Acryloyl chloride (11.5 mL, 142 
mmol) was added dropwise over about 10 minutes, and the reaction was stirred for 2 
N
O
8
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hours. 1N HCl (200 mL) was then added, and the aqeous phase was extracted with 
CH2Cl2 (3 x 150 mL). The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated. Silica gel chromatography (9:1 Hexane/EtOAc ! 
1:1 Hexane/EtOAc ! 100% EtOAc) afforded 8 as a light yellow oil (13.51 g, 74% 
yield over 2 steps), which matched previously reported spectroscopic data.2 
1H NMR (500 MHz, CDCl3) mixture of rotamers δ 6.40 (m, 2 H), 5.76 (m, 1 H), 
5.68 (m, 1 H), 5.09 (m, 2 H), 4.00-4.26 (m, 1 H), 3.56 (m, 2 H), 2.32-2.65 (m, 2 H), 
2.18 (m, 1 H), 1.76-2.02 (m, 4 H). 
 
8 (11.72 g, 70.9 mmol) was dissolved in CH2Cl2 (1.4 L). The reaction was purged 
by bubbling N2 through the solution for 20 minutes, at which point Grubbs’ 2nd 
Generation catalyst (700 mg, .83 mmol, 1.17 mol%) was added. The reaction was 
stirred overnight (12 hours) under an atmosphere of N2 at room temperature and was 
concentrated. Silica gel chromatography (1:1 CH2Cl2/Et2O ! 1:1 CH2Cl2/EtOAc ! 
20:1 CH2Cl2/MeOH) afforded 15 as a light brown oil (9.42 g, 96% yield). 15 
matched previously reported spectroscopic data.2 
1H NMR (500 MHz, CDCl3) δ 6.50 (m, 1 H), 5.96 (dd, J = 9.7, 2.9 Hz, 1 H), 3.67 
(m, 2 H), 3.47 (m, 1 H), 2.47 (dt, J = 17.2, 5.6 Hz, 1 H), 2.22 (m, 1 H), 2.13 (m, 1 
H), 2.02 (m, 1 H), 1.79 (m, 1 H), 1.61 (m, 1 H).  
N
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 To a solution of 10 (9.42 g, 68.7 mmol) in CCl4 (335 mL) and pyridine (335 mL) 
was added solid I2 (53.0 g, 210 mmol). The resulting mixture was heated at 60 oC 
for 20 hours under an atmosphere of N2. The reaction was cooled to room 
temperature and sat. aq. Na2S2O3 (600 mL) was added followed by 1N HCl (200 
mL). The organic layer was separated, and the aqueous phase extracted with EtOAc 
(3 x 300 mL). The combined organic layers were washed with brine (2 x 350 mL), 
dried over MgSO4 and concentrated. Purification by silica gel chromatography (1:1 
EtOAc/Hexane ! 2:1 EtOAc/Hexane) yielded iodide 11 as a white solid (7.76 g, 
43% yield). Rf = 0.59 (silica gel, 1:1 CH2Cl2/Et2O) 
1H NMR (500 MHz, CDCl3) δ 7.18 (dd, J = 7.0, 2.3 Hz, 1H), 3.79 (m, 1H), 3.67 (m, 
1H), 3.55 (m, 1H), 2.44 (ddd, J = 17.1, 6.9, 4.8 Hz, 1H), 2.33 – 2.15 (m, 2H), 2.10 
(m, 1H), 1.81 (m, 1H), 1.60 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 159.1, 146.8, 
98.2, 56.9, 45.8, 34.2, 33.6, 23.3. IR (film): cm-1 3041, 2969, 2941, 2880, 1649, 
1429, 1276. HRMS (ESI, m/z) calcd for C9H11NOI [M+H]+ 263.9885, found 
263.9895. 
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Carbon monoxide gas was bubbled from a balloon through a solution of iodide 11 
(1.80 g, 7.11 mmol) in MeOH (35 mL) and MeCN (180 mL) for 10 minutes. To the 
resulting solution was added PdCl2(dppf).CH2Cl2 (500 mg, 0.61 mmol) followed by 
NEt3 (6.50 mL, 46.6 mmol). Carbon monoxide was then bubbled through the 
solution for a further 10 minutes, and the mixture was then stirred under a balloon of 
CO gas at 60 oC for 1.5 hr. The reaction mixture was cooled to room temperature 
under air and concentrated under reduced pressure. The residue was washed with 
sat. aq. NaHCO3 (80 mL) and extracted with CH2Cl2 (3 x 80 mL). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated. 
Purification by column chromatography (1:1 CH2Cl2/EtOAc! 15:1 CH2Cl2/MeOH) 
yielded ester 16 as a light brown oil that solidifies upon standing (1.28 g, 93%). The 
product contains a contaminant with a mass of [M+CH3OH], presumed as resulting 
from Michael addition of MeOH, and was carried forward in the next step and is 
presumed to react. Concentration of a sample from acetic acid gave a 
characterizable sample of 12. Rf = 0.20 (silica gel, 1:1 CH2Cl2/Et2O). 
1H NMR (600 MHz, CDCl3) δ 7.34 (dd, J = 6.8, 2.2 Hz, 1H), 3.83 (s, 3H), 3.74 (m, 
1H), 3.66 (m, 1H), 3.52 (ddd, J = 12.1, 10.1, 7.4 Hz, 1H), 2.61 (m, 1H), 2.35 – 2.19 
(m, 2H), 2.04 (m, 1H), 1.82 (m, 1H), 1.67 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 
165.2, 159.9, 145.6, 130.6, 56.2, 52.4, 44.7, 33.6, 30.9, 23.4. IR (film): cm-1 2968, 
2950, 2884, 1739, 1662, 1613, 1445, 1266. HRMS (ESI, m/z) calcd for C10H14NO3 
[M+H]+ 196.0974, found 196.0973. 
 
57
 To a stirred solution of 12 (4.43 g, 22.73 mmol) in CH2Cl2 (225 mL) was added 
(buta-1,3-dien-2-yloxy)(tert-butyl)dimethylsilane (8.28 g, 45 mmol). Then ZnCl2 
(1M in Diethyl Ether, 23 mL, 23 mmol) was added in one portion and the reaction 
was stirred for 1.5 hours at room temperature. At this time, more diene was added 
(1.14 g, 6.2 mmol) and the reaction stirred a further 30 minutes until all starting 
material was consumed as determined by TLC analysis. The reaction was quenched 
by adding sat. aq. NaHCO3 (250 mL). The layers were separated, and the aqueous 
layer was further extracted with CH2Cl2 (3 x 100 mL). The combined organic layers 
were washed with brine/sat. NaHCO3 (1:1, 200 mL), dried over MgSO4, and 
concentrated under reduced pressure. Silica gel chromatography (1:1 
EtOAc/Hexanes ! 2:1 EtOAc/Hexanes) afforded Diels−Alder adduct 14 (7.88 g, 
91% yield) as a light orange oil and as a single diastereomer. Rf = 0.59 (silica gel, 
1:1 CH2Cl2/Et2O). 
1H NMR (500 MHz, CDCl3) δ 4.84 (m, 1H), 3.77 (m, 1H), 3.73 (s, 3H), 3.59 (m, 
1H), 3.30 (ddd, J = 12.7, 10.0, 3.0 Hz, 1H), 2.86 – 2.66 (m, 2H), 2.61 (ddt, J = 16.8, 
4.2, 2.0 Hz, 1H), 2.19 (ddd, J = 17.7, 6.8, 2.0 Hz, 1H), 2.13 – 1.88 (m, 4H), 1.76 (m, 
2H), 1.50 (m, 1H), 0.89 (s, 9H), 0.09 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 173.5, 
168.3, 148.2, 101.3, 55.1, 53.6, 52.7, 44.6, 33.9, 32.9, 31.9, 29.2, 26.8, 25.8, 22.2, 
18.1, -4.3, -4.4. IR (film): cm-1 2953, 2934, 2892, 2856, 1730, 1647, 1442, 1247, 
1178. HRMS (ESI, m/z) calcd for C20H34NO4Si [M+H]+ 380.2257, found 380.2263. 
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 To a stirred solution of cycloadduct 14 (62 mg, 0.163 mmol) in CH2Cl2 (2 mL) was 
added TFA (50 µL). The solution was stirred for 5 minutes and quenched with sat. 
aq. NaHCO3 (4 mL). The mixture was diluted with CH2Cl2 (~8 mL) was added, and 
the mixture was directly filtered through a phase separator and concentrated. 
Purification by silica gel chromatography (1:1 EtOAc/CH2Cl2 ! 10:1 
CH2Cl2/MeOH) yielded pure ketone 15 as a colorless oil (43 mg, 99% yield). Rf = 
0.22 (1:1 CH2Cl2/Et2O) 
1H NMR (500 MHz, CDCl3) δ 3.76 (m, 1H), 3.74 (s, 3H), 3.54 (m, 1H), 3.45 (ddd, J 
= 12.4, 9.7, 2.4 Hz, 1H), 2.75 (m, 1H), 2.54 (m, 1H), 2.50 – 2.28 (m, 5H), 2.10 (m, 
2H), 2.05 (m, 1H), 1.90 (m, 2H), 1.84 (m, 1H), 1.52 (m, 1H). 13C NMR (125 MHz, 
CDCl3) δ 210.5, 173.4, 166.6, 55.0, 53.4, 53.1, 45.4, 42.6, 37.2, 37.1, 33.6, 31.5, 
29.4, 22.4. IR (film): cm-1 2955, 2887, 1720, 1641, 1269, 1241, 1212. HRMS (ESI, 
m/z) calcd for C14H20NO4 [M+H]+ 266.1392, found 266.1380. 
 
 
To a solution of 15 (1.27 g, 4.79 mmol) in MeOH (14 mL) and H2O (4.8 mL) was 
added LiOH.H2O (12.63 mmol). The reaction was left to stir overnight, and was 
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acidified with 1 M HCl. The aqueous mixture was extracted with EtOAc, organic 
layers were dried over MgSO4, and concentrated to afford the corresponding crude 
acid (487 mg, ~42% yield). This crude material was suspended in toluene (10 mL), 
and cooled to 0 oC. To this solution was added triethylamine (0.45 mL, 3.23 mmol) 
followed by diphenylphosphoryl azide (0.49 mL, 2.28 mmol). The reaction was 
stirred for 1 hour, and was directly applied to a column of silica gel and the product 
was eluted (1:1 CH2Cl2/Et2O) to afford acyl azide 16 (302 mg, 54%) as a colorless 
oil. 
1H NMR (500 MHz, CDCl3) δ 3.74 (m, 1 H), 3.54 (m, 1 H), 3.47 (dt, J = 12.0, 1.7 
Hz, 1 H), 2.77 (m, 1 H), 2.31-2.54 (m, 6 H), 2.12 (m, 1 H), 2.05 (m, 1 H), 1.79-1.86 
(m, 3 H), 1.54 (m, 1 H). 13C NMR (150 MHz, CDCl3) δ 210.0, 180.5, 166.0, 55.1, 
54.7, 45.6, 42.6, 37.0, 36.8, 33.6, 31.6, 29.4, 22.5. IR (film): cm-1 2964, 2884, 2141, 
1708, 1631, 1453. LRMS: ESI(+)-MS for C13H16N4O3 m/z: 298.9 [M+Na+]+, 575.3 
[2M+Na+]+. 
 
 
Acyl azide 16 (302 mg, 1.09 mmol) was dissolved in anhydrous toluene (10 mL) 
and heated to 85 oC. After 20 minutes, TLC analysis indicated full conversion to the 
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corresponding isocyanate. To the reaction was added 4-methoxybenzyl alcohol (1.0 
mL, 8.06 mmol). The reaction was then sealed and heated in a 120oC oil bath for 5 
hours. After cooling, the reaction was concentrated and purified by silica gel 
chromatography (1:1 CH2Cl2/Et2O until excess PMBOH elutes, then flush with 
1:1:0.25 CH2Cl2/Et2O/MeOH) to afford carbamate 17 as a white solid (366 mg, 86% 
yield). 
1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2 H), 6.87 (d, J = 8.6 Hz, 2 H), 
5.49 (br s, 1 H), 5.02 (d, J = 11.8 Hz, 1 H), 4.96 (d, J = 11.8 Hz, 1 H), 3.80 (s, 3 H), 
3.65 (m, 1 H), 3.50 (m, 1 H), 3.41 (m, 1 H), 3.27 (m, 1 H), 2.68 (dd, J = 15.1, 6.9 
Hz, 1 H), 2.37-2.49 (m, 3 H), 2.17-2.31 (m, 2 H), 2.10 (m, 1 H), 1.97 (m, 1 H), 1.77-
1.82 (m, 2 H), 1.50 (m, 1 H). 13C NMR (150 MHz, CDCl3) δ 211.4, 170.0, 159.8, 
156.1, 130.1, 128.4, 114.2, 66.8, 58.0, 55.5, 55.1, 46.2, 43.5, 35.7, 33.8, 33.4, 32.1, 
22.9. LRMS: ESI(+)-MS for C21H26N2O5 m/z: 387.23 [M+H+]+, 773.73 [2M+H+]+. 
 
 
 
 
To a solution of 14 (692 mg, 1.83 mmol) in anhydrous toluene (62 mL) was added 
silica gel (40-63 µm, oven-dried for 24 hr, 1.89 g). The resulting mixture was stirred 
vigorously in a sealed vial at 110 oC 14 hours, at which point more silica gel (1.30 g) 
was added, and the mixture stirred a further 24 hours. During the course of the 
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reaction, small aliquots were periodically taken and reaction progress was 
monitored by 1H NMR. The reaction was cooled and filtered to remove silica gel, 
which was washed with copious amounts of CH2Cl2. Purification by silica gel 
chromatography (1:1 CH2Cl2/Et2O) yielded 18 as a colorless oil (469 mg, 10:1 ratio 
of product:starting material, 67% yield). Rf = 0.53 (1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 4.66 (br s, 1H), 3.70 (s, 3H), 3.69 (m, 1H), 3.39 (m, 
1H), 2.96 (m, 1H), 2.58 (m, 1H), 2.12 – 1.87 (m, 5H), 1.82 (m, 2H), 1.72 (m, 1H), 
1.52 (m, 1H), 0.90 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H). 13C NMR (150 MHz, CDCl3) 
δ 174.4, 166.5, 153.0, 105.2, 55.8, 53.0, 52.8, 45.2, 37.1, 33.4, 31.8, 28.4, 26.7, 
25.7, 22.5, 18.2, -4.1, -4.2. IR (film): cm-1 2955, 2933, 2891, 2858, 1731, 1641, 
1455, 1248, 1176, 840. HRMS (ESI, m/z) calcd for C20H34NO4Si [M+H]+ 380.2257, 
found 380.2249. 
 
 
 
To a -78 oC stirred solution of 18 (469 mg, 1.23 mmol) in CH2Cl2 (22 mL) was 
added a solution of PhSeCl (345 mg, 1.81 mmol, dissolved in 2.70 mL CH2Cl2) 
dropwise over ca. 1 minute. The reaction was stirred for 10 minutes at -78 oC, then 
allowed to stir at room temperature for a further 2 minutes. The reaction was 
quenched with sat. aq. NaHCO3 (50 mL), and the aqueous phase was extracted with 
CH2Cl2 (3 x 40 mL). The combined organic layers were washed with brine, dried 
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over MgSO4 and concentrated. The crude mixture was quickly filtered through a 
short column of silica gel (1:1 CH2Cl2:Et2O) to obtain the corresponding crude 
phenylselenide. This material was immediately dissolved in CH2Cl2 (13 mL), and 
H2O2 (0.4 mL, 30 wt% in H2O) was added. The mixture was stirred for 15 minutes 
and quenched with sat. aq. NaHCO3 (20 mL). The aqueous phase was extracted with 
CH2Cl2 (3 x 20 mL), and the combined organic layers were washed with brine, dried 
over MgSO4 and concentrated. Purification by silica gel chromatography (1:1 
CH2Cl2/Et2O) yielded pure enone 19 (168 mg, 51% yield overall) as a crystalline 
white solid. Rf = 0.35 (silica gel, 1:1 CH2Cl2/Et2O).  mp: 114-118oC  
1H NMR (600 MHz, CDCl3) δ 5.96 (s, 1H), 3.75 (s, 3H), 3.66 (m, 1H), 3.52 (m, 
1H), 3.45 (m, 1H), 3.03 (ddd, J = 13.8, 5.4, 2.0 Hz, 1H), 2.93 (ddd, J = 18.1, 13.8, 
5.4 Hz, 1H), 2.83 (ddd, J = 12.8, 11.1, 1.7 Hz, 1H), 2.76 (dd, J = 12.8, 3.7 Hz, 1H), 
2.51 (m 1H), 2.24 (m, 1H), 2.07 (m, 1H), 1.97 (td, J = 13.9, 5.0 Hz, 1H), 1.85 (m, 
1H), 1.63 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 198.2, 168.7, 165.5, 156.0, 
127.0, 57.7, 53.9, 53.4, 45.9, 38.0, 35.0, 33.8, 30.4, 22.4.  IR (film): cm-1 2977, 
2958, 2926, 2887, 1739, 1653, 1628, 1441, 1344, 1223, 1166. HRMS (ESI, m/z) 
calcd for C14H18NO4 [M+H]+ 264.1236, found 264.1246. 
 
 
To a stirred solution of ketone 15 (111 mg, 0.42 mmol) in AcOH (0.84 mL) was 
added phenylhydrazine hydrochloride (79 mg, 0.55 mmol). The mixture was heated 
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at 90oC under N2 for 3 hours, at which point the reaction was concentrated under 
reduced pressure. Purification by silica gel chromatography (1:1 CH2Cl2/Et2O ! 
20:1 CH2Cl2/MeOH) afforded indole 23 as a light orange foam (96 mg, 67% yield). 
Rf = 0.22 (1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 7.94 (br s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 
7.9 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 7.08 (t, J = 7.9 Hz, 1H), 3.79 (s, 3H), 3.79 (m, 
1H), 3.66 (dt, J = 12.8, 8.6 Hz, 1H), 3.34 (m, 1H), 2.98 (m, 1H), 2.86 (ddd, J = 12.5, 
4.3, 2.3 Hz, 1H), 2.81 (dt, J = 13.2, 3.5 Hz, 1H), 2.75 – 2.60 (m, 2H), 2.23 (td, J = 
12.5, 5.9 Hz, 1H), 2.08 (m, 1H), 1.90 (m, 2H), 1.55 (m, 2H). 13C NMR (150 MHz, 
CDCl3) δ 174.4, 167.0, 136.2, 135.8, 126.4, 121.5, 119.6, 118.6, 111.0, 108.3, 55.3, 
55.0, 52.9, 45.5, 36.5, 33.2, 30.3, 29.1, 22.3, 20.3. IR (film): cm-1 3259, 2969m 
2952, 2883, 1734, 1674, 1624, 1459, 1330, 1252. HRMS (ESI, m/z) calcd for 
C20H23N2O3 [M+H]+ 339.1709, found 339.1715. 
 
 
To a solution of ketone 17 (16.0 mg, 0.041 mmol) in AcOH (0.5 mL) was added 
phenylhydrazine hydrochloride (8.9 mg, 0.062 mmol). The reaction was then stirred 
at 80 oC for four hours. At this time, the reaction was cooled to room temperature 
N
NH
H H
OO
O
OMe
HN
25
64
and concentrated. Purification by preparative TLC (1:1 CH2Cl2/Et2O) afforded 25 as 
a colorless oil (6.7 mg, 36% yield) 
1H NMR (600 MHz, CDCl3) δ 7.86 (br s, 1 H), 7.51 (d, J = 7.8 Hz, 1 H), 7.29 (m, 3 
H), 7.14 (t, J = 7.8 Hz, 1 H), 7.07 (t, J = 7.8 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 2 H), 5.33 
(br s, 1 H), 5.00 (m, 2 H), 4.41 (m, 1 H), 3.81 (s, 3 H), 3.58 (m, 1 H), 3.28 (m, 1 H), 
3.00 (m, 1 H), 2.67 (m, 3 H), 2.52 (m, 2 H), 2.05 (m, 1 H), 1.88 (m, 2 H), 1.53 (m, 1 
H), 1.46 (m, 1 H). 13C NMR (150 MHz, CDCl3) δ 169.1, 159.8, 155.4, 136.8, 135.0, 
130.1, 128.7, 127.0, 121.5, 119.6, 119.0, 114.1, 111.0, 109.7, 66.6, 60.7, 55.8, 55.5, 
46.0, 35.5, 33.2, 31.3, 30.0, 22.5, 20.9.  
 
 
 
A stirred solution of enol ether 14 (6.45 g, 17.01 mmol) in DMSO (34 mL) and THF 
(17 mL) was cooled in an ice bath for 10 minutes, until the mixture became a 
partially-frozen slurry. To the rapidly stirring mixture was added solid (o-
nitrophenyl)phenyliodonium fluoride (7.33 g, 21.26 mmol) in one portion.34 The 
resulting dark brown mixture was stirred for 2 minutes, at which time the ice bath 
was removed and the mixture stirred at room temperature for a further 20 minutes. 
Water (250 mL) was added, and the mixture was extracted with EtOAc (4 x 150 
mL). The combined organic layers were washed with brine (100 mL), dried over 
MgSO4 and concentrated. Silica gel chromatography (1:1 CH2Cl2:Et2O) afforded a 
N
O
O H
MeO2C
H
O2N
27
H
65
2.2:1 diastereomeric mixture of nitroarene 27 (3.090 g, 47% yield) as a light yellow 
foam. For characterization purposes, the diastereomers can be easily separated by 
preparative TLC using a 1:1 CH2Cl2:Et2O eluent system. 
 
Nitroarene S27, major diastereomer: Rf = 0.50 (silica gel, 1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 8.08 (dd, J = 8.3, 1.4 Hz, 1H), 7.62 (td, J = 7.6, 1.4 
Hz, 1H), 7.45 (ddd, J = 8.3, 7.6, 1.4 Hz, 1H), 7.39 (dd, J = 7.6, 1.4 Hz, 1H), 4.30 
(m, 1H), 3.88 (m, 1H), 3.76 (s, 3H), 3.68 (m, 1H), 3.55 (ddd, J = 12.7, 9.9, 2.6 Hz, 
1H), 3.26 (dd, J = 12.7, 4.7 Hz, 1H), 2.99 (m, 1H), 2.76 (t, J = 13.4 Hz, 1H), 2.70 – 
2.54 (m, 2H), 2.21 – 2.03 (m, 2H), 2.03 – 1.88 (m, 2H), 1.83 (m, 1H), 1.54 (m, 1H). 
13C NMR (150 MHz, CDCl3) δ 206.1, 173.0, 165.4, 149.0, 133.8, 132.9, 129.8, 
128.4, 125.6, 55.6, 55.5, 53.4, 49.4, 45.4, 43.0, 39.6, 35.7, 33.5, 30.4, 22.6. IR 
(film): cm-1 2972, 2953, 2884, 1727, 1639, 1521, 1346, 908. HRMS (ESI, m/z) 
calcd for C20H23N2O6 [M+H]+ 387.1556, found 387.1542. 
 
Minor Diastereomer 27: Rf = 0.43 (silica gel, 1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 8.03 (dd, J = 8.2, 1.3 Hz, 1H), 7.61 (td, J = 7.6, 1.3 
Hz, 1H), 7.52 – 7.37 (m, 2H), 4.32 (br s, 1H), 3.81 (s, 3H), 3.67 (m, 2H), 3.50 (m, 
1H), 3.10 – 2.87 (m, 2H), 2.73 (m, 1H), 2.64 (m, 1H), 2.36 (dd, J = 15.9, 3.4 Hz, 
1H), 2.20 (dt, J = 11.9, 5.8 Hz, 1H), 2.12 (m, 1H), 2.09 – 1.97 (m, 2H), 1.87 (m, 
1H), 1.61 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 207.67, 173.64, 167.66, 148.34, 
134.13, 133.48, 128.66, 125.67, 54.21, 53.22, 52.25, 45.88, 42.58, 34.97, 34.22, 
33.90, 31.84, 22.40. 13C NMR (150 MHz, CDCl3) δ 207.7, 173.7, 167.7, 148.4, 
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134.1, 133.5, 128.7, 125.7, 54.2, 53.2, 52.2, 45.9, 42.6, 35.0, 34.2, 33.9, 31.8, 22.4. 
IR (film): cm-1 2953, 2884, 1727, 1635, 1530, 1350, 912. HRMS (ESI, m/z) calcd 
for C20H23N2O6 [M+H]+ 387.1556, found 387.1541. 
 
 
To a solution of nitroaryl ketone 27 (700 mg, 1.81 mmol) in EtOAc (24 mL) and 
AcOH (6 mL) was added 10% Pd/C (96 mg, 0.090 mmol) and Pd(PPh3)4 (32 mg, 
0.028 mmol). H2 was bubbled from a balloon through the reaction mixture for 10 
minutes, and the reaction stirred under 1 atm H2 for 8.5 hours. Reaction progress 
was monitored by occasionally withdrawing an aliquot and analyzing for 
disappearance of starting material by 1H NMR in DMSO-d6. The entire reaction 
contents were concentrated under reduced pressure, and the residue was 
resuspended in DMF (4.9 mL) and cooled to 0oC. NaH (60% in mineral oil, 250 mg, 
6.25 mmol) was then added, and the mixture stirred for 10 minutes. Benzyl bromide 
(0.35 mL, 2.95 mmol) was then added and the reaction was stirred at room 
temperature for 45 minutes until all starting material had disappeared by TLC 
analysis. The mixture was then recooled to 0oC and carefully quenched with sat. aq. 
NH4Cl (30 mL). The aqueous mixture was extracted with EtOAc (4 x 25 mL), the 
combined organic layers washed with brine (2 x 30 mL), dried over MgSO4 and 
concentrated under reduced pressure. Purification by silica gel chromatography (1:1 
N
N
H HBnO
MeO2C
O
28
67
CH2Cl2:Diethyl Ether) afforded alkylated N-hydroxyindole 28 as a yellow foam 
(758 mg, 94% yield). Rf = 0.60 (silica gel, 1:1 CH2Cl2/Et2O). 
1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 7.6 Hz, 1H), 7.43 – 7.30 (m, 6H), 7.18 (t, 
J = 7.6 Hz, 1H), 7.10 (t, J = 7.6 Hz, 1H), 5.13 (d, J = 10.9 Hz, 1H), 5.10 (d, J = 10.9 
Hz, 1H), 3.76 (m, 1H), 3.71 (s, 3H), 3.55 – 3.43 (m, 3H), 3.32 (ddd, J = 12.7, 10.0, 
2.9 Hz, 1H), 3.14 (d, J = 15.9 Hz, 1H), 2.90 (m, 1H), 2.49 (m, 1H), 2.28 (dd, J = 
17.2, 4.8 Hz, 1H), 2.14 – 1.86 (m, 3H), 1.86 – 1.68 (m, 2H), 1.52 (m, 1H). 13C NMR 
(125 MHz, CDCl3) δ 172.8, 168.5, 135.0, 133.8, 130.8, 130.2, 129.2, 128.8, 123.4, 
121.9, 119.9, 118.5, 108.3, 103.2, 79.5, 55.0, 54.8, 52.8, 44.6, 34.1, 32.0, 28.7, 23.7, 
23.5, 22.1. IR (film): cm-1 3055, 3031, 2952, 2887, 1727, 1638, 1452, 1219, 904. 
HRMS (ESI, m/z) calcd for C27H29N2O4 [M+H]+ 445.2127, found 445.2112. 
 
 
 
To a room temperature solution of 28 (1.470 g, 3.31 mmol) in CH2Cl2 (18 mL) was 
added Pb(OAc)4 (1.830 g, 4.12 mmol) followed by acetic acid (9 mL). The resulting 
red solution was stirred at room temperature for 30 minutes and concentrated under 
reduced pressure. The residue was washed with 50 mL sat. aq. NaHCO3 and 
extracted into CH2Cl2 (3 x 50 mL). The combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated. The crude acetate (29) was then 
dissolved in anhydrous MeOH (33 mL) and THF (10 mL). K2CO3 (1.830 g, 13.26 
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mmol) was added and the resulting mixture was stirred vigorously for 6.5 hours, at 
which point all of the acetate was consumed as judged by TLC. The mixture was 
quenched with sat. aq. NH4Cl (50 mL), and extracted with EtOAc (4 x 50 mL). The 
combined organic layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. Silica gel chromatography (1:1 
CH2Cl2/Diethyl Ether) afforded alcohol 30 as a light yellow foam and as a single 
unassigned diastereomer. (1.12 g, 73% overall). Rf = 0.34 (silica gel, 1:1 
CH2Cl2/Et2O). 
1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.9 Hz, 1H), 7.47 – 7.32 (m, 6H), 7.24 (t, 
J = 7.4 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 5.33 (d, J = 10.4 Hz, 1H), 5.25 (d, J = 10.4 
Hz, 1H), 4.42 (t, J = 5.0 Hz, 1H), 3.87 – 3.76 (m, 1H), 3.73 (s, 3H), 3.58 (d, J = 16.2 
Hz, 1H), 3.45 (td, J = 12.4, 6.4 Hz, 1H), 3.34 (ddd, J = 12.4, 10.0, 3.0 Hz, 1H), 3.12 
(d, J = 16.2 Hz, 1H), 3.02 (ddd, J = 10.0, 5.8, 3.8 Hz, 1H), 2.66 (d, J = 5.0 Hz, 1H), 
2.15 – 1.94 (m, 2H), 1.88 – 1.70 (m, 1H), 1.54 (m, 1H). 13C NMR (125 MHz, 
CDCl3) δ 173.7, 168.0, 134.9, 134.6, 131.6, 130.1, 129.3, 128.9, 123.3, 122.5, 
120.3, 119.6, 108.8, 105.6, 80.0, 64.0, 55.2, 54.1, 52.9, 44.8, 41.0, 33.9, 26.8, 23.9, 
22.1. IR (film): cm-1 3368, 2953, 2888, 1723, 1616, 1465, 1320, 1213, 916. HRMS 
(ESI, m/z) calcd for C27H29N2O5 [M+H]+ 461.2076, found 461.2064. 
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Alcohol 30 (1.331 g, 2.89 mmol) was dissolved in CH2Cl2 (120 mL), and activated 
MnO2 (oven-dried for 12 hours, 13.30 g, 153 mmol) was added. The mixture was 
stirred at room temperature for 18 hours, at which point the reaction contents were 
filtered through a pad of celite. The filter cake was further washed with CH2Cl2 
(~200 mL), and the filtrate was concentrated to yield ketone 31 (1.130g, 85% yield) 
as a pale yellow foam, which did not require any additional purification. Rf = 0.67 
(1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 7.65 (d, J = 8.1 Hz, 1H), 7.56 (m, 2H), 7.48 – 7.36 
(m, 3H), 7.33 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.12 (ddd, J = 
8.1, 7.0, 1.1 Hz, 1H), 5.34 (d, J = 9.6 Hz, 1H), 5.25 (d, J = 9.6 Hz, 1H), 4.25 (d, J = 
16.3 Hz, 1H), 3.83 (s, 3H), 3.67 (dt, J = 12.7, 8.8 Hz, 1H), 3.55 (m, 1H), 3.51 – 3.40 
(m, 2H), 3.25 (ddd, J = 12.7, 9.8, 2.5 Hz, 1H), 2.99 (dt, J = 13.6, 4.3 Hz, 1H), 2.10 
(m, 1H), 2.03 – 1.89 (m, 1H), 1.86 – 1.64 (m, 2H), 1.46 (m, 1H). 13C NMR (150 
MHz, CDCl3) δ 185.1, 172.8, 165.3, 137.7, 134.5, 130.2, 129.3, 128.8, 128.4, 127.4, 
124.5, 121.8, 121.5, 120.8, 110.0, 80.8, 57.0, 56.2, 53.4, 48.4, 45.4, 33.4, 27.1, 26.8, 
22.4. IR (film): cm-1 3036, 3032, 2950, 2880, 1727, 1655, 1445, 1232, 1079. HRMS 
(ESI, m/z) calcd for C27H27N2O5 [M+H]+ 459.1920, found 459.1904. 
 
 
To a -70oC solution of KHMDS (1M in THF, 4.8 mL, 4.8 mmol) was added a 
solution of ketone 31 (1.130 g, 2.47 mmol) in THF (24 mL) dropwise over 10 
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minutes. The reaction was stirred for a further 5 minutes, and quenched with sat. aq. 
NH4Cl (30 mL). The dry ice/acetone bath was removed, and 20 mL more sat. 
NH4Cl was added. The mixture was extracted with EtOAc (4 x 50 mL), the 
combined organic layers washed with brine (2 x 50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The compound was purified by silica gel 
chromatography (1:1 Hexane/EtOAc ! 1:1 CH2Cl2/Et2O) to afford trans ketone 32 
(907 mg, 80% yield) as a light yellow solid. Rf = 0.54 (1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 7.64 (d, J = 7.8 Hz, 1H), 7.55 (m, 2H), 7.37 (m, 3H), 
7.32 (t, J = 7.8 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 5.33 (d, J 
= 9.6 Hz, 1H), 5.24 (d, J = 9.6 Hz, 1H), 4.24 (d, J = 16.6 Hz, 1H), 3.69 (dt, J = 12.6, 
8.8 Hz, 1H), 3.54 (s, 3H), 3.52 (m, 1H), 3.13 (d, J = 16.6 Hz, 1H), 3.03 (dd, J = 
12.1, 2.6 Hz, 1H), 2.86 (ddd, J = 13.6, 4.4, 2.8 Hz, 1H), 2.31 – 2.09 (m, 2H), 2.04 
(m, 1H), 1.87 (m, 1H), 1.62 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 185.9, 170.3, 
164.7, 136.9, 134.5, 130.3, 129.3, 128.7, 127.8, 127.5, 121.8, 121.4, 121.3, 120.8, 
110.1, 80.8, 59.5, 57.1, 53.3, 51.9, 45.5, 33.2, 30.9, 25.2, 22.2. IR (film): cm-1 3069, 
3031, 2973, 2952, 2872, 1724, 1681, 1638, 1438, 1205, 1176. HRMS (ESI, m/z) 
calcd for C27H27N2O5 [M+H]+ 459.1920, found 459.1908. 
 
 
To a 0oC solution of ketone 32 (855 mg, 1.86 mmol) in THF (25 mL) was added a 
solution of Tebbe Reagent (0.5M in PhMe, 13 mL, 6.5 mmol) over a period of about 
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1 minute. The resulting solution was stirred at room temperature for 30 minutes, 
recooled to 0oC and carefully quenched by the slow addition of sat. aq. NaHCO3 (60 
mL). The mixture was extracted with EtOAc (4 x 50 mL), the combined organic 
layers washed with brine (2 x 50 mL), dried over MgSO4 and concentrated. 
Purification by silica gel chromatography (1:1 CH2Cl2:Et2O) yielded olefin 34 as a 
light yellow foamy solid (657 mg, 77% yield). Rf = 0.54 (1:1 CH2Cl2/Et2O) 
1H NMR (600 MHz, CDCl3) δ 7.58 (d, J = 7.9 Hz, 1H), 7.47 – 7.34 (m, 7H), 7.26 (t, 
J = 7.9 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 5.97 (s, 1H), 5.16 (s, 1H), 4.94 (d, J = 9.7 
Hz, 1H), 4.90 (d, J = 9.7 Hz, 1H), 4.01 (d, J = 16.1 Hz, 1H), 3.72 (m, 1H), 3.61 (m, 
1H), 3.55  (m, 1H), 3.48 (s, 3H), 3.00 (m, 1H), 2.87 (d, J = 16.1 Hz, 1H), 2.54 – 
2.31 (m, 2H), 2.23 (m, 1H), 2.06 (m, 1H), 1.87 (m, 1H), 1.70 (m, 1H). 13C NMR 
(150 MHz, CDCl3) δ 170.7, 166.9, 135.4, 135.3, 134.3, 130.6, 129.7, 129.2, 128.8, 
123.8, 123.2, 120.6, 119.7, 110.9, 109.2, 107.8, 78.3, 59.1, 55.4, 52.6, 45.6, 44.9, 
33.6, 29.9, 27.2, 22.4. IR (film): cm-1 3066, 3031, 2973, 2955, 2883, 1728, 1680, 
1638, 1330, 1205, 735. HRMS (ESI, m/z) calcd for C28H29N2O4 [M+H]+ 457.2127, 
found 457.2107. 
 
Ester 34 (500 mg, 1.09 mmol) was dissolved in 1,4-Dioxane (10 mL) and MeOH 
(10 mL). To the resulting solution was added aq. NaOH (820 mg dissolved in 1.25 
mL H2O, 20.5 mmol), and the mixture was heated at 55oC for 18 hours. The 
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reaction mixture was cooled to room temperature and quenched by the addition of 
0.5M HCl (75 mL). The mixture was extracted with EtOAc (4 x 50 mL), the 
combined organic layers washed with brine (2 x 50 mL), dried over MgSO4 and 
concentrated. The crude carboxylic acid was immediately resuspended in anhydrous 
toluene (11 mL), and NEt3 (0.95 mL) and diphenylphosphoryl azide (0.95 mL) were 
added. The mixture was stirred for 45 minutes at room temperature, and the entire 
reaction contents were loaded onto a column of silica gel and purified (1:1 
EtOAc/Hexanes ! 2:1 EtOAc/Hexanes) to yield acyl azide S-1 as a colorless foam 
(362 mg, 71% yield overall). Rf = 0.70 (silica gel, 1:1 CH2Cl2/Et2O). 
1H NMR (500 MHz, CDCl3) δ 7.58 (d, J = 7.8 Hz, 1H), 7.40 (m, 6H), 7.29 (d, J = 
7.2 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 6.03 (s, 1H), 5.22 (s, 1H), 4.98 (d, J = 9.7 Hz, 
1H), 4.93 (d, J = 9.7 Hz, 1H), 3.98 (d, J = 16.5 Hz, 1H), 3.71 (m, 1H), 3.64 – 3.48 
(m, 2H), 2.99 (dd, J = 11.8, 3.0 Hz, 1H), 2.90 (d, J = 16.5 Hz, 1H), 2.58 – 2.36 (m, 
2H), 2.24 (m, 1H), 2.09 (m, 1H), 1.90 (m, 1H), 1.72 (m, 1H). 13C NMR (125 MHz, 
CDCl3) δ 178.3, 165.9, 135.2, 134.6, 134.1, 130.5, 129.6, 129.2, 128.8, 124.0, 
122.9, 120.7, 119.6, 110.0, 109.1, 108.4, 78.4, 59.1, 56.3, 45.7, 44.9, 33.4, 30.0, 
27.0, 22.3. IR (film): cm-1 3062, 3037, 2973, 2943, 2891, 2128, 1716, 1628, 1173. 
HRMS (ESI, m/z) calcd for C27H26N5O3 [M+H]+ 468.2036, found 468.2029. 
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Acyl azide S-1 (362 mg, 0.77 mmol) was dissolved in anhydrous toluene (5.6 mL) 
and heated to 90oC for 20 minutes under a nitrogen atmosphere (N2 starts visibly 
bubbling from reaction mixture within about 1 minute of heating at 90oC). To the 
resulting formed isocyanate was added 2-(trimethylsilyl)ethanol (1.4 mL, 9.76 
mmol) and the reaction mixture was heated at 90 oC for 9 hours, at which point the 
entire reaction contents were loaded onto a column of silica gel and eluted (2:1 
Hexanes/Acetone ! 1:1 Hexanes/Acetone) to yield carbamate 35 as a light yellow 
foamy solid (285 mg, 66% yield). Rf = 0.62 (silica gel, 1:1 CH2Cl2/Et2O) 
1H NMR (500 MHz, CDCl3) δ 7.51 (d, J = 7.8 Hz, 1H), 7.48 – 7.36 (m, 6H), 7.29 (t, 
J = 7.6 Hz, 1H), 7.15 (t, J = 7.8 Hz, 1H), 6.13 (s, 1H), 5.26 (s, 1H), 5.05 (d, J = 9.6 
Hz, 1H), 4.98 (d, J = 9.6 Hz, 1H), 4.86 (s, 1H), 3.98 (m, 2H), 3.84 (m, 1H), 3.75 – 
3.57 (m, 1H), 3.52 (m, 2H), 3.07 (d, J = 16.5 Hz, 1H), 2.94 (m, 1H), 2.26 (m, 1H), 
2.19 – 1.98 (m, 2H), 1.82 (m, 1H), 0.82 (m, 2H), -0.05 (s, 9H). 13C NMR (125 MHz, 
CDCl3) δ 167.9, 155.9, 135.0, 134.6, 134.0, 130.2, 129.8, 129.4, 128.9, 124.1, 
123.1, 120.8, 119.3, 110.2, 109.1, 106.4, 78.9, 63.1, 59.7, 57.6, 47.2, 45.7, 34.5, 
32.8, 25.7, 22.9, 17.5, -1.4. IR (film): cm-1 3431, 3062, 2952, 2893, 1724, 1641, 
1330, 1247, 1226. HRMS (ESI, m/z) calcd for C32H40N3O4Si [M+H]+ 558.2788, 
found 558.2787. 
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To a room temperature solution of carbamate 35 (200 mg, 0.34 mmol) in CH2Cl2 
(18 mL) was added TFA (50 mL, 0.65 mmol), and the mixture was stirred for 30 
minutes, whereupon more TFA (50 µL, 0.65 mmol) was added. After stirring for an 
additional 45 minutes, sat. aq. NaHCO3 (20 mL) was added. The aqueous phase was 
further extracted with CH2Cl2 (3 x 30 mL), the combined organic layers washed 
with brine, dried over MgSO4 and concentrated. Purification by silica gel 
chromatography (1:1 CH2Cl2/Et2O ! 1:1:0.1 CH2Cl2/Et2O/MeOH) afforded 
bicyclic carbamate 40 as a white crystalline solid (124 mg, 80% yield). Rf = 0.22 
(1:1 CH2Cl2/Et2O). 
1H NMR (600 MHz, CDCl3) δ 7.56 (m, 2H), 7.52 (d, J = 7.6 Hz, 1H), 7.48 – 7.39 
(m, 4H), 7.30 (t, J = 7.6 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 5.48 (s, 1H), 5.22 (d, J = 
9.4 Hz, 1H), 5.08 (d, J = 9.4 Hz, 1H), 3.67 (m, 1H), 3.63 – 3.45 (m, 3H), 2.85 (d, J 
= 16.3 Hz, 1H), 2.46 (m, 1H), 2.34 (m, 1H), 2.26 (m, 1H), 2.10 (m, 4H), 1.88 (m, 
1H), 1.61 (m, 1H), 1.49 (m, 1H). 13C NMR (150 MHz, CDCl3) δ 167.7, 152.4, 
134.7, 134.2, 130.7, 130.0, 129.3, 128.9, 124.4, 122.2, 121.0, 119.5, 109.6, 107.5, 
80.2, 75.5, 58.5, 56.8, 45.7, 43.1, 33.8, 33.6, 25.3, 22.6, 20.2. IR (film): cm-13242, 
3054, 2962, 2887, 1702, 1638, 1344, 1068. HRMS (ESI, m/z) calcd for C27H28N3O4 
[M+H]+ 458.2065, found 458.2080.  
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To a 0oC solution of 40 (145 mg, 0.317 mmol) in CH2Cl2 (11.5 mL) was added 
Me3Al dropwise (2M solution in toluene, 2.90 mL, 5.80 mmol). The reaction was 
stirred for 1.5 hours at 0oC, and was carefully quenched with sat. aq. NaHCO3 (30 
mL). The mixture was extracted with EtOAc (4 x 40 mL), the combined organic 
layers washed with brine, dried over MgSO4 and concentrated. The crude amine 
(42) was then redissolved in CH2Cl2 (3 mL), and 4-dimethylaminopyridine (48 mg, 
0.39 mmol) was added followed by Boc2O (0.10 mL, 0.43 mmol). The reaction was 
stirred for 1 hour, and loaded directly onto preparative TLC plates  (100% Hexanes 
then 1:1 CH2Cl2/Et2O) to yield isocyanate 43 (49 mg, 34% yield) as an amorphous 
white solid. Rf = 0.80 (silica gel, 1:1 CH2Cl2/Et2O) 
1H NMR (500 MHz, CDCl3) δ 7.65 – 7.41 (m, 6H), 7.25 (d, J = 7.4 Hz, 3H), 7.14 (t, 
J = 7.4 Hz, 1H), 5.33 (d, J = 10.1 Hz, 1H), 5.23 (d, J = 10.1 Hz, 1H), 3.78 (dt, J = 
12.2, 8.9 Hz, 1H), 3.62 (d, J = 16.1 Hz, 1H), 3.52 – 3.31 (m, 2H), 2.92 (d, J = 16.1 
Hz, 1H), 2.28 – 2.14 (m, 2H), 2.07 (m, 1H), 1.92 (dd, J = 12.3, 1.8 Hz, 1H), 1.89 – 
1.80 (m, 1H), 1.60 (m, J = 4.1 Hz, 1H), 1.55 (s, 3H), 1.54 (s, 3H). 13C NMR (150 
MHz, CDCl3) δ 168.3, 137.9, 134.6, 133.8, 129.1, 129.0, 128.8, 126.8, 123.4, 122.4, 
120.2, 118.8, 108.7, 102.3, 78.6, 61.8, 59.9, 49.5, 45.5, 35.6, 34.2, 33.5, 28.6, 26.1, 
22.4, 21.4. IR (film): cm-1 2969, 2894, 2234 (sharp), 1649, 1452. HRMS (ESI, m/z) 
calcd for C28H30N3O3 [M+H]+ 456.2287, found 456.2280. 
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1H NMR (500 MHz, CDCl3) δ 7.54 (m, 3 H), 7.40-7.48 (m, 4 H), 7.23 (ddd, J = 6.7, 
6.0, 0.9 Hz, 1 H), 7.12 (ddd, J = 6.7, 6.0, 0.8 Hz, 1 H), 5.31 (d, J = 8.4 Hz, 1 H), 
5.26 (d, J = 8.4 Hz, 1 H), 3.71 (m, 1 H), 3.47 (m, 2 H), 3.34 (d, J = 13.0 Hz, 1 H), 
2.80 (d, J = 13.0 Hz, 1 H), 2.17 (m, 1 H), 2.11 (m, 1 H), 2.04 (m, 1 H), 1.97 (dd, J = 
10.3, 1.1 Hz, 1 H), 1.84 (m, 1 H), 1.77 (m, 1 H), 1.60 (m, 1 H), 1.55 (s, 3 H), 1.54 
(s, 3 H). 13C NMR (125 MHz, CDCl3): δ 173.2, 138.2, 134.7, 134.1, 129.2, 129.0, 
128.9, 124.1, 122.4, 120.1, 119.0, 108.7, 103.4, 78.6, 60.1, 56.8, 49.8, 45.3, 35.4, 
34.9, 33.6, 29.2, 25.6, 22.6, 22.1. UPLC/MS: ESI(+)-MS for C27H31N3O2 m/z: 430.4 
[M+H+]+. 
 
Isocyanate 43 (61 mg, 0.13 mmol) was suspended in 5 mL anhydrous MeOH and 
heated in a Biotage microwave reactor (closed system) at 100 oC for 13 hours. The 
resulting solution was concentrated and purified by preparative TLC (1:1 
CH2Cl2/Et2O) to yield carbamate 44 as an amorphous white solid (43 mg, 84%). Rf= 
0.26 (1:1 CH2Cl2/Et2O) 
1H NMR (500 MHz, CDCl3): δ 8.15 (s, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 
7.6 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 4.92 (s, 1H), 3.95 – 
3.78 (m, 1H), 3.61 – 3.34 (m, 6H), 2.92 (d, J = 15.8 Hz, 1H), 2.25 – 1.99 (m, 6H), 
1.97 – 1.70 (m, 2H), 1.40 (s, 3H), 1.34 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
168.8, 156.2, 141.1, 136.6, 127.7, 122.0, 119.8, 118.5, 110.9, 104.2, 60.5, 57.4, 
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52.1, 50.3, 45.7, 34.8, 34.3, 32.7, 30.3, 24.7, 22.9. IR (film): cm-1 3424, 3266, 2969, 
2869, 1724, 1634, 1502, 1455, 1244, 911. HRMS (ESI, m/z) calcd for C22H27N3O3 
[M+H]+ 382.2131, found 382.2137 
 
 
To a solution of 44 (10.0 mg, 0.026 mmol) in 1,1,1,3,3,3-hexafluoro-2-propanol (0.8 
mL) was added PhI(OAc)2 (14.0 mg, 0.043 mmol). The reaction was stirred for 30 
minutes and was then concentrated. Purification by preparative TLC afforded 56 as 
a colorless oil (5.5 mg, 55% yield). 
1H NMR (600 MHz, CDCl3) δ 7.55 (d, J = 7.6 Hz, 1 H), 7.45 (d, J = 7.2 Hz, 1 H), 
7.40 (m, 1 H), 7.26 (m, 1 H), 3.78 (m, 1 H), 3.77 (s, 3 H), 3.47 (m, 1 H), 3.41 (m, 1 
H), 3.11 (d, J = 14.0 Hz, 1 H), 2.15 (m, 1 H), 2.06 (m, 3 H), 2.00 (m, 1 H), 1.81-
1.69 (m, 2 H), 1.65 (m, 1 H), 1.50 (d, J = 14.0 Hz, 1 H), 1.46 (s, 3 H), 1.14 (s, 3 H). 
13C NMR (150 MHz, CDCl3): δ 186.7, 169.5, 153.4, 153.3, 136.2, 130.8, 126.9, 
123.6, 131.1, 86.5, 60.6, 58.1, 55.5, 53.4, 45.0, 39.8, 35.5, 33.3, 28.0, 25.6, 22.5, 
21.4. LRMS: ESI(+)-MS for C22H25N3O3 m/z: 380.9 [M+H+]+, 402.8 [M+Na+]+, 
782.3 [2M+Na+]+. 
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 56 (5.4 mg, 0.0142 mmol) was massed into a 1-dram glass vial, and a solution of 
sodium 2-methyl-2-propanethiolate (23.9 mg, 0.21 mmol) in anhydrous DMF (0.45 
mL) was added. The vial was sealed under argon and stirred in a 60 oC oil bath for 
55 minutes, at which point UPLC/MS analysis indicated full conversion. The 
reaction was cooled to room temperature and quenched upon the addition of 
saturated aqueous NH4Cl (2 mL) and brine (3 mL). The mixture was extracted with 
CH2Cl2 (3 x 8 mL). The combined organic layers were further washed with brine, 
filtered through a phase separator and concentrated. Purification by preparative TLC 
(20:1 CH2Cl2/MeOH) afforded 2 as a light yellow solid  (4.1 mg, 79% yield). 
1H NMR (600 MHz, MeOH-d4) δ 7.56 (d, J = 7.6 Hz, 1 H), 7.52 (d, J = 7.6 Hz, 1 
H), 7.47 (td, J = 7.6, 1.0 Hz, 1 H), 7.34 (td, J = 7.6, 1.0 Hz, 1 H), 3.62 (td, J = 12.3, 
9.0 Hz, 1 H), 3.53 (m, 1 H), 3.39 (ddd, J = 12.2, 10.0, 1.7 Hz, 1 H), 3.17 (d, J = 14.0 
Hz, 1 H), 2.23 (ddd, J = 13.0, 4.0, 1.6 Hz, 1 H), 2.17 (m, 1 H), 2.05 (m, 1 H), 2.04 
(dd, J = 12.6, 1.6 Hz, 1 H), 1.87 (m, 2 H), 1.73 (td, J = 13.0, 11.5 Hz, 1 H), 1.65 (m, 
1 H), 1.50 (s, 3 H), 1.28 (s, 3 H). 13C NMR (150 MHz, MeOH-d4): δ 187.5, 167.4, 
155.2, 153.8, 137.3, 132.0, 128.2, 124.4, 121.7, 88.0, 61.6, 58.2, 52.3, 46.6, 40.6, 
36.9, 33.5, 27.7, 25.7, 23.2, 21.6. LRMS: ESI(+)-MS for C21H23N3O3 m/z: 366.2 
[M+H+]+, 388.2 [M+Na+]+ 
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 Lactam 44 (43 mg, 0.11 mmol) was dissolved in THF (1.14 mL) in a flame dried 25 
mL round bottom flask. The solution was cooled to -45oC in an acetone/dry ice bath, 
and DIBAL-H (1M in PhMe, 1.0 mL, 1.0 mmol) was added dropwise over 1 
minute. The reaction was then stirred for 2 hours, maintaining the reaction bath 
temperature between -40 oC and -30 oC the entire time by periodically adding more 
dry ice. The reaction was then allowed to warm to -15 oC over 20 minutes, and was 
quenched with an aqueous solution of KCN (375 mg dissolved in 1.18 mL H2O).  
The mixture was stirred for 45 minutes vigorously at room temperature, at which 
point sat. aq. Na/K tartrate (8 mL) and sat. NaHCO3 (2 mL) were added and stirred 
vigorously until the reaction mixture became turbid. The mixture was further diluted 
with 8 mL sat. aq. Na/K tartrate and extracted with EtOAc (3 x 20 mL), the 
combined organic layers were washed with brine (15 mL), dried over MgSO4 and 
concentrated . Purification by preparative TLC (1:1 Hexane/EtOAc) afforded 58 as 
an amorphous white solid and as a single diastereomer (21 mg, 47% yield). Further 
elution of the preparative TLC plate (1:1 CH2Cl2/EtOAc) afforded recovered 
starting material 44 (7.5 mg, 17% yield, 64% brsm). Rf= 0.53 (silica gel, 1:1 
Hexane/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 7.79 (br s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 
7.8 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 5.06 (s, 1H), 4.78 (s, 
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1H), 4.03 (d, J = 16.0 Hz, 1H), 3.51 (s, 3H), 3.04 (d, J = 16.0 Hz, 1H), 3.00 (dt, J = 
8.6, 2.7 Hz, 1H), 2.54 (m, 2H), 2.09 (dd, J = 13.0, 3.5 Hz, 1H), 2.01 (m, 2H), 1.89 
(m, 1H, 1.81 (m, 1H), 1.52 (m, 1H), 1.39 (s, 3H), 1.32 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 155.2, 139.0, 136.4, 127.6, 121.9, 119.6, 118.7, 115.9, 110.6, 105.1, 58.4, 
58.2, 56.4, 51.9, 50.9, 46.6, 34.0, 30.7, 30.5, 27.4, 24.9, 21.3. IR (film): cm-1 3370, 
2962, 2880, 2822, 1713, 1512, 1463, 1241, 907. HRMS (ESI, m/z) calcd for 
C23H28N4O5 [M+H]+ 393.2291, found 393.2300. 
 
 
To a room temperature solution of 58 (21.0 mg, 0.053 mmol) in 1,1,3,3-hexafluoro-
2-propanol (2 mL) was added PhI(OAc)2 (23 mg, 0.071 mmol), and the mixture was 
allowed to stand for 8 minutes. The reaction mixture was concentrated under 
reduced pressure and purified by preparative TLC (1:1 Hexane/EtOAc) to yield S-2 
(15.0 mg, 71% yield) as a colorless oil. Rf= 0.50 (silica gel, 1:1 Hexane/EtOAc). 
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 
7.39 (d, J = 7.4 Hz, 1H), 7.26 (t, 7.4 Hz, 1 H), 3.83 (s, 1H), 3.80 (s, 3H), 3.05 (td, J 
= 8.6, 2.9 Hz, 1H), 2.54 (q, J = 8.6 Hz, 1H), 2.42 (m, 1H), 2.19 (d, J = 13.4 Hz, 1H), 
2.04 – 1.94 (m, 2H), 1.91 (d, J = 13.4 Hz, 1H), 1.90 – 1.73 (m, 3H), 1.68 (m, 1H), 
1.59 (m, 1H), 1.45 (s, 3H), 1.09 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 186.2, 
153.4, 152.8, 135.6, 131.0, 126.7, 123.0, 121.3, 115.3, 86.0, 63.4, 59.3, 55.9, 55.6, 
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51.7, 50.8, 39.9, 38.3, 30.3, 27.5, 27.4, 21.5, 21.4. IR (film): cm-1 2969, 2955, 2869, 
2819, 1674, 1580, 1308, 1262, 904. HRMS (ESI, m/z) calcd for C23H26N4O2 
[M+H]+ 391.2134, found 391.2146. 
 
 
A solution of sodium 2-methyl-2-propanethiolate (50 mg, 0.45 mmol) in anhydrous 
DMF (1.2 mL) was added to S-2 (15.0 mg, 0.038 mmol) in a 10 mL round bottom 
flask. The stirred mixture was heated to 60oC for 1.5 hours, at which point the 
reaction was cooled to room temperature and quenched with sat. aq. NH4Cl (5 mL) 
and brine (5 mL). The mixture was extracted with EtOAc (3 x 10 mL), the 
combined organic layers washed with brine (5 mL), dried over MgSO4 and 
concentrated. Purification by preparative TLC (1:1 Hexane/EtOAc) afforded 1 as a 
colorless gum (11.1 mg, 74% yield). Rf = 0.38 (silica gel, 1:1 Hexane/EtOAc) 
1H NMR (600 MHz, CDCl3) δ 7.58 (dd, J = 8.1, 1.0 Hz, 1H), 7.50 – 7.35 (m, 2H), 
7.28 (td, J = 7.5, 1.0 Hz, 1H), 6.25 (s, 1H), 3.92 (s, 1H), 3.00 (td, J = 8.8, 2.7 Hz, 
1H), 2.55 (q, J = 8.8 Hz, 2H), 2.50 (m, 1H), 2.47 (d, J = 13.5 Hz, 1H), 2.07 (m, 1H), 
2.01 (t, J = 3.2 Hz, 1H), 1.99 (m, 2H), 1.97 – 1.85 (m, 2H), 1.82 (dd, J = 12.5, 3.5 
Hz, 1H), 1.50 (m, 1H), 1.49 (s, 3H), 1.25 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 
184.5, 152.8, 151.7, 135.3, 131.2, 127.0, 123.2, 121.5, 113.1, 86.3, 61.5, 58.6, 54.8, 
50.7, 49.1, 39.4, 38.2, 30.2, 27.6, 27.3, 22.1, 21.5. IR (film): cm-1 3406, 3249, 2973, 
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2933, 2876, 2819, 1713, 1578, 1362, 1083, 800. HRMS (ESI, m/z) calcd for 
C22H25N4O2 [M+H]+ 377.1978, found 377.1993. 
 
1H NMR (600 MHz, DMSO-d6) δ 7.59 (s, 1H), 7.55 (m, 2H), 7.47 (t, J = 7.6 Hz, 
1H), 7.32 (t, J = 7.4 Hz, 1H), 4.45 (s, 1H), 2.99 (td, J = 8.6, 2.6 Hz, 1H), 2.78 (d, J = 
13.5 Hz, 1H), 2.28 (m, 2H), 1.91 (m, 2H), 1.83 (m, 1H), 1.78 (d, J = 13.5 Hz, 1H), 
1.75 (m, 1H), 1.64 (dd, J = 12.5, 3.0 Hz, 1H), 1.61 – 1.47 (m, 2H), 1.37 (s, 3H). 
1.12  (s, 3H). 13C NMR (150 MHz, DMSO- d6) δ 185.5, 152.6, 150.9, 135.9, 130.7, 
126.6, 123.2, 120.7, 113.0, 85.3, 60.2, 58.0, 54.0, 49.8, 49.0, 36.3, 30.4, 29.5, 26.9, 
26.4, 21.6, 21.1. 
 
 
 
 
 
 
To a solution of olefin 35 (100 mg, 0.18 mmol) in acetone (2.65 mL) and H2O (0.26 
mL) was added N-methylmorpholine N-oxide monohydrate (49 mg, 0.36 mmol) 
followed by OsO4 (2% solution in H2O, 100 µL, 0.008 mmol). The reaction was 
stirred overnight at room temperature, and was quenched with saturated aqueous 
Na2S2O3 (5 mL). The mixture was extracted with EtOAc (3 x 10 mL), dried over 
N
H H
NHO
N
BnO
O
O
HO
67
83
MgSO4, and concentrated to afford the crude diol. To a solution of ¾ of this crude 
material in CH2Cl2 (4 mL) was added TFA (0.07 mL, 0.91 mmol). The reaction was 
stirred for 1 hour, and was quenched upon the addition of saturated aq. NaHCO3 (5 
mL). The mixture was extracted with CH2Cl2 (3 x 10 mL), the combined organic 
layers were dried (MgSO4) and concentrated. Purification by preparative TLC (1:1 
EtOAc/CH2Cl2) afforded cyclic carbamate 67 as a white solid (29 mg, 
approximately 45% yield overall). 
1H NMR (600 MHz, CDCl3) δ 7.51-7.54 (m, 3 H), 7.42 (m, 3 H), 7.38 (d, J = 8.2 
Hz, 1 H), 7.31 (t, J = 7.5 Hz, 1 H), 7.17 (t, J = 7.5 Hz, 1 H), 5.57 (br s, 1 H), 5.18 
(m, 2 H), 4.92 (d, J = 11.9 Hz, 1 H), 4.09 (d, J = 11.9 Hz, 1 H), 3.63 (m, 1 H), 3.52 
(m, 2 H), 2.87 (d, J = 16.3 Hz, 1 H), 2.75 (m, 1 H), 2.49 (m, 1 H), 2.21 (m, 1 H), 
2.08 (m, 1 H), 1.85 (m, 1 H), 1.58 (m, 1 H), 1.45 (q, J = 12.2 Hz, 1 H). 13C NMR 
(150 MHz, CDCl3): δ 167.6, 151.8, 135.1, 133.9, 130.1, 129.7, 129.1, 128.4, 124.8, 
122.7, 121.3, 119.6, 110.4, 109.7, 80.8, 77.8, 60.0, 58.5, 57.1, 45.8, 38.8, 33.8, 33.6, 
25.1, 22.6. LRMS: ESI(+)-MS for C27H27N3O5 m/z: 496.2 [M+Na+]+. 
 
 
To a solution of 35 (20.0 mg, 0.036 mmol) in CH2Cl2 (1 mL) was added I2 (20.0 
mg, 0.079 mmol). The reaction was stirred for 15 minutes at room temperature, and 
was quenched upon the addition of a solution of saturated aq. NaHCO3 and Na2S2O3 
(3 mL, 1:1). The mixture was diluted with CH2Cl2, and filtered through a phase 
N
H H
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N
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O
O
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separator and concentrated. Purification by preparative TLC (1:1 CH2Cl2/Et2O) 
afforded 68 as a white solid (10.4 mg, 50% yield). 
1H NMR (600 MHz, CD2Cl2) δ 7.55 (m, 3 H), 7.44 (m, 4 H), 7.31 (t, J = 7.8 Hz, 1 
H), 7.16 (t, J = 7.8 Hz, 1 H), 5.51 (s, 1 H), 5.19 (d, J = 9.5 Hz, 1 H), 5.10 (d, J = 9.5 
Hz, 1 H), 4.74 (d, J = 10.5 Hz, 1 H), 3.59-3.66 (m, 3 H), 3.48-3.52 (m, 2 H), 2.9 (m, 
1 H), 2.94 (d, J = 16.3 Hz, 1 H), 2.28 (m, 2 H), 2.07 (m, 1 H), 1.87 (m, 1 H), 1.59 
(m, 1 H), 1.40 (m, 1 H). HSQC 13C NMR correlations (150 MHz, CD2Cl2) 129.9, 
129.0, 124.3, 120.7, 119.5, 80.0, 57.5, 53.3, 45.1, 40.7, 33.6, 33.5, 24.0, 22.3, 2.8. 
LRMS: ESI(+)-MS for C27H26IN3O4 m/z: 606.1 [M+Na+]+. 
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Crystal data and structure refinement for compound 19 
 
Empirical formula: C14H17NO4 
Formula Weight: 263.28 
Temperature: 130(2) K 
Wavelength: 0.71073 Å 
Crystal system, space group: Triclinic, P -1 
Unit Cell Dimensions: a = 6.9183(8) Å alpha = 68.2765 (13) deg. 
    b =  9.7324 (11) Åbeta = 79.1821 (15) deg. 
    c = 10.5986 (12) Å gamma = 79.3466 (15) deg. 
Volume: 645.93 (13) A^3 
Z, Calculated Density: 2, 1.354 Mg/m^3 
Absorption coefficient: 0.99 mm^-1 
F(000): 280 
Crystal size: 0.77 x 0.56 x 0.44 mm 
Theta range for data collection: 2.086 to 30.489 deg. 
Limiting indices: -9<=h<=9, -13<=k<=13, -15<=l<=15 
Relections collected / unique: 10400 / 3912 [R(int) = 0.0282] 
Completeness to theta = 25.242 99.9% 
Absorption correction: Empirical 
Max. and min. transmission: 0.7461 and 0.6568 
Refinement method: Full-matrix least-squares on F^2 
Data / restraints / parameters: 3912 / 0 / 173 
Goodness-of-fit on F^2: 1.017 
Final R indices [I>2sigma(I)]: R1 = 0.375, wR2 = 0.1070 
R indices (all data): R1 = 0.0398, wR2 = 0.1104 
Extinction coefficient: n/a 
Larges diff. peak and hole: 0.490 and -0.274 e.A^-3 
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Crystal data and structure refinement for compound 40 
 
Empirical formula: C28H28Cl3N3O4 
Formula Weight: 576.88 
Temperature: 130(2) K 
Wavelength: 0.71073 Å 
Crystal system, space group: Triclinic, P -1 
Unit Cell Dimensions: a = 11.434 (2) Å alpha = 70.709 (3) deg. 
    b =  11.498 (3) Å beta = 64.880 (3) deg. 
    c = 12.393 (3) Å gamma = 66.319 (3) deg. 
Volume: 1325.6 (5) Å ^3 
Z, Calculated Density: 2, 1.445 Mg/m^3 
Absorption coefficient: 0.387 mm^-1 
F(000): 600 
Crystal size: 0.37 x 0.17 x 0.15 mm 
Theta range for data collection: 1.850 to 30.724 deg. 
Limiting indices: -16<=h<=16, -16<=k<=16, -17<=l<=17 
Relections collected / unique: 19653 / 8081 [R(int) = 0.0353] 
Completeness to theta = 25.242 98.8% 
Absorption correction: Empirical 
Max. and min. transmission: 0.7461 and 0.6727 
Refinement method: Full-matrix least-squares on F^2 
Data / restraints / parameters: 8081 / 0 / 344 
Goodness-of-fit on F^2: 1.111 
Final R indices [I>2sigma(I)]: R1 = 0.1746, wR2 = 0.4746 
R indices (all data): R1 = 0.1935, wR2 = 0.4843 
Extinction coefficient: n/a 
Larges diff. peak and hole: 2.883 and -1.865 e. Å ^-3 
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Chapter 3: Introduction to the Total Chemical Synthesis and Folding of  
All-L and All-D KRas(G12V) 
 
Targeting Ras Signaling Through the Means of Chemical Protein Synthesis 
 
 The RAS oncogene encodes small GTPases involved in cellular signaling, 
controlling a variety of phosphorylation cascades involved in cellular growth and target 
gene transcription. Scolnick and co-workers initially identified Ras in 1979 as a 21 kDa 
protein encoded by the Harvey and Kirsten rat sarcoma viruses in transformed cells.1,2 In 
1982, three independent laboratories identified sequence homologs of these cancer-
inducing genes within human bladder and lung cancer cells, thereby establishing RAS as 
an endogenous human oncogene.3,4,5 Since these seminal discoveries, the four human 
isoforms of this oncogenic protein (HRas, NRas, KRas-4A, and KRas-4B) have been 
implicated in over 30% of all human cancers, with higher prevalence in certain cancers of 
particular mortality, including 71% of pancreatic cancer cases (Table 1).6 Of the four 
human Ras isoforms, KRas-4B is responsible for a vast majority of these cancers. 
Table 1: Selected frequency of mutated Ras isoforms in cancer (adapted from Ref. 6 
based on the Catalogue of Somatic Mutations in Cancer (COSMIC) version 67) 
 
 
 The functional significance of Ras in cellular signaling was established within the 
first years following the initial discoveries of this human gene homolog. Ras is a GTP-
Tissue HRas (%) KRas (%) NRas (%) total Ras%
0%
<1%
1%
0%
0%
1%
9%
10%
71%
19%
35%
35%
26%
1%
8%
5%
<1%
<1%
6%
<1%
2%
18%
2%
1%
71%
20%
42%
35%
28%
20%
19%
16%
Pancreas
Lung
Colon
Small Intestine
Biliary Tract
Skin
Cervix
Urinary Tract
Selected Frequency of Mutated Ras Isoforms in Cancers
binding protein, which controls intracellular signaling cascades, as governed by 
activation of receptor tyrosine kinases (RTKs), such as extracellular epidermal growth 
factor (EGF) binding.7 This extracellular signaling recruits proteins known as guanine 
nucleotide exchange factors (GEFs), such as the Son of Sevenless protein (SOS), which 
facilitate nucleotide exchange of GDP-bound Ras to allow for GTP binding (Figure 1).8,9 
Conversely, although Ras itself is a GTPase, its innate hydrolysis of GTP is slow, and 
requires the aid of GTPase activating proteins (GAPs) to facilitate hydrolysis of GTP to 
GDP. 10,11 The structural differences between GDP- and GTP-bound states of Ras govern 
its effector binding and signal transduction. This renders Ras as a crucial molecular 
switch at the intersection between the extracellular environment and cytosolic 
phosphorylation cascades that regulate transcription and growth. In its GTP-bound state, 
Ras binds several effector proteins, initiating biological outcomes including cellular 
proliferation, survival, differentiation and apoptosis. Most significantly as tied to its 
carcinogenesis, Ras mediates signal transduction primarily via the BRaf-MEK-ERK and 
PI3K-AKT-mTOR pathways, each independently implicated in cancer.12,13  
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 Figure 1: Primary Ras signaling pathways involved in cancer. 
 Structurally, Ras proteins are comprised of two main peptide regions – the 
catalytic G-region (residues 1-166) and the hypervariable region (residues 167-188 or 
189) (Figure 2). This C-terminal hypervariable region is a non-conserved polypeptide 
portion linking the catalytic region of the protein to a lipidated tail for lipid-bilayer 
anchoring. This region terminates in a –CAAX motif (a four-residue sequence comprised 
of: Cys-Aliphatic-Aliphatic-Any Amino Acid) for recognition and post-translational 
modification. Variation within this region is responsible for the differential localization 
and processing of Ras isoforms within the cell.14,15 Within the G-region of Ras, residues 
1-86 are entirely conserved across all Ras isoforms.16 The GTP-binding active site of Ras 
(and contact points for effector binding) consists of three main regions: 1) the P-loop, 
which binds to the β-phosphate of GTP, 2) the switch I domain, which binds the γ-
phosphate of GTP, 3) the switch II domain, which also binds the γ-phosphate of GTP, is 
Primary Ras Signaling Pathways:
Ras
GDP
Ras
GTP
EGF
Receptor
GEFs (eg. SOS)
GAPs
Ligand
Inactive Active
Raf
MEKPI3K
ERKPDK
Proliferation
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Grb2
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important for nucleoside recognition, and contains Gln61 as a critical catalytic residue for 
GTP hydrolysis.17,18 Conformational changes in the Switch I and II regions largely 
control the “on” and “off” states of Ras signaling. Although several sequence mutations 
are tolerated with regard to Ras function, specific single point mutations are remarkably 
capable of transforming proto-oncogenic Ras into a constitutively active oncogenic form 
by obstructing effector binding and by reducing intrinsic GTPase activity.19-22 Mutations 
at Gly12 or Gly13 within the P-loop sterically impede GAP interactions for GTP 
hydrolysis, therefore locking Ras in a GTP-bound “on” state.23 Additionally, Gln61 in the 
switch II region is important for coordination of a water molecule in GTP hydrolysis, and 
mutation of this residue can also lead to cancer development.24 
 
Figure 2: Primary structure of KRas-4B with highlighted key structural regions 
 
Strategies for Targeting Ras 
 The direct inhibition of Ras is a logical approach to targeting Ras-driven cancers. 
However, most approaches report only limited success. Figure 3 highlights general 
strategies for targeting Ras signaling.25,26 These strategies include:  1) direct inhibition of 
RasGTP binding to its effectors, 2) prevention of RasGTP formation by inhibiting Ras-
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GEF interactions or by stabilizing RasGDP. For clarity, this thesis only highlights 
approaches for the direct targeting of Ras. However, significant research centered on 
indirect targeting of Ras by inhibiting upstream or downstream kinase pathways is 
equally important but will not be discussed here in detail. These strategies are 
complicated, as inhibition of downstream targets results in a variety of negative feedback 
loops, which can cause paradoxical activation of Ras pathways, and inhibition of 
upstream targets such as the EGFR often lead to resistance.27,28 Additionally, particular 
effort has focused on the inhibition of Ras post-translational modification pathways to 
prevent anchoring of the protein at the cellular lipid bilayer, largely through the 
development of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase 1 
inhibitors (GGTIs) among others.29 Unfortunately, despite promising preclinical data 
surrounding FTIs, this strategy has generally proven futile in clinical trials with regard to 
KRas-driven cancers.30 Other promising strategies in cancer treatment, such as synthetic 
lethal screening, may hold promise for treating Ras-driven cancers, but successes in this 
area have not been realized.31  
 
Figure 3: Therapeutic strategies for targeting Ras-driven cancers 
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 Direct targeting of Ras using small molecules is particularly challenging. The 
primary reason for this is the lack of known or available hydrophobic binding pockets 
within the protein structure, with the exception being the GTP-binding active site. 
Unfortunately, targeting of the active site of Ras is largely futile, due to the unyielding 
affinity of Ras for its nucleotide substrate (picomolar range) and the high concentration 
of GTP within cells. Ras binding with GEFs or effectors are also governed by large 
protein-protein interactions (PPIs), targeting of which via a small molecule approach is 
difficult.32,33 In recent years, advances in methods such as fragment-based drug screening 
and in silico methods have enabled identification of shallow binding pockets and small 
molecules that disrupt these PPIs.25 Despite these developments, the majority of 
identified small molecules lack the potency required for clinical application.34 
Highlighted in Figure 4 are representative examples of these identified small molecules 
and their general mechanisms.35-38 In a most-promising strategy, work by the Shokat and 
Gray labs in 2013 identified small molecules that covalently target cysteine in mutant 
KRas(G12C) (5 and 6).39,40 Although the KRas(G12C) mutant represents a small 
percentage of all KRas-driven cancers, this mutation is found in a relatively high 
percentage of lung cancers (7% of lung cancers; 40% of KRas-driven lung cancers), 
rendering it a therapeutically relevant mutation. In the case of Shokat’s inhibitor (5), the 
molecule occupies a previously unidentified allosteric binding pocket, blocking effector 
binding, and structurally favoring GDP over GTP binding. On the other hand, 
electrophilic GDP analog 6 covalently binds to KRas(G12C) and occupies the active site, 
favoring the GDP-bound “off” conformation. 
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 Figure 4: Representative small molecules that target Ras. (A) Ras-GEF inhibitors. (B) 
Ras-Raf inhibitors. (C) Electrophilic covalent inhibitors of KRas(G12C) 
 
Aside from small molecules, peptides have shown promise in the direct targeting 
of PPIs, including those associated with Ras biology.41 Of particular significance, 
constrained α-helical peptides represent a promising class of cell-penetrating modulators 
of PPIs with improved bioavailability over unconstrained peptides, and have been 
recently developed in the context of Ras biochemistry (Figure 5). In 2011, a 
collaborative venture between the Arora and Bar-Sagi labs identified a cell-penetrant 16-
mer α-helical peptide based on the structure of the SOS αH helix (7). This constrained 
peptide, designed using hydrogen bond surrogate (HBS) tethering, directly inhibits the 
SOS-Ras interaction.42,43 It was demonstrated that inhibition by this peptide decreases 
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levels of RasGTP upon EGFR activation, and attenuates Ras signaling as marked by 
decreased phosphorylation levels of downstream ERK. In 2015, Walensky and co-
workers at the Dana-Farber Cancer Institute identified a cell-penetrating hydrocarbon 
stapled peptide based on a similar sequence, but with improved binding affinity (8).44,45 
Moreover, this peptide was shown to impair the viability of several cancer cell lines 
containing oncogenic mutations at Gly12, Gly13, and Gln61. 
 
Figure 5: Synthetic α-helical peptide inhibitors of Ras-SOS interactions. 
 
Our Approach Toward Targeting Ras: Mirror Image Yeast Surface Display (YSD) 
to Identify all-D Amino Acid Peptide Inhibitors of Oncogenic Ras 
 
Recently, Verdine and co-workers developed a class of miniproteins that bind to 
the Ras effector domain with high affinity and inhibit Ras-effector interactions.46 These 
peptides were discovered by screening unbiased combinatorial libraries with yeast 
surface display (YSD), demonstrating that it is possible to identify high-affinity Ras 
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ligands from naïve libraries.47 With these results in mind, we wondered if mirror-image 
YSD could be used to identify high-affinity Ras binders composed of all D-amino acids.48 
Unnatural, D-residue peptides have been shown to garner augmented bioavailability over 
their L-residue peptide counterparts and may be less prone to eliciting an immune 
response.49 Mirror-image display has successfully afforded useful peptide ligands in the 
context of various disease types, including HIV/AIDS, Alzheimers’ Disease, and cancer. 
Figure 6 highlights the basic principles of mirror image display. Crucial to this method is 
the chemical synthesis of an all-D amino acid form of the protein target of interest. The 
power of combinatorial biological expression libraries, capable of expressing up to 1013 
different polypeptides, can then be exploited by screening against the all-D protein. Upon 
selection and structure determination of ligands, the all-D amino acid form of the ligand 
can be prepared to bind the biological target interest.  
 
Figure 6: Principle concepts behind mirror-image yeast surface display (YSD) 
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In a related example, Lu and co-workers utilized mirror-image phage display to 
identify all-D dodecapeptide inhibitors of the p53-MDM2 interaction.50,51 Notably, 
MDM2 is an intracellular target and serves as a negative regulator of the tumor-
suppressor protein, p53. Overexpression of MDM2 is implied in cancers, and p53 
inhibition by MDM2 disrupts its regulatory biological functions in the cell cycle and 
prevention of tumor growth. For use in mirror image phage display, all-D MDM2[25-
109]  was prepared using a combination of solid-phase peptide synthesis (SPPS) and 
Native Chemical Ligation (NCL) strategies. The researchers identified several α-helical 
all-D amino acid sequences that bind to the p53-binding domain of MDM2. The most 
potent sequence identified from their libraries, DPMI-γ (sequence: H-
DWWPLAFEALLR-NH2, consisting of all-D residues), competes with p53[15-29] 
binding to MDM2 with a Kd value of 53 ± 6 nM. Subsequent structural optimization of 
sequences found through this method yielded even more potent binders with sub-
nanomolar affinity.52  
The intracellular nature of regulatory protein inhibition presents a separate 
challenge for peptide-based therapies, which are frequently unable to traverse the cellular 
membrane. Despite potent binding affinity, DPMI-γ is incapable of passing through the 
lipid bilayer. However, the authors were successful in delivering the peptide into cells 
and observing cytotoxicity by encapsulation of the D-peptide within liposomes. In vivo 
experiments resulted in inhibition of glioblastoma tumor growth in mouse models. 
Additionally, Pentelute and co-workers demonstrated that these D-peptides can also be 
delivered intracellularly by utilizing proteins derived from Bacillus anthracis involved in 
transport of Anthrax toxins into cells. Conjugation of an MDM2-p53 inhibitor to the 
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lethal factor (LF) of anthrax toxin enables transport across the cell membrane.53 Although 
intracellular delivery of peptide therapeutics remains a global challenge, these results 
highlight that D-peptides have potential as therapeutics, and novel technologies for their 
delivery are becoming available. 
 
Methods for the Synthesis of Large Polypeptides and Proteins 
Critical to our strategy for targeting KRas is the total chemical protein synthesis 
and proper folding of an all-D residue protein variant. Since a seminal report by R. Bruce 
Merrifield in 1963, solid-phase peptide synthesis (SPPS) has become state of the art for 
peptide and protein synthesis – a development for which Merrifield was awarded the 
Nobel Prize in 1984.54 The development of SPPS was groundbreaking, enabling the use 
of excess reagents and a single reaction flask to achieve high yielding syntheses of 
polypeptides and proteins previously unattainable by classical solution-based methods.55 
Modern SPPS is a general and efficient means to generate peptide fragments up to 
approximately 40-60 amino acids, with sequence-specific determination of the overall 
efficiency.56 The advent of powerful methods for the synthesis of longer peptide 
sequences via ligation strategies further enables our ability to address biological 
questions. Most notably, the development of Native Chemical Ligation (NCL) by Kent 
and co-workers in 1994 has enabled the synthesis of functional proteins well beyond 
lengths attainable by SPPS.57 Scheme 1A highlights the principle of the NCL reaction 
between two appropriate peptide partners. The reaction proceeds through an initial 
reversible transthioesterification reaction between a C-terminal thioester (9) and an N-
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terminal cysteine residue (10). The intermediary ligated thioester (11) subsequently 
undergoes S ! N acyl transfer to irreversibly form the native peptide bond (12).  
Due to the relative scarcity of cysteine within proteins, our laboratory and others 
have worked to extend the utility of NCL. In the first permutations of alternative 
solutions, a non-natural Cys residue can be introduced, and subsequently desulfurized 
post-ligation to provide a native Ala residue (Scheme 1B). Dawson and co-workers 
demonstrated that following NCL at a non-native cysteine residue as the nucleophilic 
peptide reactant, the β-thiol can be desulfurized through the action of Pd/Al2O3 or Raney 
nickel, yielding an alanine residue.58,59 In 2007, our laboratory demonstrated that 
desulfurization can be accomplished under free radical conditions, utilizing VA-044 or 
V-50 as radical initiators at ambient or slightly elevated temperatures in the presence of 
tris(2-carboxyethyl)phosphine (TCEP) and a thiol co-catalyst (2-methyl-2-
propanethiol).60 Moreover, these conditions innocuous to sensitive residues, such as 
methionine, which are incompatible with previously reported methods. Our metal-free 
desulfurization (MFD) method has evolved since these initial reports to include many 
other amino acids bearing a β-thiol moiety, extending the utility and number of 
disconnection sites available for NCL.61 
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 Scheme 1: (A) Native Chemical Ligation (NCL) and (B) desulfurization of NCL 
products 
 
 Aside from NCL-based approaches reliant on an initial transthioesterification 
step, it is instructive to feature other methods for solution-phase peptide ligation that are 
independent of cysteine. Figure 7 highlights representative examples of such 
transformations. Bode and co-workers developed a chemoselective reaction between a C-
terminal ketoacid and N-terminal hydroxylamine or hydroxylamine derivative.62 This 
ketoacid-hydroxylamine transformation (termed KAHA ligation) takes place through the 
intermediacy of an oxime, followed by loss of CO2 and H2O to yield the desired amide 
bond. Highlighted is the chemoselective ligation between 15 and 16 in the synthesis of 
GLP-1[7-36] 17, along with a small amount of epimer at Glu21.63 Another well-applied 
method for the synthesis of long polypeptide chains is the “thioester method,” entailing 
the Ag(I)-mediated activation of C-terminal alkyl thioesters in the presence of any N-
terminal nucleophile, requiring only partial protection of Lys and Cys residues.64 One 
example is showcased in the synthesis of the 90-residue HU-type DNA binding protein 
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(HBs, 20). With the N-terminus of 18 as well as the 12 additional Lys residues within 18 
and 19 orthogonally protected with tert-butyloxycarbonyl (Boc) groups, these peptides 
underwent ligation in the presence of AgNO3 and N-hydroxysuccinimide (HOSu) to yield 
HBs[1-90] 20 in 33% yield after deprotection.65 In an impressive feat, this method was 
later applied in the synthesis of a 141-residue glycopeptide containing 6 tandem repeats 
of a highly glycosylated MUC2 fragment (not shown).66 A complementary approach 
developed by our laboratory involved the chemoselective amide bond formation between 
an ortho-disulfide phenolic ester 21 and the N-terminus of a second peptide fragment 22 
under reducing conditions to form glycopeptide 23.67 Notably, the alkyl thioester survives 
this transformation, and the ligated glycopeptide 23 could then be applied in a second 
Ag(I)-mediated fragment coupling. Sparsely applied for peptides, but mechanistically 
unique is the Staudinger-type ligation described by Raines and co-workers.68 Reaction of 
an (ortho-phosphino)arylthioester (24) with an azide nucleophile (25) generates 
iminophosphorane intermediate 26, which undergoes S ! N acyl transfer and hydrolysis 
of the phosphorus-nitrogen bond to generate peptide 27.   
105
 Figure 7: Alternative peptide ligation methods independent of cysteine 
In addition to the above described methods for cysteine-free direct amide-bond 
formation of fully deprotected or minimally protected peptides, a number of strategies to 
facilitate peptide ligation were developed based on temporal auxiliaries either on the N-
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terminal or C-terminal reacting partner with designed functionality for favorable post-
ligation cleavage (Figure 8). One such example is the ligation between 28 and 29 
through the assistance of a mercaptoarene auxiliary on the nucleophilic fragment.69 Upon 
reduction with TCEP, 28 undergoes ortho-mercaptoaryl ester rearrangement (OMER), 
followed by transthioesterification with 29, and lastly S ! N acyl transfer to yield the 
desired glycopeptide 30. This auxiliary was later removed in a 2-step sequence, involving 
S-methylation of the auxiliary followed by deprotection under acidic conditions (not 
shown). To highlight one example of an electrophilic auxiliary, Li and co-workers 
described an auxiliary based on a salicylaldehyde ester that will undergo chemoselective 
ligation with N-terminal serine or threonine residues.71 This work is based on previous 
work by Tam and co-workers, which demonstrated a similar ligation at Ser, Thr and Cys, 
but without successful auxiliary removal.72 Shown in Figure 8 is the application of this 
method to a synthesis of human erythrocyte acylphosphatase. The reaction between 31 
and 32 proceeds via aldehyde capture to form an N,O-benzylidine acetal intermediate 
(not shown), which undergoes O ! N acyl transfer to generate pseudoproline 33. 
Removal of the auxiliary could then be effected through treatment with TFA to generate 
the native amide bond (not shown). 
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 Figure 8: Auxiliary-based cysteine-free ligations 
 
Chemoselective Reactions of Isonitriles with Thiocarboxylic Acids: Application to 
Peptide and Protein Synthesis 
 
Our laboratory has a long-standing interest in the utility of isonitriles in organic 
synthesis, particularly as a powerful tool for amide bond synthesis. My work builds upon 
years of studies that has allowed us to explore isonitrile mediated activation of thioacids 
for medium- and large peptide ligations. In this thesis, our work in the context of 
polypeptide synthesis is briefly highlighted. Scheme 2 shows the reactivity differences of 
carboxylic acids (34) compared to thiocarboxylic acids (40) when treated with an 
isonitrile (35). Under thermal conditions, carboxylic acids undergo activation with 
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isonitriles to generate a presumed formimidate carboxylate mixed anhydride (FCMA, 36) 
intermediate. Depending on the steric nature of R2 on the isonitrile and the presence of an 
exogenous nucleophile, such as an amine, alcohol, or HOBt, 36 can either undergo 
acylation with a nucleophile to generate 37, or alternatively can undergo 1,3-O ! N acyl 
transfer to produce N-formylamide 39.72,73 Intriguingly thiocarboxylic acids were found 
to produce presumed thio-FCMA (41) intermediates at ambient temperature, which 
undergo similar reactivity.74,75  
In an application to peptide synthesis, our laboratory demonstrated that amino 
acid thiocarboxylic acids can undergo efficient amide coupling at room temperature. 
Adamantyl or tert-butyl isocyanides were used as bulky, hindered isonitriles to prevent 
undesired rearrangements (i.e. S ! N intramolecular shift, see Scheme 2). This strategy 
was applied in a total synthesis of oxytocin 50 (Scheme 3) using iterative isonitrile 
coupling/deprotection reactions in the C ! N direction.76 It should be mentioned that in 
addition to amide bond synthesis via isonitrile activation of thiocarboxylic acid reactants, 
thioacids have previously been utilized as precursors to amides through other reactivity 
modes with coupling partners such as isocyanates, azides, and sulfonamides.77,78,79 We 
have also demonstrated the utility of amino acid isonitriles in the synthesis of N-
methylated peptides (Scheme 4). One example is the coupling of leucine thioacid 51 with 
valine isocyanide 52 en route to cyclosporine A.80 Reduction of the intermediary N-
thioformyl dipeptide 53 yielded N-methylated dipeptide 54 in 62% overall yield. 
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 Scheme 2: Reactivity of carboxylic acids and thiocarboxylic acids with isonitriles 
 
Scheme 3: Application of iterative isonitrile-activated coupling of thiocarboxylic acids to 
a total synthesis of oxytocin (50) 
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 Scheme 4: Synthesis of N-methylated peptides through the means of amino acid 
isonitriles en route to cyclosporine A. 
 
The capacity to chemoselectively activate thiocarboxylic acids under ambient 
conditions opens the door for the ligation of peptides with minimally protected side-
chains. Indeed, we previously demonstrated that thioacids are also activated under 
oxidative, yet mild, conditions promoted by reactions in DMSO open to air (Figure 
9A).81 Oxidative activation of thioacid 55 in the presence of HOBt yielded ligation 
product 57 in 82% yield. In an impressive realization of isonitrile-mediated peptide 
ligation, our laboratory recently demonstrated the coupling of two large peptide 
fragments via activation of C-terminal thioacid 58 and nucleophilic capture with 59 to 
generate a 101-amino acid sequence 60 after Fmoc removal en route toward granulocyte-
colony stimulating factor (G-CSF).81 Although this fragment was obtained in low yield, it 
is noteworthy that a more conventional approach for assembly via NCL-MFD at an 
“alanine disconnection” failed to deliver the putative sequence. Currently we are studying 
the further utility of this method for medium- and large peptide ligations at non-
epimerizable residues Gly and Pro. Fortunately, both glycine and proline are relatively 
abundant amino acids, and such disconnections aid in the complementarity of this 
approach to NCL.  
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 Figure 9: Peptide ligation of C-terminal thioacids (A) Oxidative peptide coupling of C-
terminal thiocarboxylic acids. (B) Isonitrile-mediated ligation en route toward G-CSF. 
 
Conclusion: 
With an understanding of the literature methods for peptide synthesis and previous 
approaches for targeting Ras, the following section will highlight our synthetic approach 
to KRas, in which we are targeting a commonly mutated G12V oncogenic isoform. 
Subsequent biochemical experiments seek to establish the proper folding of Ras in a 
GTP-bound state, for which GppNHp will be utilized as a non-hydrolyzable GTP analog. 
Although the synthesis of wt HRas was previously described, our synthetic approach 
towards this target is distinct. Moreover, synthesis of an all-D variant and folding of the 
mirror-image protein with a mirror-image nucleotide substrate has never been 
demonstrated. These synthetic studies and subsequent mirror image YSD experiments 
will seek to identify new, all-D amino acid residue peptides to target Ras-GTP and block 
effector interactions. 
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Chapter 4: Total Chemical Synthesis and Folding of All-L and All-D KRas(G12V) 
 
Retrosynthesis of KRas(G12V)[1-166]: 
Our goal is to identify all-D peptide inhibitors of oncogenic KRas using mirror-
image yeast surface display (YSD). Critical to this aim is completion of a total synthesis 
of the target protein using all-D amino acid residues. Highlighted in Figure 1 is the 
primary structure of the KRas G-region, consisting of 166 amino acid residues. We are 
targeting a G12V mutant commonly associated with various cancers. In our study, we 
opted to not include the hypervariable region (HVR) as it is not critical for GTPase 
activity and effector binding.1 However, it has been recently hypothesized that the HVR 
of KRas-4B may play a more complex role in its higher association with human cancers 
than other isoforms due to its ability to bind calmodulin.2,3 It has also been recently 
suggested that the HVR of KRas-4B may in fact play a more important structural role in 
Ras-effector binding events than previously thought.4,5 
In a retrosynthetic fashion, we proposed that the G-region of KRas could be 
dissected into five simpler peptidyl sequences obtained through Fmoc-based SPPS. 
Utilization of the native cysteine residues within the full sequence reduces the synthetic 
challenge to three NCLs at Cys51, Cys80, and Cys118. We found the synthesis of 
KRas[118-166] entirely by SPPS to be possible, but inefficient, with poor isolated 
recovery of the desired peptide. Therefore, this 49-residue sequence was further 
dissected to enable its efficient preparation. In the absence of available cysteine residues 
within KRas[118-166] for NCL, two alternative disconnection strategies were 
hypothesized. One potential option would entail disconnection between Ser145-Ala146, 
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in which a non-native Cys146 residue would be utilized for NCL followed by MFD 
(Cys146 ! Ala146) to yield the native sequence.6 Alternatively, the chemoselective 
isonitrile-mediated activation of C-terminal thiocarboxylic acids represents a 
complementary ligation strategy that does not rely on cysteine. Given recent precedent 
from our laboratory, we hypothesized that a C-terminal thioacid at Gly138 could serve 
as a potential disconnection site.7 Here, Gly138 was chosen as a median residue site and 
selected as an ideal acyl donor that cannot epimerize upon activation. Due to associated 
sequence-specific challenges, this retrosynthetic disconnection would provide a 
worthwhile opportunity to further demonstrate the potential of this ligation strategy. 
Notably, this ligation (Gly138-Ile139) would require the efficient bimolecular reaction 
of a hindered β-branched nucleophile at Ile139. Additionally, this strategy would 
require efficient orthogonal protection and deprotection of side-chain nucleophiles at 
Lys128, Lys147, and Lys165.  
 
Figure 1: Retrosynthetic disconnection sites toward KRas(G12V) [1-166]  
 Shown in Scheme 1 is our first generation approach towards KRas(G12V)[1-
166]. Projected steps would include a kinetically controlled NCL between arylthioester 
2 and alkyl thioester 3 would provide KRas[51-117].8 Coupling of KRas[118-138] (4) 
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and KRas[139-166] (5) would be accomplished using an isonitrile-mediated ligation, or 
alternatively assembled via NCL-MFD as described. The merger of KRas[51-117] with 
KRas[118-166] by NCL followed by removal of the N-terminal thiazolidine (Thz) 
protecting group would then yield KRas[51-166].9 Finally, NCL of KRas[1-50] (1) with 
KRas[51-166] would yield the desired sequence. This strategy was designed with the 
intention of synthesizing a variety of oncogenic mutated KRas isoforms, with mutations 
commonly at Gly12 or Gly13 within the P-loop. Therefore, sequence mutants of 
KRas[1-50] could be quickly synthesized and convergently ligated to KRas[51-166] in 
a final step. 
 
Scheme 1: First generation approach toward KRas(G12V) 
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Synthesis of KRas(G12V)[1-166] 
In the forward direction, the synthesis of KRas[118-166] was indeed 
accomplished utilizing an isonitrile-mediated ligation approach (Scheme 2). For 
controlled ligation between 4 and 5, orthogonal protection of the three Lys side-chain ε-
amines as well as the C-terminal Cys β-thiol group were necessary. Lys side-chains 
were protected as allyloxycarbamates (Alloc). Cys118 was orthogonally protected as a 
tert-butyl disulfide. The C-terminal thioacid was synthesized by Sakakibara C-terminal 
elongation of fully protected peptide 7, utilizing H-Gly-STmob (8).10 Upon acid 
mediated global side-chain deprotection, the C-terminal thioacid is unveiled to yield 4 
in 26% yield. Upon activation with tert-butyl isocyanide in the presence of HOBt, 4 and 
5 undergo coupling to efficiently generate the Alloc-protected ligation product. It was 
found that the direct addition of piperidine effects N-terminal Fmoc removal in the same 
reaction pot. This crude intermediate could be utilized in a subsequent Alloc-removal 
step under reductive conditions (Pd, PhSiH3). Final HPLC purification afforded the 
fully-deprotected fragment 10 in 56% yield.  
 
 
 
Scheme 2: Synthesis of KRas[118-166] (10) via isonitrile-mediated activation of 4. 
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With an efficient synthesis of KRas[118-166] 10 at hand, we turned our attention to 
completion of the full length sequence. Aryl thioester KRas[51-79] 2 and alkyl thioester 
KRas [80-117] 3 were ligated under kinetically-controlled NCL conditions to 
selectively deliver 11 in 27% yield. This sequence was subjected to ligation with 
KRas[118-166] (10) via NCL, followed by in situ removal of the N-terminal Thz 
protecting group upon the addition of methoxylamine hydrochloride. This two-step one 
pot process provided 12 isolated in 46% yield. 
 
Scheme 3: Synthesis of KRas[51-166] (12) 
 
With 12 in hand, we attempted ligations with KRas[1-50] (1). We found the 
synthesis and handling of this sequence to be extremely difficult, likely due to the 
hydrophobic nature of the N-terminal sequence. Full-length Ras is known to be 
hydrophobic and insoluble, especially in the absence of a bound nucleotide substrate.11 
Becker and co-workers completed a synthesis of HRas via the ligation of HRas[1-50] 
with HRas[51-166].12 However, they note similar solubility problems and required an 
amphiphilic detergent additive in this ligation. Moreover, the final protein was obtained 
with a loss of 18 Da, suggesting an unassigned dehydration or deamination took place 
during the ligation or during purification. In our hands, synthesis of 1 was greatly aided 
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by strategic placement of acid labile 2-hydroxy-4-methoxybenzyl (Hmb) groups 
incorporated within the amide backbone.13 Installation of a tertiary amide within 
peptides is known to disrupt secondary structure and minimize aggregation. This in turn 
improves SPPS efficiency and augments the solubility of difficult sequences.14,15,16 By 
conventional design, the Hmb group can also be rendered temporarily acid-stable if the 
phenol moiety is acylated. We found that Hmb groups improved synthesis of 1, which 
had relatively high solubility in guanidine buffer and could be directly applied in NCL 
with 12 without the need for solubilizing agents. Furthermore, the ligation product 13 
could be deprotected upon treatment with TFA/H2O without dehydration. However, the 
yield and ease of purification for this NCL was difficult to consistently reproduce. The 
reason for this inconsistency is still unclear. We noted that different batches of peptide 1 
tended to undergo NCL with varying efficiency. In some cases, aggregated peptide 
would precipitate from the ligation mixture, wherein the desired protein could not be 
recovered.  Moreover, in successful cases, HPLC separation of product from unreacted 
starting materials was difficult, as their HPLC retention times are coincident.  
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 Scheme 4: Capricious NCL between 1 and 12 followed by Hmb removal 
 
In an effort to improve the reproducibility of our synthetic route, it was 
hypothesized that altering the ligation order of events to give full-length protein may 
address solubility and purification issues (Scheme 5). Perhaps by initially ligating 
KRas[1-50] (14) with KRas[51-79] (15), issues in aggregation previously observed 
could be attenuated in the final steps. This strategy would require only slight 
modifications in N-terminal protecting groups and C-terminal thioesters. Indeed, 14 
successfully underwent kinetic chemical ligation with 15 to afford KRas[1-79] 16 in 
36% isolated yield. NCL between 17 and 10 proceeded smoothly, yielding KRas[80-
166] 18 in 56% yield after Thz removal. Finally, NCL at this new disconnection point 
between Leu79 and Cys80 proceeded to yield the full-length sequence. Following 
treatment with TFA/H2O, 13 was obtained in 19% yield over 2 steps. Moreover, 
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unreacted starting materials 16 and 18 are easily separated by HPLC purification, with 
greatly different retention times from the full-length sequence.  
 
Scheme 5: Revised successful synthetic route towards KRas(G12V) [1-166] (13) 
 
Figure 2: (A) High resolution mass spectrum of Hmb-protected KRas[1-166]; (B) ESI-
(+)-MS of deprotected KRas[1-166] (13) 
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Application of Optimized Synthetic Route to the Synthesis of a Biotinylated 
KRas(G12V) Variant 
 
 
With a reproducible synthetic route at hand, this chemistry was replicated to 
incorporate a biochemical label within KRas(G12V). We chose to label the C-terminus 
of the peptide, because it is furthest from nucleotide and effector binding sites. Two 
new C-terminal fragments, 19 and 22, were synthesized by SPPS using an Fmoc-PEG 
Biotin NovaTag™ resin. These two fragments were then applied in a comparative 
synthesis of biotin-labeled KRas[118-166], featuring two projected synthetic routes 
utilizing chemistry developed in our laboratory (Scheme 6). In one permutation of our 
synthesis, 19 efficiently underwent isonitrile-mediated ligation with 4 similarly as 
previously described. Shown in Figure 3 is characterization of each step in this 
sequence by UPLC. After 44 hours of reaction (Figure 3A), only a trace amount of 
nucleophilic peptide fragment 19 remains. Upon addition of piperidine (Figure 3B), 
Fmoc removal is efficient. Interestingly, in addition to observed hydrolysis at the C-
terminus of KRas[118-138], the reaction of the C-terminus with piperidine was also 
observed, yielding the corresponding C-terminal amide. This result suggests that even 
after 44 hours, there is still active acyl donor present in the reaction mixture. Finally, 
after Alloc removal, purified 21 (Figure 3D) is obtained in 56% isolated yield over the 
3-step sequence.  
We compared this route to a more conventional NCL-MFD strategy. Utilizing a 
non-native C146 residue, 22 underwent NCL with thioester 23 as anticipated to yield 24 
in 82% isolated yield. This fragment was subjected to radical dethiylation upon 
treatment with VA-044, TCEP, and tert-butylthiol with high effiency at room 
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temperature. Finally, Acm removal upon treatment with AgOAc provided the analogous 
fragment KRas[118-166] (25). Overall, this 3-step sequence afforded 25 in 57% yield. 
The comparable ease of reaction setup in each study suggests that in certain cases, 
isonitrile-mediated ligations at C-terminal Gly thioacids can also provide facile access 
to large peptides. This method should be considered as a complementary strategy to 
NCL-MFD, and as an alternative option especially for hydrophobic sequences lacking 
available or median cysteine residues. Moreover, although both of these synthetic 
strategies require multi-step assembly and deprotection, we contend that the isonitrile-
mediated ligation approach may be preferable due to intermediary purification ease in 
cases where the overall yields are similar – requiring only precipitation upon addition of 
diethyl ether with no desalting or HPLC necessary to isolate intermediates. 
 
Scheme 6: Comparative syntheses of biotinylated KRas[118-166] using isonitrile-
mediated ligation or NCL-MFD strategies. 
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 Figure 3: UPLC traces for the isonitrile-mediated coupling sequence between 19 and 4. 
(A) Isonitrile-mediated ligation (t = 44 hr); (B) Fmoc removal upon addition of 
piperidine (t = 30 min; *denotes non-peptidyl UV peak, which disappears after ether 
precipitation, and is assumed to be derived from piperidine or Fmoc); (C) Crude alloc 
removal; (D) Purified KRas[118-166] (21). 
 
Completion of biotinylated KRas(G12V) was achieved as outlined in Scheme 7. 
Peptides 17 and 21 underwent NCL as anticipated, followed by Thz removal to afford 
26 in 63% isolated yield. Finally, NCL with KRas[1-79] (16) efficiently afforded the 
desired Hmb-derived full-length sequence, with full consumption of 16 observed within 
6-8 hours at neutral pH. Moreover, it was found that the ligation product (27) could be 
nearly entirely recovered by exploiting solubility differences between 26 and 27. Upon 
dilution of the NCL with H2O, 26 remains entirely dissolved while the hydrophobic 
ligation product 27 precipitates and can be collected by centrifugation (Figure 4). 
Exposure of the resulting precipitate to Cocktail R effects quantitative Hmb removal 
with suppression of methionine oxidation to afford biotinylated KRas(G12V)[1-166] in 
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21% yield over the entire sequence. Considering reactants fully converge to the desired 
product during each step in this sequence, the relatively low yield is largely attributed to 
the hydrophobic nature of full-length KRas, which complicates solubility during 
purification.  
 
Scheme 7: Synthesis of biotinylated KRas(G12V)[1-166] (28) 
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Figure 4: (A) NCL between 16 and 26 (t = 2 hr). * denotes absorption peak from 
MPAA (B) Isolated 27 from H2O dilution of the NCL (after completion, t ~ 6.5 hr) (C) 
Supernatant from H2O dilution, containing excess 27. Only trace 16 remains solubilized 
in the supernatant. (D) High resolution mass spectrum of deprotected 28 following 
treatment with Cocktail R. 
 
With all-L and all-D variants of biotinylated KRas(G12V) in hand using the 
route described in Scheme 7, we sought to establish the biochemical competency of this 
enantiomeric pair of proteins in collaboration with the laboratory of Gregory Verdine at 
Harvard University. Folding conditions for the all-D protein were established using the 
mirror-image L-nucleotide as substrate, synthesized according to literature protocols. 
Highlighted in Scheme 8 is our synthetic route towards L-GppNHp as a non-
hydrolyzable GTP analog. Starting with L-ribose (29), treatment with methanol under 
acidic conditions generated kinetically-favored methyl glycoside 30. Subsequent 
acetylation and exchange of the methyl glycoside for acetate afforded L-ribose 
pentaacetate 31 in 87% yield over the entire sequence.17 Regio- and stereoselective 
glycosylation with protected guanine derivative 32 afforded protected guanosine 33.18 
Upon global deprotection with ammonia, L-Guanosine was subjected to regioselective 
phosphorylation using Nishizawa’s conditions to afford the corresponding 5’-
monophosphate (34).19 Finally, utilizing a procedure described by Yount entailing 
activation of the monophosphate with diphenylphosphoryl chloride, followed by 
displacement with tributylammonium imidodiphosphate, 34 was converted to 
enantiomeric GppNHp 35 and isolated as the sodium salt.20 
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 Scheme 8: Synthesis of L-GppNHp (35). 
 
 We adopted a previously reported refolding protocol, which entailed 
solubilization of the proteins in guanidine buffer and rapid refolding into denaturant-
free buffer, yielding monomeric proteins with moderate efficiency.12,21 Analytical gel 
filtration shows an initial eluting peak assigned as aggregate, with a second peak eluting 
with similar retention time as the standard recombinant KRas(G12V) (Figure 5). 
Monomeric proteins could be isolated by gel filtration with greater than 90% purity, and 
CD analysis of the folded proteins closely matched that of recombinant KRas. All-D 
residue KRas(G12V) properly bears opposite signal to that of synthetic and 
recombinant L-residue KRas(G12V). Comparison of A260/A280 values showed an 
increase from 0.6-0.7 for the unfolded to 1.0-1.1 for the recombinant and folded 
proteins, consistent with association with guanine nucleotides, which possess an 
absorption maximum at 252 nm.22  
 To further probe the nucleotide-binding of our synthetic proteins, we refolded 
both in the presence of fluorescent mant-GppNHp ((2’/3’)-O-(N-
O
OHHO
OH
OH
MeOH
Dowex (H+)
O
OHHO
OMe
OH
1. Ac2O, pyridine
2. H2SO4
    AcOH, Ac2O
    (87%, 3 steps)
O
OAcAcO
OAc
OAc
N
NN
N
OCONPh2
NAc
TMS TMSTMSOTf
PhMe, 80oC
(73%)
O
OAcAcO
OAc
N
N
N
N
OCONPh2
NHAc
1. NH3, MeOH (57%)
2. POCl3, H2O
    P(O)(OMe3), 0oC
    (57%)
O
OHHO
N
NH
N
N
O
NH2
ClP(O)(OPh)2, NBu3
then
OPO3H2
O
OHHO
N
NH
N
N
O
NH2
OP
O
O
OP
O
O
H
NP
O
O
HO
3 Na+ P2O6NH5.x NBu3(23%)
29 30 31
(32)
333435
133
methylanthaniloyl)guanosine-5’-O-[(β,γ)-imidotriphosphate]) analogs, which exhibit an 
increase in fluorescence upon binding to Ras. This fluorescence output phenomenon has 
been used to study Ras-ligand binding interactions.23 The enantiomeric pair of proteins 
folded with mant-GppNHp nucleotides of corresponding stereochemistry exhibited 
comparable nucleotide dissociation behavior relative to recombinant KRas. This is 
marked by a decrease in fluorescence upon the addition of excess unlabeled GppNHp of 
correlated stereochemistry (Figure 5D-F). Interestingly, preliminary experiments found 
that at high assay concentration of nucleotide, both synthetic all-D KRas(G12V) and 
recombinant KRas(G12V) underwent nucleotide exchange with either antipode of 
nucleotide. However, at lower concentration (10 µM nucleotide), good exchange 
selectivity was observed only for the nucleotide of correlated stereochemistry.  
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 Figure 5: Analysis of folded proteins (A) Crude and purified folded synthetic proteins; 
(B) CD analysis of folded synthetic proteins and recombinant KRas(G12V); (C) 
Comparative analysis of A260/A280 values for unfolded and folded synthetic proteins; 
(D) Nucleotide exchange assay for recombinant KRas(G12V); (E) Nucleotide exchange 
assay for synthetic L-KRas(G12V); (F) Nucleotide exchange assay for synthetic D-
KRas(G12V). 
 
 We also investigated the effect of adding different Ras-binding peptide ligands 
to our synthetic proteins. This included addition of the Ras-binding domain (RBD) of 
B-Raf, a Ras effector known to slow dissociation, as well as RDA44, a recently 
discovered Ras-binding miniprotein that stops nucleotide dissociation.24 RDA44 was 
added either as the all-L residue or all-D residue peptide. In the case of synthetic L-
KRas(G12V), the addition of the B-Raf RBD slowed dissociation in a similar manner to 
that observed with recombinant KRas(G12V). The addition of the B-Raf RBD had no 
observed effect on nucleotide dissociation from synthetic D-KRas(G12V). Similarly, 
addition of RDA44 (all L-amino acid residues) slowed nucleotide dissociation for 
A
B
C
D
E
F
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recombinant and synthetic L-KRas, with no effect observed on all D-residue KRas. 
Conversely, addition of an all D-residue version of RDA44 does indeed slow nucleotide 
dissociation for all-D KRas as anticipated and had no effect on recombinant or synthetic 
L-KRas. These results demonstrate that folding, nucleotide association, and peptide 
binding profiles of both mirror-images of synthetic KRas(G12V) resemble that of 
recombinant KRas(G12V) and exhibit the expected enantiodiscrimination. 
With the in vitro biochemical activity of our synthetic pair of enantiomeric 
proteins confirmed, future steps will be taken to utilize this material in the search for 
new cancer therapeutics. We anticipate that our synthetic folded protein will be a useful 
tool in mirror-image YSD for the discovery of new, all-D peptide inhibitors of Ras-
effector interactions. In preparation for these studies, over 5 mg (~260 nmol) of all-D 
residue KRas(G12V) was recently prepared through this method. Moreover, chemical 
protein synthesis enables site-specific modification of the target of interest, and our 
described synthetic route may enable library synthesis of oncogenic forms of all-D 
KRas for use in mirror-image YSD. 
 
Further Exploration of Isonitrile-Mediated Ligations: Application to a Total 
Chemical Synthesis of HIV-1 Protease 
 
The HIV-1 protease is an aspartyl protease enzyme essential for the proliferation of the 
HIV virus which causes AIDS.25 The protease serves to post-translationally process 
proteins critical to the HIV virus replication and structure, such as reverse transcriptase, 
integrase, and structural proteins that make up the viral coat and core. For these reasons, 
HIV-1 protease inhibitors are an important class of drugs in retroviral treatment.26 
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Structurally, the protease is a 21.4 kDa homodimeric protein, consisting of two 99-
residue monomeric polypeptides (Figure 6). HIV-1 protease and non-natural analogs 
thereof have been chemically synthesized through a variety of strategies. These include 
synthesis of its entire sequence by SPPS as well as modular syntheses via ligation 
strategies.27-34 A large body of early chemical synthesis, structural and biochemical 
studies on this enzyme were conducted in the Kent laboratory.  
One of the strategies targeting this protein relies on the use of NCL-
desulfurization to ligate smaller fragments synthesized by SPPS. Recently, Qi and co-
workers completed a synthesis of azide-labelled HIV-1 protease (I66A), such that an 
azide-alkyne cycloaddition could be utilized in later studies.35 Their preliminary 
strategy toward this goal of bioorthogonally-labeled HIV-1 protease (Scheme 9) relied 
on integration of an alkyne within the sequence via incorporation of Fmoc-
propargylglycine (Fmoc-Pra) replacing native Lys41. In this approach, the full-length 
protein was disconnected at Ala28 and Ala71, with projected NCLs at these positions 
followed by MFD (Cys ! Ala). A 16-residue polyarginine solubility tag containing a 
portion of immature HIV-1 protease, initially devised by Kent and co-workers, was 
appended at the C-terminus.32 This Arg-rich tag abrogates known aggregation within 
the C-terminal region of the protein and facilitates handling and purification. After 
assembly and folding, the protease is known to self-cleave this solubility tag through an 
autoprocessing mechanism to reveal the 99-residue protein as its active homodimer. 
This autoprocessing is mechanistically similar to maturation of HIV-1 protease in 
vivo.36 Despite successful NCL disconnections, the propargylglycine residue ultimately 
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proved unstable to free radical desulfurization, affording a covalent adduct with TCEP 
(41) under these conditions and barring the use of their NCL-desulfurization strategy. 
 
Figure 6: Primary sequence of HIV-1 Protease (I66A) and appended Arg-rich 
sequence. 
 
Scheme 9: Failed NCL-MFD approach towards alkynylated HIV-1 Protease 
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 With these results indicating that functionality such as alkynes and azides are 
incompatible with MFD, we wondered if a combined isonitrile-mediated ligation and 
NCL strategy could serve as a complementary approach toward the synthesis of HIV-1 
protease. The I66A mutation does not affect protease activity, and targeting an I66A 
mutant would reduce the steric impediment of an NCL at that disconnection site.35 
Shown in Scheme 10 is our projected synthesis toward this target.  
As in earlier examples of isonitrile-mediated ligation described for the synthesis 
of KRas[118-166], lysine residue side-chains will be orthogonally masked using Alloc 
groups, and cysteine will be incorporated as the tert-butyl disulfide. In this approach, 
HIV[1-66] (46) would be synthesized via the chemoselective isonitrile-mediated 
ligation between thioacid 42 and thioester 43. In particular, this disconnection would 
require the efficient removal of five Alloc-protected lysine sidechains in addition to the 
N-terminal Fmoc group. Moreover, this approach would require us to demonstrate the 
compatability of a C-terminal thioester on 43 − functionality that poses conceivable 
complications during each of the three steps in the ligation protocol. Separately, 
HIV[67-95] (44) would undergo isonitrile-mediated ligation with HIV[96-115] (45), 
which contains a polyarginine solubility tag, to generate 47. Peptides 46 and 47 would 
then be subjected to NCL conditions reliant on native Cys67 to generate the full-length 
sequence, HIV[1-115] (48). Finally, 48 would undergo autoproteolytic cleavage to 
remove the solubilizing polyarginine tag according to literature precedent to afford 
folded HIV protease [1-99] (49). Moreover, successful autoprocessing will serve to 
further demonstrate that isonitrile-mediated ligations can be used to produce 
catalytically active enzyme.  
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 Scheme 10: Proposed synthesis of HIV-1 Protease (I66A) using combined isonitrile-
mediated ligation and NCL strategies. 
 
 In practice, our devised synthetic scheme was successful. Thioacids 42 and 44 
could be accessed relatively easily through synthesis. However, difficulty in solubility 
of these partially protected peptides in aqueous solvents − likely due to loss of cationic 
charge as a result of amine protection − precluded isolation of large quantities of these 
materials. Nonetheless, 42 underwent isonitrile activation and chemoselective ligation 
with thioester 43 (Scheme 11). After 48 hours, the reaction was quenched upon the 
addition of a solution of DBU and DMF, which efficiently removed the N-terminal 
Fmoc group without affecting the C-terminal thioester. Finally, global removal of five 
Alloc-protected lysine sidechains was effected upon treatment of this crude intermediate 
with PdCl2(dppf) and PhSiH3 to afford deprotected ligation product 46 in 19-30% yield. 
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Again, the C-terminal thioester remained inert under these deprotection conditions, with 
no observed side reactions such as Fukuyama-type reduction of the alkyl thioester.37 
 
Scheme 11: Synthesis of HIV Protease (I66A) [1-66] via isonitrile-mediated ligation 
 
Figure 7: Characterization of isonitrile-mediated coupling sequence between 42 and 43 
(A) UPLC trace of crude Alloc removal step in the synthesis of 46; (B) UPLC trace of 
purified 46; (C) Integrated ESI-(+)-MS trace of 46. * Denotes associated TFA 
molecules. 
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 Completion of the synthesis of HIV-1 protease was accomplished through an 
isonitrile-mediated ligation between 44 and 45, providing 47 in 39% yield over the 
entire sequence (Scheme 12). With the two halves of the protease assembled via 
isonitrile-mediated ligation, we then took advantage of native Cys67 for NCL between 
46 and 47, providing the full-length 115-residue sequence 48 in 52% isolated yield. 
With realization of our combined strategy, we were able to verify that our strategy 
affords proper bond-disconnections and catalytically-active protein by applying a 
modified literature protocol for cleavage of the C-terminal polyarginine tag. This was 
accomplished by initial dissolution of 48 in guanidine buffer, followed by gradient 
dialysis at 4 oC into 25 mM NaOAc (pH = 5.5, containing 10% glycerol). After 10 
hours, only a trace amount of unfolded protein remained solubilized, with the major 
constituent corresponding to proteolysis between Phe99 and Pro100 (Figure 8). 
 
 
142
 Scheme 12: Completion of the synthesis of HIV-1 Protease and autoproteolytic 
cleavage upon folding. 
 
 
Figure 8: Folding of synthetic HIV-1 protease (A) UPLC trace of 48 (λ = 214 nm); (B) 
UPLC trace of folding solution (t = 9.5 hr, λ = 214 nm); (C) ESI-(+)-MS of purified 48; 
(D) Integrated ESI-(+)-MS of folded HIV-1 Protease (49). 
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Future Outlook: 
 The studies in this section highlight the potentially general utility of the 
isonitrile-mediated ligation in the synthesis of large polypeptides and proteins. 
Application of an isonitrile-based approach enabled a total chemical synthesis of 
KRas(G12V), which displayed biochemical viability and nucleotide binding. Moreover, 
a comparative analysis of this strategy with a more conventional NCL-MFD strategy in 
the synthesis of biotin-labeled KRas[118-166] gave similar overall yields for both three-
step sequences. We further demonstrated that this method, even without optimization, 
enabled completion of a total synthesis of HIV-1 Protease (I66A). Importantly, a C-
terminal alkyl thioester was compatible with our isonitrile-mediated ligation sequence, 
enabling a ligation sequence in the N to C direction. These results highlight that 
isonitrile-mediated peptide ligation should be considered by others in the field of 
chemical protein synthesis, especially in cases where NCL-MFD is inefficient or 
incompatible with specific functionality.  Moreover, in such an instance, this strategy 
can be viewed as an alternative to kinetically controlled NCL.8 
 One major limitation to our method thus far is the requirement for orthogonal 
amine protection of Lys residues and the N-terminus of the peptide fragments. 
Examples shown in this thesis have used orthogonal protection either in the form of 
Fmoc or Alloc protecting groups. Although we have demonstrated that even as many as 
five Alloc-protected amines can be globally deprotected, a major limitation is the 
hydrophobicity they impart on peptidyl fragments, complicating handling and 
purification. This is especially true for larger peptide fragments, which are often 
inherently hydrophobic. Nakahara and co-workers have previously described this issue 
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in the context of Ag(I)-mediated peptide thioester ligations, suggesting the use of Fmoc-
azidolysine as an orthogonally protected form of lysine, which can be converted to the 
native amine under reducing conditions.38 In our hands, incorporation of this residue 
within peptides yields even more hydrophobic sequences than Fmoc-Lys(Alloc)-OH.  
 One conceivable solution to this problem is to synthesize a novel protecting 
group, which retains the positive charge of Lys residues in the form of a non-
nucleophilc tertiary amine. Remarkably, only one example of this type of amino 
protection has been described in the context of peptide synthesis according to our 
knowledge, and has been used only sparsely in the literature not for the purpose of 
increasing peptide polarity.39 Figure 9 shows the structure of Fmoc-Lys(Pydec)-OH 
(52), which bears a carbamate protecting group conjugated to a 2-pyridyl disulfide 
moiety. This protecting group can be conveniently removed upon treatment with 
dithiothreitol or TCEP in aqueous buffer, or upon the action of ethanethiol and DBU in 
organic solvent. In our hands, incorporation of 52 does seem to afford sequences with 
improved polarity (marked by faster elution on reverse-phase HPLC). However, 
preliminary experiments revealed that Lys(Pydec) is unstable within thioacid-containing 
peptides. This is likely due to the highly activated nature of the pyridyl disulfide bond. 
It would also be preferable to use a more basic tertiary amine to maintain cationic 
charge. A few hypothetical examples of such charge-retaining protecting groups for 
lysine or N-terminal modification are shown in Figure 10, each bearing a tertiary amine 
and different linkers. Potential methods for cleavage are highlighted, including redox-
mediated deprotection of 53, organometallic deprotection of 54, or cleavage of 55 upon 
exposure to stronger acids such as trifluoromethanesulfonic acid (TfOH). Potential 
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application of this strategy to peptide synthesis is highlighted in Figure 10. The 
protecting group can be incorporated directly by SPPS using the corresponding 
protected lysine residue. Alternatively, the para-nitrophenylcarbamate (60) could be 
prepared and used to directly protect lysine residues within a larger expressed protein, 
while maintaining overall charge. This would enable subsequent isonitrile-mediated 
ligation at the C-terminus of an expressed protein without reliance on cysteine for 
expressed-protein ligation.40 
 
 
Figure 9: Structure of Lys(Pydec)-OH (52), and proposed Lys protecting groups which 
retain cationic charge. 
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 Figure 10: Potential application of charge-retaining Lys protecting groups. (A) 
Application to isonitrile-mediated ligation; (B) Direct protection of expressed protein 
side-chains, and reaction of C-terminal thioacid with peptide nucleophile to produce 
modified expressed proteins without reliance on cysteine. 
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Part I. Outline of Synthetic Scheme Towards Biotinylated KRas(G12V) [1-166] 
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Materials and General Procedures.  
General Considerations. All commercially available materials were used without 
purification (Aldrich, Novabiochem, TCI America). 2,2’-Azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride (VA-044) was purchased from Wako Pure Chemical 
Industries. HATU was purchased from Genscript (Piscataway, New Jersey). Bond-
Breaker™ (0.5 M aqueous TCEP, pH = 7.0) solution was purchased from 
ThermoScientific. L-Ribose was purchased from Carbosynth Limited. All solvents were 
reagent grade or HPLC grade. All reactions were performed under an atmosphere of 
purified dry Argon (Ar) unless otherwise indicated. Low-resolution mass spectral 
analyses were performed with a JOEL JMS_DX_303-HF mass spectrometer or Waters 
Micromass ZQ mass spectrometer. Analytical TLC was performed on E. Merck silica 
gel 60 F254 plates and flash column chromatography was performed on E. Merck silica 
gel 60 (40-63 µm). Yields refer to chromatographically pure compounds. 
UPLC-MS, HPLC Methods for Analysis and Purification: 
UPLC-MS analysis. UPLC-MS analyses were performed using a WatersAcquity™ 
Ultra Performance LC systed equipped with Acquity UPLC® BEH C18, 1.7 µL, 2.1 x 
100 mm, Acquity UPLC® C8, 1.7 µL, 2.1 x 100 mm, Acquity UPLC® C4, 1.7 µL, 2.1 x 
100 mm columns at a flow rate of 0.3 mL/min. 
Preparative HPLC. All separations involved a mobile phase of 0.05 v/v% TFA in 
water (solvent A) and 0.05% v/v% TFA in acetonitrile (solvent B). Preparative 
separations were performed using a Rainin HPLC solvent delivery system equipped 
with a Rainin UV-1 detector and Agilent Dynamax reverse phase HPLC column 
Microsorb 100-8 C18 (250 x 21.4 mm), or Microsorb 300-5 C8 (250 x 21.4 mm) or 
Microsorb 300-5 C4 (250 x 21.4 mm). Alternatively, xBridge Prep C8 5µm OBD (19 x 
150 mm) or xBridge Prep C4 5µm OBD (19 x 150 mm) columns were employed. 
Solid-Phase Peptide Synthesis (SPPS) by Fmoc-Strategy. Automated SPPS was 
performed on an Applied Biosystems Pioneer continuous flow peptide synthesizer or a 
Biotage Alstra Microwave Peptide Synthesizer. Peptides were synthesized using 
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automated Fmoc- protocols. The deblock mixtures consisted of a mixture of 96:2:2 of 
DMF / DBU / piperidine, or 20% piperidine in DMF with or without 0.1 M Oxyma 
Pure. The appropriate Boc- or Fmoc- amino acids and Fmoc- protected pseudoproline 
dipeptides (obtained from Novabiochem® in the case of all-L KRas, or synthesized as 
described in the text in the case of all-D KRas) were employed as indicated. C-terminal 
thioesters were prepared with using a modification of elongation methods as described. 
Standard Amino Acid Residues Used. 
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-
Cys(StBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gln(Trt)-OH, Fmoc-
Glu(OtBu), Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, 
Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Boc-Thz-OH. 
Representative Microwave-Assisted SPPS Protocol. 
Prior to synthesis: Swell resin (0.1 mmol scale, DMF, 50oC, 10 min) 
Deprotection: add 20% Piperidine in DMF (5 mL, 50oC, 5 min) / Wash with DMF. 
Or 20% Piperidine in DMF containing 0.1M OxymaPure (5 mL, 3 min 
RT, then replace solution, 5 min RT) / Wash with DMF 
Coupling: add amino acid (4 equiv, 0.5 M in DMF), add OxymaPure (4 equiv, 0.5 M in 
DMF), add DIC (4 equiv, 0.5 M in DMF), additional DMF added (to reach 3 mL 
volume), coupling (room temp, 2 min, then 50oC for 8 minutes) / Wash with DMF 
Peptide Cleavage and Deprotection: 
Mild Cleavage from Trityl Resin to Access Fully Protected Peptides. Upon 
completion of automated synthesis on a 0.1 mmol scale, the peptide resin was washed 
into a peptide synthesis vessel with CH2Cl2. The resin was then subjected to a cleavage 
cocktail (1:1:8 acetic acid / TFE / CH2Cl2) for 30 min (3 x 10 mL), filtering after each 
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treatment. The combined cleavage solutions were then concentrated under reduced 
pressure to a minimum volume of acetic acid, precipitated with water, shell frozen, and 
lyophilized. 
Acid Labile Protecting Group Removal. Peptides were subjected to cocktail B (~3 
mL / 100 mg of peptide) consisting of TFA (88% by volume), water (5 % by volume), 
phenol (5% by weight), and triisopropylsilane (2% by volume). Alternatively, peptides 
were subjected to cocktail R, consisting of TFA (90% by volume), Thioanisole (5% by 
volume), 1,2-ethanedithiol (3% by volume), and anisole (2% by volume). The resulting 
solution was either concentrated to half its original volume with Ar stream and 
precipitated with ice-cold diethyl ether (10 volume equivalents) or directly precipitated 
upon the addition of ice-cold diethyl ether (10 volume equivalents). Centrifugation of 
the resulting precipitate and decantation afforded a white pellet, which was further 
washed twice with ice-cold diethyl ether, centrifuged, and decanted as before. The solid 
was then dissolved in water/acetonitrile (1:1, 0.1% TFA) and lyophilized. The resulting 
solid was purified by RP-HPLC. 
Kinetic Chemical Ligation (KCL) Buffer. The buffer required for kinetic chemical 
ligation (KCL) was freshly prepared prior to the reaction. Guanidine.HCl (1.146 g, 12 
mmol), Na2HPO4 (56.6 mg, 0.4 mmol), and TCEP.HCl (10.8 mg, 0.04 mmol) were 
weighed into a 14 mL centrifuge vial. The resulting solids were solubilized in H2O (2 
mL), and the pH was adjusted to the desired pH with 5M NaOH. The resulting solution 
was degassed by argon sparge with sonication for at least 15 minutes before use. 
Native Chemical Ligation Buffer. 
The buffer required for native chemical ligation (NCL) was freshly prepared prior to the 
reaction. Guanidine.HCl (1.146 g, 12 mmol), Na2HPO4 (56.6 mg, 0.4 mmol), and 
TCEP.HCl (10.8 mg, 0.04 mmol), and 4-mercaptophenylacetic acid (MPAA) (67 mg, 
0.4 mmol) were weighed into a 14 mL centrifuge vial. The resulting solids were 
solubilized in H2O (1.8 mL), the pH was adjusted to the desired pH (generally 6.8-7.2) 
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with 5M NaOH, and the final volume adjusted to reach 2 mL. The resulting solution 
was degassed by argon sparge with sonication for at least 15 minutes before use. 
Representative procedure for first-residue loading of NovaSyn® TGT alcohol 
resins: 
A suspension of Novasyn TGT Trityl-OH resin (1.36 g, 0.258 mmol, 0.19 mmol/g 
loading) in anhydrous toluene (12 mL) was treated with AcCl (1.40 mL) and heated at 
60oC for 3.5 hours with moderate agitation. The resin was then filtered into an oven-
dried peptide vessel, and washed with anhydrous toluene (2 x 15 mL) followed by 
CH2Cl2 (3 x 15 mL), and finally the vessel was capped with a rubber septum and placed 
under an argon atmosphere. Separately, Fmoc-D-Glu(OtBu)-OH (276 mg, 0.65 mmol) 
was dissolved in anhydrous CH2Cl2 (12 mL) and N,N-diisopropylethylamine (0.45 mL, 
2.58 mmol). This solution was carefully added to the washed resin via syringe. The 
reaction vessel was agitated for 2.5 hours at room temperature under argon. The solvent 
was then filtered with nitrogen pressure, and the resin was washed with 17:2:1 
CH2Cl2/MeOH/DIPEA (2 x 20 mL, 10 min each). The resin was further washed with 
CH2Cl2 (3 x 15 mL), then DMF (3 x 15 mL), then finally CH2Cl2 (2 x 15 mL) and dried 
under high vacuum. Fmoc loading was estimated by the method of Gude and co-
workers41 following cleavage with 2% DBU in DMF and measurement of UV 
absorbance at 304 nm, and found to be 0.16 mmol/g.  
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Part III: Synthesis of Peptidyl Fragments, Thioesters and Thioacids 
 
Synthesis of KRas[51-79] aryl thioester 2 
	
Synthesized on a 0.1 mmol scale starting from Fmoc-Phe-OH loaded NovaSyn TGT 
resin. Non-standard amino acids (used at the indicated positions) were Fmoc-Asp(tBu)-
Thr(ΨMe,Mepro)-OH, and Fmoc-Asp(Mpe)-OH. Cleavage from resin using 8:1:1 
CH2Cl2/TFE/AcOH according to the general protocol afforded the crude fully protected 
peptide. 	
To a 0 oC solution of crude protected peptide (384 mg, 69.1 µmol) in CHCl3 (2.5 mL) 
was added HCl-H-Leu-SPh42 (51 mg, 0.196 mmol) followed by HOOBt (0.319 mmol) 
and EDC (37 µL, 0.209 mmol). The reaction was stirred in an ice bath for 2 hours, at 
which point UPLC/MS analysis indicated a small amount of residual starting material. 
Additional EDC (30 µL, 0.169 mmol) was added and the reaction was stirred for a 
further 40 minutes. At this point, the reaction was quenched upon the addition of 8 mL 
CHCl3 (+5% AcOH). The organic mixture was washed with H2O (3 mL), and then 
concentrated. Global deprotection with cocktail B (8 mL, 3.75 hours, argon) followed 
by precipitation with diethyl ether according to the general procedure afford the crude 
peptide. The solid residue was further purified by RP-HPLC to afford KRas[51-79] (2) 
as a white solid (40.0 mg, 17% yield). 
 HPLC conditions: C8 X-bridge column 5 µm OBD, 20-70% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min. TR = 16 min.  
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ESI-MS(+) for peptide 2. Chemical Formula = C149H225N37O48S4. MW = 3430.89 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1716.44, found: 1716.02; [M+3H+]3+ m/z: 
1144.63, found: 1144.46; 
 
Synthesis of KRas[80-117] (3) 
 
 
Synthesized on a 0.1 mmol scale starting from Fmoc-Asn(Trt)-OH loaded NovaSyn 
TGT resin. Non-standard amino acids (used at the indicated positions) were Fmoc-
Lys(Boc)-Ser(ΨMe,Mepro)-OH and Fmoc-Asp(tBu)-Ser(ΨMe,Mepro)-OH. Cleavage from 
resin using 8:1:1 CH2Cl2/TFE/AcOH according to the general protocol afforded the 
crude fully protected peptide. 
 
To a 0 oC solution of the crude protected peptide (215 mg, 28.8 µmol) in CHCl3 (1.3 
mL) was added HCl.H-Lys(Alloc)-SAlkyl S-19 (31 mg, 68.7 µmol) and HOOBt (19 
mg, 0.117 mmol) followed by EDC (15 µL, 84.8 µmol). The reaction was stirred for 1 
hour, at which point UPLC/MS analysis indicated full conversion. The reaction was 
warmed to room temperature, and PhSiH3 (88 µL, 0.71 mmol) was added followed by 
Pd(PPh3)4 (12 mg, 10.4 µmol). The reaction was stirred for 1 hour, and was quenched 
upon the addition of 6 mL CHCl3 (+5% AcOH). The organic mixture was washed with 
H2O (2 mL) and then concentrated. Global deprotection using Cocktail R (6 mL, 2.5 hr, 
argon) and precipitation according to the general procedure yielded the crude peptide. 
Purification by RP-HPLC afforded 3 as a white solid (42 mg, 32% yield). 
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HPLC conditions: C8 xBridge column 5 µm OBD, 10-60% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min.  
ESI-MS(+) for peptide 3. Chemical Formula = C201H320N56O60S3. MW = 4577.28 
g/mol. ESI calculated for [2M+5H+]5+ m/z: 1831.91, found: 1831.57; [M+3H+]3+ m/z: 
1526.76, found: 1526.54; [M+4H+]4+ m/z: 1145.53, found: 1145.05; [M+5H+]5+ m/z: 
916.45, found: 916.30; [M+6H+]6+ m/z: 763.88, found: 763.83; [M+7H+]7+ m/z: 654.89, 
found: 654.78. 
 
Synthesis of KRas(G12V) [118-138] thioacid (4): 
 
 
Synthesized on a 0.1 mmol scale using Fmoc-Tyr(tBu)-OH Novasyn TGT resin. Non-
standard amino acids (used at the indicated positions) were Fmoc-Asp(OMpe)-OH, 
Fmoc-Asp(tBu)-Thr(ΨMe,Mepro)-OH, and Fmoc-Lys(Alloc)-OH. Following synthesis, 
the resin was cleaved under mild conditions using 8:1:1 CH2Cl2:TFE:AcOH according 
to the general procedure to afford the crude protected peptide. 
 
To a 0oC solution of this protected peptide (269 mg, 65.4 µmol) in CHCl3 (2.50 mL) 
was added HOOBt (49.0 mg, 0.30 mmol) followed by TFA-Gly-STmob7 (74.0 mg, 0.19 
mmol) and EDC (53 uL, 0.30 mmol). After stirring at this temperature for 1 hour, the 
reaction was quenched by the addition of 5% AcOH in CHCl3 (10 mL). The organic 
layer was washed with H2O (4 mL), and the aqueous layer was extracted once more 
with 5 mL 5% AcOH solution in CHCl3. The combined organic layers were 
concentrated and subjected to cocktail B deprotection (9 mL, 2.5 hours, argon). The 
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peptide was directly precipitated by the addition of cold ether, the mixture was 
centrifuged and ether was decanted. The ether wash was repeated once more, and the 
resulting residue was dissolved in 1:1 MeCN/H2O and lyophilized. RP-HPLC 
purification of the residue afforded thioacid 4 as a white solid (45.0 mg, 26% yield). 
 
HPLC conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm). 30-70% 
MeCN/H2O (0.05% TFA) over 30 min. Flow Rate: 15 mL/min. Tr = 13.3 min.  
 
ESI-MS(+) for peptide 4: Chemical Formula = C119H180N30O38S3. MW = 2735.10 
g/mol. ESI calculated for [2M+3H+]3+ m/z: 1824.40,  found 1824.00; [M+2H+]2+ m/z: 
1368.55, found: 1368.32; [M+3H+]3+ m/z: 912.70, found: 912.35. 
 
Synthesis of KRas[139-166] (5) 
 
 
Synthesized on a 0.2 mmol scale, starting with Fmoc-His(Trt)-OH NovaSyn TGT 
Resin. Resin cleavage and global deprotection was accomplished using Cocktail R (20 
mL, 2 hours). The peptide was precipitated with cold diethyl ether according to the 
general procedure. Purification of a portion of this crude material by RP-HPLC afforded 
5 as a white solid (21.5 mg) 
HPLC conditions: C8 xBridge column 5 µm OBD, 15-60% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min. TR = 18.0 min. 
ESI-MS(+) for peptide 5. Chemical Formula = C156H244N42O47. MW = 3459.92 g/mol. 
ESI calculated for [M+2H+]2+ m/z: 1730.96, found: 1730.48; [2M+5H+]5+ m/z: 1384.96, 
found: 1384.55; [M+3H+]3+ m/z: 1154.30, found: 1153.83; [M+4H+]4+ m/z: 865.98, 
found: 865.75; [M+5H+]5+ m/z: 692.98, found: 692.73. 
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Synthesis of KRas(G12V) [1-50] MPAA thioester (14): 
 
 
 
Synthesized on a 0.1 mmol scale using a Biotage Alstra microwave peptide synthesizer, 
using Fmoc-Glu(tBu)-OH Novasyn TGT resin. Non-standard amino acids (used at the 
indicated positions) were Fmoc-(Dmb)Gly-OH, Fmoc-Val-(Hmb)Gly-OH dipeptide, 
Fmoc-Asp(Mpe)-OH, Fmoc-Lys(Boc)-Ser(ΨMe,Mepro)-OH and Fmoc-Asp(OtBu)-
Ser(ΨMe,Mepro)-OH. The peptide was synthesized according to the general microwave 
SPPS protocol using 20% Piperidine in DMF as deblock, with the following variations: 
(a) The residue after Fmoc-(Dmb)Gly-OH was double coupled, each cycle for 30 
minutes. (b) Coupling of Fmoc-Val-(Hmb)Gly-OH dipeptide was performed for 45 
minutes. 
 
After synthesis, the Hmb groups were acetylated using the following procedure: The 
resin (assumed 0.1 mmol) was swelled in 10 mL DMF for 10 minutes, and the solution 
drained. To the resin was added a premade solution of Ac2O (0.19 mL, 2.0 mmol) and 
DIEA (0.4 mL, 2.3 mmol) in DMF (8.0 mL). After 2 hours, the solution was drained, 
and the resin was washed with 3 x 10 mL DMF. Following acetylation, the resin was 
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cleaved under mild conditions using 8:1:1 CH2Cl2:TFE:AcOH according to the general 
procedure to afford the crude protected peptide. 
 
To a solution of this protected peptide (260 mg, 29.8 µmol) in CHCl3 (1.5 mL) was 
added HOOBt (19.4 mg, 0.119 mmol) and HCl-D-Thr-SPh43 (19.2 mg, 0.078 mmol). 
The mixture was cooled to 0oC, and EDC (21.0 uL, 0.119 mmol) was added. The 
reaction was stirred for 1.5 hours, at which point additional EDC (10 uL, 0.056 mmol) 
was added. After 45 minutes, the reaction was quenched by the addition of 5% AcOH in 
CHCl3. The mixture was washed with H2O (4 mL), and the aqueous phase was 
extracted once with 5% AcOH/CHCl3 (5 mL). The combined organic layers were 
concentrated, and subjected to cocktail B deprotection (8 mL, 2.5 hr, argon balloon). 
The peptide was precipitated with cold ether (~60 mL), and the mixture centrifuged. 
The resulting pellet was dissolved in 1:1 MeCN/H2O (0.1 % TFA) and lyophilized to 
afford the crude peptide (189 mg). 
 
A portion of the obtained crude peptide (88 mg) was dissolved in 10.0 mL argon-
degassed thiol buffer (200 mM MPAA, 200 mM Na2HPO4, 6M Gn.HCl, 20 mM 
TCEP.HCl, pH~6.8). The mixture was stirred for 8 hours at room temperature under 
argon, at which point the acetyl groups had been fully deprotected by UPLC/MS 
analysis. The reaction was directly subjected to RP-HPLC purification to afford 14 as a 
white solid (15.4 mg, 19% yield overall). 
 
HPLC conditions: Microsorb 300-5 C4 (250 x 21.4 mm) column. 30-65% MeCN/H2O 
(0.05% TFA) over 30 minutes. Flow rate: 20 mL/min. Tr=12.5 min.  
 
ESI-MS(+) of peptide 14: Chemical Formula = C273H418N62O85S2. MW = 5992.82 
g/mol. ESI calcd. for [M+3H+]3+ m/z: 1998.61, found:  1998.83; [2M+7H+]7+ m/z: 
1713.23, found: 1713.50; [M+4H+]4+ m/z: 1499.20, found: 1499.08; [M+5H+]5+ m/z: 
1199.59, found: 1199.46, [M+6H+]6+ m/z: 999.80, found: 999.91; [M+7H+]7+ m/z: 
857.12, found: 857.42. 
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Synthesis of KRas(G12V) [51-79] Alkyl Thioester (15): 
 
Synthesized on a 0.1 mmol scale using Fmoc-Phe-OH Novasyn TGT resin. Non-
standard amino acids (used at the indicated positions) were Fmoc-Asp(Mpe)-OH and 
Fmoc-Asp(tBu)-Thr(ΨMe,Mepro)-OH. Following synthesis, the resin was cleaved under 
mild conditions using 8:1:1 CH2Cl2:TFE:AcOH according to the general procedure to 
afford the crude protected peptide. 
 
To a 0oC solution of this protected peptide (333 mg, 64.4 µmol) in CHCl3 (3.5 mL) was 
added HCl-H-D-Leu-SAlkyl S-18 (55.2 mg, 0.195 mmol) and HOOBt (37.5 mg, 0.23 
mmol), followed by the addition of EDC (40.6 µL, 0.23 mmol). The reaction was stirred 
at this temperature for 90 minutes, and was quenched upon the addition of 5% AcOH in 
CHCl3 (~6 mL). The reaction mixture was washed with H2O (3 mL), the aqueous layer 
was extracted once with 5% AcOH in CHCl3 (5 mL), and the combined organic layers 
were directly concentrated. The residue was subjected to cocktail R deprotection (8 mL, 
2 hours, argon balloon). The peptide was directly precipitated upon the addition of cold 
diethyl ether (80 mL) and the solids were collected upon centrifugation. The resulting 
pellet was further washed with cold diethyl ether (2 x 20 mL), suspended in 1:1 
MeCN/H2O (0.1% TFA), and lyophilized. Purification of the residue by RP-HPLC 
afforded 15 as a white solid (50.0 mg, 22% yield). 
 
HPLC Conditions: Microsorb 300-5 C8 (250 x 21.4 mm) column. 25-75% MeCN/H2O 
(0.05% TFA) over 30 minutes. Flow Rate: 20 mL/min. Tr = 15.5 minutes. 
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ESI-MS(+) for peptide 15: Chemical Formula = C147H229N37O50S4. MW = 3442.90 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1722.45, found: 1722.35; [M+3H+]3+ m/z: 
1148.63, found: 1148.55; [M+4H+]4+ m/z: 861.72, found: 861.67. 
 
Synthesis of KRas(G12V) [80-117] Alkyl Thioester (17): 
 
 
Synthesized on a 0.1 mmol scale starting with Fmoc-Asn(Trt)-OH Novasyn TGT resin. 
Non-standard amino acids (used at the indicated positions) were Fmoc-Asp(tBu)-
Ser(ΨMe,Mepro)-OH, and Fmoc-Lys(Boc)-Ser(ΨMe,Mepro)-OH. Following synthesis, the 
resin was cleaved under mild conditions using 8:1:1 CH2Cl2:TFE:AcOH according to 
the general procedure to afford the crude protected peptide. 
 
To a 0oC solution of this crude protected peptide (all L-amino acids, 248 mg, 0.034 
mmol) in CHCl3 (1.6 mL) was added HOOBt (21.2 mg, 0.13 mmol) and HCl-
Lys(Alloc)-SAlkyl (S-19) (35.0 mg, 0.091 mmol). EDC (17.0 µL, 0.096 mmol) was 
then added, and the reaction was stirred at this temperature for 40 minutes, at which 
point the reaction was complete by UPLC/MS analysis. The mixture was warmed to 
room temperature for 15 minutes, and PhSiH3 (99 µL, 0.80 mmol) and Pd(PPh3)4 (14.0 
mg, 0.012 mmol) were added. The reaction was stirred for 2 hours, and was then diluted 
with 5% AcOH/CHCl3 (8 mL). The mixture was washed with H2O (2 mL) and 
extracted once further with 5% AcOH/CHCl3 (~5 mL). The combined organic layers 
were directly concentrated and subjected to cocktail R deprotection (6.5 mL, 1.5 hours, 
argon balloon). The peptide was precipitated by the addition of cold ether, the mixture 
centrifuged, and ether was decanted. The resulting pellet was dissolved in 1:1 
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MeCN/H2O (0.1% TFA), shell-frozen and lyophilized. The crude peptide was purified 
by HPLC to obtain 17 (35.0 mg, 22% yield) as a white solid.  
 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 20-60% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 15 mL/min. Tr = 8.2 minutes.  
 
ESI-MS(+) for compound 17: Chemical Formula = C202H320N56O60S3.  MW = 4589.29 
g/mol. ESI calculated for [2M+5H+]5+ m/z: 1836.71, found: 1836.15; [M+3H+]3+ m/z: 
1530.76, found: 1530.29; [M+4H+]4+ m/z: 1148.32, found: 1147.83; [M+5H+]5+ m/z: 
918.86, found: 918.62; [M+6H+]6+ m/z: 765.88, found: 765.63  
 
Synthesis of KRas(G12V) [139-166] (22) with biotin label: 
 
Synthesized on 0.05 mmol scale beginning with Fmoc-PEG Biotin NovaTag™ resin 
(purchased from Novabiochem). The resin was directly cleaved by the addition of 
Cocktail R (90/5/3/2 TFA/thioanisole/1,2-ethanedithiol/anisole) for 2.5 hours under 
argon and precipitated with ether according to the general protocol. The residue was 
purified by RP-HPLC to afford 19 as a white solid (20.7 mg, 11% yield).  
 
HPLC conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 20-70% MeCN 
(0.05% TFA) against H2O (0.05% TFA) over 30 min. Flow Rate: 15 mL/min. Tr = 13.8 
min.  
 
ESI-MS(+) for peptide 19: Chemical Formula = C176H280N46O51S. MW = 3888.51 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1945.25, found: 1944.92; [2M+5H+]5+ m/z: 
1556.40, found: 1556.06; [M+3H+]3+ m/z: 1297.17, found: 1296.87; [M+4H+]4+ m/z: 
973.12, found: 972.92; [M+5H+]5+ m/z: 778.70, found: 778.62. 
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Synthesis of KRas[146-166] with biotin label (22): 
 
Synthesized on 0.1 mmol scale beginning with Fmoc-PEG Biotin NovaTag™ resin 
(purchased from Novabiochem). This fragment was synthesized using the microwave 
SPPS general procedure. Deblock used was 20% piperidine in DMF plus 0.1M 
oxymapure. The resin was directly cleaved by the addition of Cocktail R (90/5/3/2 
TFA/thioanisole/1,2-ethanedithiol/anisole) for 1.5 hours under argon and precipitated 
with ether according to the general protocol. The residue was purified by RP-HPLC to 
afford 22 as a white solid (42.0 mg, 14% yield).  
 
HPLC conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm). 10-65% 
MeCN/H2O (0.05% TFA) over 30 min. Flow Rate: 16 mL/min. Tr = 15.4 min.  
 
ESI-MS(+) for peptide 22: Chemical Formula = C134H223N39O36S3. MW = 3052.68 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1527.34, found: 1526.90; [2M+5H+]5+ m/z: 
1222.07, found: 1221.83; [M+3H+]3+ m/z: 1018.56, found: 1018.23; [M+4H+]4+ m/z: 
764.17, found: 764.21; [M+5H+]5+ m/z: 611.53, found: 611.35. 
 
 
 
 
 
 
 
 
 
 
N
H
O
O
KTRQGVDDAFYTLVREIRKH
O
tBuSS
KRas [146-166] (22)
ON
H
O
S
HN NH
H
H
O
H2N
163
Synthesis of KRas(G12V) [118-138] Thioester (23): 
 
 
 
23 was synthesized using the hydrazide oxidation method.44 2-Cl-Trt-NHNHFmoc resin 
was synthesized from 2-Cl-Trt-Cl resin using a modified procedure, initially described 
by Huang, et al.45 To a 30 mL oven-dried peptide vessel was added 2-Cl-Trt-Cl resin 
(1.0 g, 1.5 mmol, loading ~ 1.5 mmol/g). The resin was swelled in 10 mL anhydrous 
CH2Cl2 for 20 minutes under argon. At this time, the solvent was drained under N2 
pressure, and the resin was resuspended in anhydrous CH2Cl2 (8 mL). Separately, 9-
fluorenylmethyl carbazate (127.5 mg, 0.5 mmol) and N,N-diisopropylethylamine (0.34 
mL, 2.0 mmol) were dissolved in anhydrous DMF (8 mL). This solution was slowly 
added to the suspended resin, and the peptide vessel was gently agitated at room 
temperature overnight under argon. The solution was filtered under N2 pressure, and the 
resin was washed with 17:2:1 CH2Cl2/MeOH/DIPEA (2 x 10 mL, for 10 minutes each). 
The resin was then consecutively washed with CH2Cl2 (2 x 8 mL), DMF (2 x 8 mL), 
CH2Cl2 (3 x 8 mL), MeOH (1 x 8 mL), and finally diethyl ether (2 x 8 mL), and the 
resin was dried under high vacuum. Fmoc loading was spectroscopically determined to 
be approximately 0.40 mmol/g. 
 
The corresponding acyl hydrazide fragment S-1 was synthesized on a 0.1 mmol scale 
using the general procedure for microwave-assisted SPPS. Deblock – 20% piperidine in 
DMF (containing 0.1M Oxyma), room temperature. Non-standard amino acids (used at 
the indicated positions) were Fmoc-Asp(Mpe)-OH and Fmoc-Cys(Acm)-OH. Cleavage 
from resin was accomplished using cocktail R (8 mL, 2 hours) followed by precipitation 
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with ether and centrifugation according to the general protocol. The crude peptide was 
purified by RP-HPLC. Purest fractions were combined, shell-frozen, and lyophilized to 
afford peptide hydrazide S-1 (88.3 mg, 27% yield) as a white solid. 
 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 10-60% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 10.5 minutes. 
 
ESI-MS(+) for peptide S-1: Chemical Formula = C137H222N40O46S. MW = 3197.58 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1599.79, found: 1599.47; [M+3H+]3+ m/z: 
1066.86, found: 1066.49; [M+4H+]4+ m/z: 800.39, found: 800.38  
 
Hydrazide S-1 (15.2 mg, 4.75 µmol) was dissolved in 950 µL oxidation buffer (6 M 
Gnd.HCl, 0.2 M NaH2PO4, pH=3) in a 15 mL conical plastic centrifuge vial. The vial 
was briefly centrifuged, and the solution was cooled in a -15oC cooling bath (dry 
ice/acetone). To this rapidly stirred solution was added NaNO2 (0.5 M in H2O, 94.8 uL, 
47.4 µmol). The reaction was stirred at this temperature for 20 minutes, and was 
quenched with MesNa (Prepared as a 0.2M solution, containing 6M Gnd.HCl, 0.2 M 
Na2HPO4, pH=7.0, 2.30 mL, 0.46 mmol). The reaction was then removed from the 
cooling bath and stirred at room temperature for 45 minutes, and purified by RP-HPLC. 
Purest fractions were combined, shell-frozen, and lyophilized to afford 23 as a white 
solid (14.5 mg, 92% yield).  
 
HPLC conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 10-60% MeCN 
in H2O (+0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 13.5 minutes 
 
ESI-MS(+) for peptide 23:  Chemical Formula = C139H224N38O49S3. MW = 3307.72 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1654.86, found: 1654.43; [M+3H+]3+ m/z: 
1103.57, found: 1103.33. 
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Part IV: Ligation procedures for the construction of KRas(G12V) 
 
Synthesis of KRas[118-166] (10) 
 
Thioacid 4 (13.4 mg, 4.9 µmol), 4 (21.5 mg, 6.2 mol), and HOBt (8.3 mg, 61 µmol) 
were weighed directly into a 1-dram glass scintillation vial with a stirbar and screwcap. 
Anhydrous DMA (1.0 mL) was added, followed by tBuNC (1.25 mg, 15.0 µmol, 
dissolved in 400 µL DMA, prepared as stock solution). The reaction was stirred for 72 
hours at room temperature, at which point the reaction was transferred via micropipette 
into a 15 mL conical centrifuge vial. Transfer was quantitated with 100 µL DMA, and 
piperidine (300 µL) was added. The mixture was stirred for 1 hour, at which point cold 
diethyl ether (10 mL) was added to precipitate the crude peptides. The vial was 
centrifuged, ether decanted, and the residue was again washed with ether, and 
centrifuged as before. The resulting solid was lyophilized from 1:1 MeCN/H2O 
(+0.05% TFA). 
The lyophilized solids were redissolved in DMF (1.50 mL, degassed with argon 
sparge), and PhSiH3 (29.6 µL, 0.24 mmol) was added followed by PdCl2(dppf) (2.40 
mg, 3.0 µmol, dissolved in 100 µL DMF). The reaction was stirred for 15 minutes, at 
which point UPLC/MS indicated full deprotection. Cold ether (10 mL) was added to 
precipitate the crude peptides, and the suspension was centrifuged and ether was 
decanted. The solid residue was dissolved in 1:1 MeCN/H2O (+0.1% TFA) and purified 
DLPSRTVDTKQAQDLARSYG
Alloc
O
FmocHN
tBuSS
SH
O
KRas [118-138] (4)
+
OHPFIETSAKTRQGVDDAFYTLVREIRKH
Alloc Alloc
O
H2N
KRas [139-166] (5)
1. tBuNC, HOBt
    DMA, room temp
2. Piperidine
3. PdCl2(dppf), PhSiH3
        (56% overall)
DLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKH
KRas [118-166] (10)
OH
O
H2N
tBuSS
166
by RP-HPLC. Combined fractions were lyophilized to afford 10 as a white solid (16.2 
mg, 56% yield overall). 
HPLC Conditions: C8 xBridge column 5 µm OBD, 20-70% MeCN (+0.05% TFA) 
against H2O (+0.05% TFA) over 30 minutes. Flow rate: 15 mL/min. Tr = 12 min. 
ESI-MS(+) for peptide 10. Chemical Formula = C248H400N72O77S2. MW = 5686.48 
g/mol. ESI calculated for [M+3H+]3+ m/z: 1896.49, found: 1895.91; [2M+7H+]7+ m/z: 
1625.70, found: 1625.32; [M+4H+]4+ m/z: 1422.62, found: 1422.20; [M+5H+]5+ m/z: 
1138.29, found: 1137.85; [M+6H+]6+ m/z: 948.74, found: 948.40; [M+7H+]7+ m/z: 
813.35, found: 813.25; [M+8H+]8+ m/z: 711.81, found: 711.63; [M+9H+]9+ m/z: 632.83, 
found: 632.73. 
 
NCL between 2 and 3 to produce KRas[51-117] (11) 
 
		
KRas[51-79] 2 (22.0 mg, 6.41 µmol) and KRas [80-117] 3 (41.5 mg, 9.0 µmol) were 
weighed into an 8 mL glass vial with a stirbar. The peptides were solubilized in ligation 
buffer (2.60 mL) and stirred under argon for 5 hours. At this point, TCEP (0.5 M, pH = 
7.0, 30 µL, 15 µmol) was added and the reaction was stirred for 10 minutes. The 
mixture was diluted with 2.5 mL 1:1 MeCN/H2O (+0.1% TFA) and purified by RP-
HPLC to afford 11 as a white solid (13.5 mg, 27% yield). 
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HPLC conditions: C8 xBridge column 5 µm OBD, 20-70% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min. TR = 13 min. 
ESI-MS(+) for peptide 11. Chemical Formula = C344H539N93O108S6. MW = 7898.00 
g/mol. ESI calculated for [M+4H+]4+ m/z: 1975.50, found: 1975.49; [M+5H+]5+ m/z: 
1580.60, found: 1579.94; [M+6H+]6+ m/z: 1317.33, found: 1316.89; [M+7H+]7+ m/z: 
1129.28, found: 1128.85.; [M+8H+]8+ m/z: 988.25, found: 988.00.; [M+9H+]9+ m/z: 
878.55, found: 878.42; [M+10H+]10+ m/z: 790.80, found: 790.68; [M+11H+]11+ m/z: 
719.00, found: 718.60. 
 
NCL and Thz removal to synthesize KRas[51-166] (12) 
 
 
KRas[51-117] (11) (10.7 mg, 1.35 µmol) and KRas[118-166] (10) (9.3 mg, 1.63 µmol) 
were weighed into a 1-dram glass vial, and NCL buffer was added (675 µL). The 
reaction was stirred under argon for 5 hours. At this point a solution of MeONH2.HCl 
(48 mg, 0.57 mmol) dissolved in NCL buffer (610 µL) was added to the reaction, and 
the mixture was further stirred for 4 hours, at which point all of the thiazolidine had 
been removed as indicated by UPLC/MS analysis. The reaction was diluted with 2 mL 
1:1 MeCN/H2O (+0.1% TFA) and purified by RP-HPLC to afford 12 as a white solid 
(8.4 mg, 46% yield).  
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HPLC conditions: C4 microsorb column, 30-65% MeCN (+0.05% TFA) over 30 min. 
Flow rate: 20 mL/min. TR = 14 min. 
ESI-MS(+) for peptide 12. Chemical Formula = C582H921N165O183S6. MW = 13350.10 
g/mol. ESI calculated for [M+7H+]7+ m/z: 1908.15, found: 1907.98; [M+8H+]8+ m/z: 
1669.76, found: 1669.35; [M+9H+]9+ m/z: 1484.34, found: 1484.23; [M+10H+]10+ m/z: 
1336.01, found:  1335.79; [M+11H+]11+ m/z: 1214.64, found: 1214.36; [M+12H+]12+ 
m/z: 1113.50, found: 1113.18; [M+13H+]13+ m/z: 1027.93, found: 1027.67; [M+14H+]14+ 
m/z: 954.58, found: 954.47; [M+15H+]15+ m/z: 891.00, found: 890.95; [M+16H+]16+ m/z: 
835.38, found: 835.38; [M+17H+]17+ m/z: 786.30, found: 786.25; [M+18H+]18+ m/z: 
742.67, found: 742.75; [M+19H+]19+ m/z: 703.64, found: 703.53.  
 
NCL between 7 and 10 to afford KRas[80-166] (18): 
 
 
KRas[80-117] (17) (11.5 mg, 2.5 µmol) and KRas[118-166] (10) (9.3 mg, 1.63 µmol) 
were weighed into a 1-dram scintillation vial. The peptides were solubilized with NCL 
Buffer (850 µL, pH ~ 7.2) and stirred under argon for 5 hours. At this point, UPLC/MS 
analysis indicated full conversion. To this solution was added methoxylamine 
hydrochloride (66 mg, 0.79 mmol) as a solution in NCL buffer (850 µL). The reaction 
was stirred a further 7 hours, and was diluted with 2 mL 1:1 MeCN/H2O (+0.1% TFA). 
Purification by RP-HPLC afforded KRas[80-166] (18) as a white solid (9.2 mg, 56% 
yield).  
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HPLC Conditions: C8 xBridge column 5µm OBD, 15-50% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min. TR = 18 min.  
ESI-MS(+) for peptide 18. Chemical Formula = C440H702N128O135S3. MW = 10041.40 
g/mol. ESI calculated for [M+6H+]6+ m/z: 1674.56, found: 1674.37; [M+7H+]7+ m/z: 
1435.49, found: 1435.18; [M+8H+]8+ m/z: 1256.18, found: 1255.83; [M+9H+]9+ m/z: 
1116.71, found: 1116.33; [M+10H+]10+ m/z: 1005.14, found: 1004.95; [M+11H+]11+ m/z: 
913.85, found: 913.75; [M+12H+]12+ m/z: 837.78, found: 837.63; [M+13H+]13+ m/z: 
773.41, found: 773.20; [M+14H+]14+ m/z: 718.24, found: 718.08; [M+15H+]15+ m/z: 
670.43, found: 670.38. 
 
KRas[1-79]-SR (16) synthesis via kinetic chemical ligation between 14 and 15: 
 
 
 
MPAA-thioester 14 (all D-residues, 12.8 mg, 2.13 µmol) and alkyl-thioester 15 (all D-
residues, 10.8 mg, 3.14 µmol) were weighed into a 1-dram glass scintillation vial 
equipped with stirbar and screwcap. The fragments were then dissolved in kinetic 
ligation buffer (1.0 mL, 6M Gnd.HCl, 0.2 M Na2HPO4, 20 mM TCEP.HCl, pH = 7.0), 
and the reaction mixture was stirred under an atmosphere of argon for 7 hours. Ethyl 3-
mercaptopropionate (25.0 uL, 0.2 mmol) was added followed by additional TCEP (0.5 
M aqueous solution, pH = 7.0, 25 uL, 12.5 µmol). After 30 minutes, the mixture was 
diluted with 1.0 mL 1:1 MeCN/H2O (+0.1% TFA) and purified by RP-HPLC. Purest 
fractions were combined and lyophilized to afford 16 as a white solid (7.1 mg, 36% 
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yield). Occasionally, a small amount of the macrocycle derived from KRas[51-79] 
coeluted with the desired fragment. In this case, the material was used as is in 
subsequent steps, and this macrocycle had no impact on later steps. 
This same reaction was run using fragments derived from all L-residues on a similar 
scale (2.00 µmol limiting reagent) to obtain the analogous all L peptide (6.0 mg, 32% 
yield). 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 20-70% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 15 mL/min. Tr = 16.5 minutes. 
 
ESI-MS(+) for peptide 16: Chemical Formula = C412H639N99O133S5. MW = 9267.50 
g/mol. ESI calculated for [M+5H+]5+ m/z: 1854.50, found: 1854.14; [M+6H+]6+ m/z: 
1545.58, found: 1545.29; [M+7H+]7+ m/z: 1324.93, found: 1324.54; [M+8H+]8+ m/z: 
1159.44, found: 1159.15; [M+9H+]9+ m/z: 1030.72, found: 1030.52;  [M+10H+]10+ m/z: 
927.75, found: 927.40.   
 
Successful NCL and Hmb removal to produce KRas[1-166] (13) 
 
 
 
KRas[1-79] 16 (2.80 mg, 0.30 µmol) and KRas[80-166] 18 (3.65 mg, 0.36 µmol) were 
weighed into a 1-dram scintillation vial and solubilized in NCL buffer (pH ~ 7.2). The 
reaction was stirred under argon for 11 hours, at which point the mixture was diluted 
with 0.5 mL 1:1 MeCN/H2O (+0.1% TFA). The mixture was desalted by passing the 
solution through a column of sephadex LH-20 with gravity filtration (~5 mL dry 
adsorbent, swelled in 1:1 MeCN/H2O containing 0.1% TFA). 3 mL fractions are 
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collected, and most of the desired compound elutes in fractions 3-5. Some of the 
ligation product coelutes in later fractions with guanidine salts, which is lyophilized 
separately, and run through a second column of Sephadex LH-20. All combined 
fractions containing the desired compound are pooled and lyophilized. The resulting 
crude peptide is treated with TFA/H2O/i-Pr3SiH (95:2.5:2.5) for 1 hour 20 min. The 
reaction mixture is cooled over a bed of dry ice, and the peptide is precipitated upon the 
addition of cold diethyl ether, and solids are collected via centrifugation. The resulting 
pellet is dissolved in 4.5 mL 1:1 MeCN/H2O (+0.1% TFA), shell-frozen, and 
lyophilized. The solids are dissolved in 300 mL solubilization buffer (6 M Gnd.HCl, 0.2 
M Na2HPO4, pH = 7.2) and purified by RP-HPLC to afford 13 as a white solid (910 µg, 
16% overall yield) 
HPLC conditions: C4 Higgins Semi-Preparative column (4.6 x 250 mm), 30-70% 
MeCN (+0.05% TFA). Flow rate: 1.5 mL/min. TR = 17.5 min. 
ESI-MS(+) for peptide 13. Chemical Formula = C831H1315N227O262S7. MW = 18902.41 
g/mol. ESI calculated for [M+10H+]10+ m/z: 1891.24, found: 1890.81; [M+11H+]11+ m/z: 
1719.40, found: 1719.38; [M+12H+]12+ m/z:1576.20, found:1576.04; [M+13H+]13+ m/z: 
1455.03, found: 1454.83; [M+14H+]14+ m/z: 1351.17, found: 1351.09; [M+15H+]15+ m/z: 
1261.16, found: 1260.86; [M+16H+]16+ m/z: 1182.40, found: 1182.33;  [M+17H+]17+ 
m/z: 1112.90, found: 1112.88; [M+18H+]18+ m/z: 1051.13, found: 1050.92; [M+19H+]19+ 
m/z: 995.86, found: 995.57; [M+20H+]20+ m/z: 946.12, found: 946.07; [M+21H+]21+ m/z: 
901.11, found: 901.15; [M+22H+]22+ m/z: 860.20, found: 860.12; [M+23H+]23+ m/z: 
822.84, found: 822.63; [M+24H+]24+ m/z: 788.60, found: 788.80. 
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Isonitrile-Mediated Ligation between 19 and 20 to produce KRas[118-166] (21): 
 
 
Thioacid 20 (all L-amino acids, 13.3 mg, 4.86 µmol) and biotin-labelled 19 (15.7 mg, 
4.03 µmol) were directly weighed into a 1-dram glass scintillation vial, and HOBt (6.7 
mg, 50.0 µmol) was added followed by tBuNC (1.3 mg, 15.5 µmol, as a freshly 
prepared stock solution in 930 µL anhydrous N,N-dimethylacetamide). The mixture was 
stirred for 48 hours, whereupon piperidine (0.200 mL) was added to remove the N-
terminal Fmoc group. After stirring for 30 minutes at room temperature, the reaction 
was transferred by micropipette into a 15 mL conical centrifuge vial. Cold diethyl ether 
(12 mL) was added to precipitate the crude peptide, the vial was centrifuged (5 minutes 
at 5000 rpm, 10oC), and ether was decanted. The residue was redissolved in 1:1 
MeCN/H2O (+0.1% TFA), shell frozen, and lyophilized.  
The resulting crude lyophilized peptide was dissolved in DMF (1.22 mL, degassed for 
30 minutes with Argon sparge), and PhSiH3 (25.0 µL, 203 µmol) was added followed 
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by PdCl2(dppf) (1.50 mg, 2.04 µmol, as a freshly prepared stock solution in 270 µL 
DMF). The reaction was stirred for 20 minutes under argon at which point UPLC/MS 
showed full deprotection. After stirring a further 10 minutes, the vial was cooled over a 
bed of dry ice for 1 minute, and cold ether (10.5 mL) was added to precipitate the 
peptide. The precipitated peptide was centrifuged, the supernatant was decanted, and the 
residue was further washed with cold ether (10 mL), and again centrifuged and decanted 
as before. The resulting crude peptide was dissolved in 4 mL 1:1 MeCN/H2O (+0.1% 
TFA), and immediately purified by RP-HPLC to afford 21 as a white solid (13.8 mg, 
56% yield).  
The analogous reaction run with peptide fragments composed of all-D amino acid 
residues gave a similar yield on a 5.14 µmol scale (limiting reagent), affording 17.8 mg 
KRas[118-166] 21 (57% yield). 
 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 20-60% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 15 mL/min. Tr = 15.4 minutes. 
 
ESI-MS for peptide 21: Chemical Formula = C268H436N76O81S3. MW = 6115.07 g/mol. 
ESI calculated for [M+4H+]4+ m/z: 1529.76, Found: 1529.61; [M+5H+]5+ m/z: 1224.01, 
found: 1223.95; [M+6H+]6+ m/z: 1020.17, found: 1019.96; [M+7H+]7+ m/z: 874.58, 
found: 874.42; [M+8H+]8+ m/z: 765.38, found: 765.26; [M+9H+]9+ m/z: 680.45, found: 
680.42  
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NCL between 22 and 23; Desulfurization of 24 and Acm Removal to produce 25: 
 
 
Thioester 23 (all L-amino acids, 4.32 mg, 1.30 µmol) and 22 (all L-amino acids, 4.40 
mg, 1.44 µmol) were each weighed directly into a 2.0 mL eppendorf plastic tube. The 
solids were solubilized in degassed NCL buffer (650 µL, 6M Gnd.HCl, 0.2 M Na2HPO4, 
0.2M MPAA, 40 mM TCEP.HCl, pH = 7.0). The vial was vortexed and centrifuged 
briefly, then stirred under argon at room temperature. After 6 hours, the reaction was 
quenched by the addition of 1:1 MeCN/H2O (0.1% TFA). The solution was purified by 
RP-HPLC. Purest fractions were combined, shell-frozen, and lyophilized to afford 24 as 
a white solid (6.60 mg, 82% yield). 
 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 15-65% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 14.5 minutes. 
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ESI-MS(+) for peptide 24. Chemical Formula = C267H433N77O82S3. MW = 6130.04 
g/mol. ESI calculated for [M+4H+]4+ m/z: 1533.51, found: 1533.43; [M+5H+]5+ m/z: 
1227.00, found: 1226.93; [M+6H+]6+ m/z: 1022.67, found: 1022.58; [M+7H+]7+ m/z: 
876.72, found:  876.70; [M+8H+]8+ m/z: 767.25, found: 767.21. 
 
Desulfurization of 24: The ligation product 24 (5.58 mg, 0.89 µmol) was weighed into 
a 2.0 mL eppendorf plastic tube, and was solubilized in 0.45 mL desulfurization buffer 
(6M Gnd.HCl, 0.2 M Na2HPO4, pH not adjusted, degassed with argon bubbling and 
sonication for 30 minutes). To this solution was added TCEP (0.5 M solution, pH = 7.0, 
0.45 mL, 225 µmol) and tBuSH (74 µL, 0.656 mmol), followed by VA-044 (freshly 
prepared 0.1M aqueous solution, 225 µL, 22.5 µmol). The reaction was then stirred 
under argon at room temperature for 4.5 hours. At this point, the desulfurization was 
determined to be complete by UPLC/MS analysis. The mixture was desalted by passing 
the solution through two stacked solid phase extraction cartidges (Seppak C18 plus, 360 
mg adsorbent). The product was eluted, collecting 2 mL fractions, with a stepwise 
gradient of 0-80% MeCN in H2O (+0.05% TFA), increasing the percentage of MeCN 
by 10% every two fractions. Guanidine salts elute in fractions 1-3, and the product 
elutes in fractions 8-13, coeluting with tBuSH in some fractions. All fractions 
containing the desulfurization product were combined and diluted with H2O, shell-
frozen, and lyophilized.  
 
ESI-MS(+) for 24 (Desulfurized): Chemical Formula = C267H433N77O82S2. MW = 
6097.98 g/mol. ESI calculated for [M+4H+]4+ m/z: 1525.49, found: 1525.62; [M+5H+]5+ 
m/z: 1220.60, found: 1220.63; [M+6H+]6+ m/z: 1017.33, found: 1017.33; [M+7H+]7+ 
m/z: 872.14, found: 872.12; [M+8H+]8+ m/z: 763.25, found: 763.31; [M+9H+]9+ m/z: 
678.55, found: 678.89  
 
To this lyophilized material (assumed 0.89 µmol) in a 15 mL plastic centrifuge tube was 
added AgOAc (14.4 mg, 86 µmol) followed by 70% aqueous AcOH (1.32 mL, degassed 
with argon sparge and sonication for 15 minutes). The resulting suspension was agitated 
at room temperature under argon. After 3 hours of stirring, UPLC/MS analysis indicated 
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quantitative deprotection. To this reaction was added 1,2-dithiothreitol (28.0 mg, 0.182 
mmol, as a solution in 0.4 mL 50% aqueous AcOH). The suspension was then agitated 
for 2 hours at room temperature, at which point the vial was centrifuged and the 
supernatant was collected. The solid pellet was then washed twice with 0.8 mL 50% 
aqueous AcOH, with centrifugation and collection of the supernatant. The combined 
supernatant solutions were concentrated partway with N2 stream, diluted with H2O, 
shell-frozen and lyophilized. The solid residue was dissolved in 1.5 mL 1:1 MeCN/H2O 
(0.1% TFA) and purified by RP-HPLC. All fractions containing the desired peptide 
were combined, shell-frozen, and lyophilized to afford 25 as a white solid (3.74 mg, 
69% yield over 2 steps, 57% yield overall) 
 
HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 15-65% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 14.5 minutes. 
 
ESI-MS(+) for peptide 25: Chemical Formula = C264H428N76O81S2. MW = 6026.90 
g/mol. ESI calculated for [M+4H+]4+ m/z: 1507.72, found: 1507.61; [M+5H+]5+ m/z: 
1206.38, found: 1206.37; [M+6H+]6+ m/z: 1005.48, found: 1005.40; [M+7H+]7+ m/z: 
861.98, found: 861.92; [M+8H+]8+ m/z: 754.36, found: 754.31; [M+9H+]9+ m/z: 670.65, 
found: 670.71.  
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NCL between 17 and 21 and Thz removal to produce KRas[80-166] (26): 
 
 
 
Thioester 17 (all D-residues, 10.32 mg, 2.20 µmol) and 21 (all D-residues, 10.83 mg, 
1.77 µmol) were directly weighed into a 2 mL plastic eppendorf tube with a stirbar. The 
fragments were dissolved in NCL buffer (0.87 mL, pH = 7.0) and stirred under argon 
for 5 hours, at which point the reaction was complete by UPLC/MS analysis. 
Methoxylamine hydrochloride (33 mg, 0.40 mmol) was added directly to the reaction, 
the reaction mixture carefully adjusted to pH~4.5 with 6M HCl, and the reaction stirred 
a further 4.5 hours at room temperature, at which point all of the thiazolidine had been 
removed as judged by UPLC/MS analysis. The reaction was diluted with 0.6 mL 1:1 
MeCN/H2O (+0.1% TFA) and purified by RP-HPLC. Combination of the purest 
fractions and lyophilization afforded 26 as a white solid (11.73 mg, 63% yield). 
The analogous reaction was run using peptides consisting of all L amino acids on a 2.25 
µmol scale (limiting reagent) to yield the all-L residue sequence (15.6 mg, 66% yield). 
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HPLC Conditions: xBridge Prep C8 column 5µm OBD (19 x 150 mm), 15-50% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 16 minutes. 
 
ESI-MS(+) for peptide 26: Chemical Formula = C460H738N132O139S4. MW = 10469.99 
g/mol. ESI calculated for [M+6H+]6+ m/z: 1745.99, found: 1745.73; [M+7H+]7+ m/z: 
1496.71, found: 1496.13; [M+8H+]8+ m/z: 1309.75, found: 1309.56; [M+9H+]9+ m/z: 
1164.99, found: 1164.04; [M+10H+]10+ m/z: 1047.99, found: 1047.50; [M+11H+]11+ m/z: 
952.81, found: 952.57; [M+12H+]12+ m/z: 873.50, found: 873.47; [M+13H+]13+ m/z: 
806.38, found: 806.46; [M+14H+]14+ m/z: 748.86, found: 748.68; [M+15H+]15+ m/z: 
699.00, found: 699.30. 
 
Synthesis of biotinylated KRas[1-166] (28) 
 
Hmb-derivative 16 (all D-amino acids, 1.66 mg, 0.185 µmol) and 26 (all D-amino acids, 
3.64 mg, 0.347 µmol) were each directly weighed into a 1.5 mL eppendorf tube 
containing a stirbar. The fragments were dissolved in NCL buffer (206 uL, pH = 7.0) 
and additional TCEP was added (0.5 M aqueous solution, pH = 7.0, 9 uL, 4.5 µmol). 
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The reaction was stirred under argon for 6.5 hours, at which point the reaction mixture 
was transferred via micropipette into a 14 mL conical centrifuge vial. The solution 
transfer was quantitated with an additional 100 µL fresh NCL buffer. The crude peptide 
was then directly precipitated by the addition of cold H2O (3 mL). The mixture was then 
frozen in liquid nitrogen, and allowed to thaw with stirring. The vial was then 
centrifuged (5000 rpm, 5 min, 10oC), and the supernatant was carefully collected via 
syringe. The resulting solid residue was further washed with H2O (2 mL), refrozen and 
thawed as before, and then centrifuged and supernatant removed as before. The 
resulting white solid pellet was dissolved in 5 mL 1:1 MeCN/H2O (+0.1% TFA), shell 
frozen and lyophilized. Analysis of the combined aqueous supernatants and the 
redissolved pellet showed that most of 26 remained in the mother liquor with only trace 
27 remaining dissolved, while the redissolved pellet consisted almost exclusively of 27. 
The crude lyophilized peptide was then subjected to cocktail R deprotection (90/5/3/2 
TFA/thioanisole/EDT/anisole, 450 uL) for 2 hours under argon. The crude peptide was 
directly precipitated upon the addition of cold ether (5.5 mL). After cooling on a bed of 
dry ice for 5 minutes, the vial was centrifuged, ether decanted, and the resulting solid 
was dissolved in 5 mL 1:1 MeCN/H2O (+0.1% TFA) and lyophilized. The residue was 
solubilized in 1.0 mL 1:1 MeCN/H2O (+0.1% TFA) with sonication, pH adjusted to 
~8.0 using 3N NaOH, and TCEP was added (0.5 M aqueous solution, pH = 7.0, 30 uL, 
15 µmol). This solution was then purified by RP-HPLC. Purest fractions were combined 
and lyophilized to yield deprotected biotinylated all-D residue KRas [1-166] 28 as a 
white solid (0.92 mg, 25% yield overall).  
The analogous reaction was run using peptides consisting of all-L residues (0.17 µmol 
limiting reagent). The overall yield was 0.73 mg (21% yield). 
 
HPLC Conditions: xBridge Prep C4 column 5µm OBD (19 x 150 mm), 20-70% 
MeCN/H2O (0.05% TFA) over 30 minutes. Flow Rate: 16 mL/min. Tr = 14.5 minutes. 
 
ESI-MS(+) for Hmb-protected KRas[1-166] 27:  Chemical Formula = 
C867H1367N231O270S8. MW = 19603.30 g/mol. ESI calculated for [M+11H+]11+ m/z: 
1783.11, found: 1782.89; [M+12H+]12+ m/z: 1634.60, found: 1634.42; [M+13H+]13+ m/z: 
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1508.94, found: 1508.98; [M+14H+]14+ m/z: 1401.24, found: 1401.16; [M+15H+]15+ m/z: 
1307.89, found: 1307.90; [M+16H+]16+ m/z: 1226.21, found: 1226.35; [M+17H+]17+ m/z: 
1154.13, found: 1153.95; [M+18H+]18+ m/z: 1090.07, found: 1090.03; [M+19H+]19+ m/z: 
1032.75, found: 1032.64; [M+20H+]20+ m/z: 981.16, found: 981.10; [M+21H+]21+ m/z: 
934.49, found: 934.36; [M+22H+]22+ m/z: 892.06, found: 891.97; [M+23H+]23+ m/z: 
853.32, found: 853.34; [M+24H+]24+ m/z: 817.80, found: 817.78. 
 
ESI-MS(+) for purified KRas[1-166] 28:  Chemical Formula = C851H1351N231O266S8. 
MW = 19331.00 g/mol. ESI calculated for [M+11H+]11+ m/z: 1758.35, found: 1758.26; 
[M+12H+]12+ m/z: 1611.91, found: 1611.85; [M+13H+]13+ m/z: 1488.00, found: 1487.72; 
[M+14H+]14+ m/z: 1381.79, found: 1381.68; [M+15H+]15+ m/z: 1289.73, found: 1289.60; 
[M+16H+]16+ m/z: 1209.19, found: 1209.22; [M+17H+]17+ m/z: 1138.11, found: 1138.00; 
[M+18H+]18+ m/z: 1074.94, found: 1074.89; [M+19H+]19+ m/z: 1018.42, found: 1018.31; 
[M+20H+]20+ m/z: 967.55, found: 967.50; [M+21H+]21+ m/z: 921.52, found: 921.50; 
[M+22H+]22+ m/z: 879.68, found: 879.63; [M+23H+]23+ m/z: 841.48, found: 841.43; 
[M+24H+]24+ m/z: 806.46, found: 806.46. 
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Part V. Preparation of specialized D-amino acid residues, α-thioester residues, and 
nucleotides 
Synthesis of Fmoc-D-Asp(Mpe)-OH: 
 
 
 
S-3: To a solution of Fmoc-D-Asp(tBu)-OH (S-2) (10.0 g, 24.3 mmol) in DMF (125 
mL) was added NaHCO3 (5.13 g, 61 mmol) followed by BnBr (8.70 mL, 73.2 mmol). 
The reaction was stirred at room temperature for 48 hours, at which point it was diluted 
with EtOAc (150 mL), and the mixture washed with brine (200 mL). The aqueous layer 
was reextracted once with EtOAc (150 mL). Combined organics were washed again 
with brine (4 x 100 mL), dried (MgSO4), and concentrated. Purification by silica gel 
chromatography (100% Hexane ! 9:1 Hexane:EtOAc ! 2:1 Hexane:EtOAc) afforded 
Fmoc-D-Asp(tBu)-OBn S-3 as a white solid (11.10 g, 91% yield). Spectroscopic data 
matched that previously reported.46 
[α]D22.1 = -15.8o (c = 0.44, CHCl3) 
Fmoc-D-Asp(tBu)-OBn S-3: 1H NMR (600 MHz, CDCl3) 7.76 (d, J = 7.5 Hz, 2H), 7.59 
(d, J = 7.1 Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.28-7.34 (m, 7H), 5.83 (d, J = 8.6 Hz, 
1H), 5.23 (d, J = 12.2 Hz, 1H), 5.17 (d, J = 12.2 Hz, 1 H), 4.64 (m, 1H), 4.41 (dd, J = 
10.4, 7.4 Hz, 1H), 4.33 (dd, J = 10.4, 7.6 Hz, 1H), 4.23 (app t, J = 7.3 Hz, 1H), 2.97 (dd, 
J = 17.0, 4.5 Hz, 1H), 2.78 (dd, J = 17.0, 4.4 Hz, 1H), 1.41 (s, 9H). 13C NMR (150 
MHz, CDCl3) 171.0, 170.2, 156.2, 144.1, 143.9, 141.5, 141.4, 135.5, 128.8, 128.6, 
FmocHN CO2H
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128.5, 127.9, 127.3, 125.4, 125.3, 120.2, 82.1, 67.7, 67.5, 50.9, 47.3, 38.0, 28.2. LRMS 
ESI(+)-MS for C30H31NO6 m/z: 524.25 [M+Na+]+. 
 
To a solution of S-3 (5.52 g, 11.01 mmol) in CH2Cl2 (110 mL) was added TFA (8.42 
mL, 110 mmol). The solution was left to stir overnight, at which point the solvent was 
removed on a rotatory evaporator. The crude material was dissolved in a minimal 
amount of Hexane/EtOAc with gentle heating, and left to precipitate in a freezer 
overnight. Solvent was decanted, and solids were washed with cold hexanes and dried 
under high vacuum to afford S-4 as a white solid (3.64 g, 74% yield). Spectroscopic 
data matched previously reported.46 
[α]D21.1 = -10.2o (c = 0.73, CHCl3), lit. [α]D21 = +12o for enantiomer (c = 1.84, CHCl3)  
Fmoc-D-Asp-OBn S-4: 1H NMR (600 MHz, CDCl3) 7.75 (d, J = 7.5 Hz, 2H), 7.58 (m, 
2H), 7.39 (t, J = 7.5 Hz, 1H), 7.27-7.40 (m, 7 H), 5.82 (d, J = 8.3 Hz, 1H), 5.21 (m, 2 
H), 4.71 (m, 1H), 4.43 (dd, J = 10.4, 7.5 Hz, 1H), 4.36 (dd, J = 10.4, 7.3 Hz, 1H), 4.21 
(app t, J = 7.1 Hz, 1H), 3.11 (dd, J = 17.5, 4.1 Hz, 1H), 2.94 (dd, J = 17.5, 4.0 Hz, 1H). 
13C NMR (150 MHz, CDCl3) 175.6, 170.6, 156.2, 144.0, 143.8, 141.5 (2 C), 135.2, 
128.8, 128.7, 128.5, 128.0, 127.3, 125.3, 120.2, 68.0, 67.6, 50.5, 47.3, 36.5. LRMS: 
ESI(+)-MS for C26H23NO6  m/z: 468.13 [M+Na+]+. 
 
To a 0oC solution of N,N’-dicyclohexylcarbodiimide (1.297g, 6.3 mmol) and 3-methyl-
3-pentanol (0.912 mL, 7.4 mmol) in anhydrous CH2Cl2 (15 mL) was added a solution of 
Fmoc-D-Asp-OBn (S-4) (2.50 g, 5.68 mmol) and 4-dimethylaminopyridine (170 mg, 
1.40 mmol) in CH2Cl2 (10 mL) over ca. 3-4 minutes. The reaction was stirred at 0 oC 
for 10 minutes, then warmed to room temperature for 8 hours. The mixture becomes 
very thick with white solids, which is difficult to stir, and this solid breaks up as the 
reaction proceeds until it becomes a finer brownish suspension. Solids were filtered 
through celite and washed with CH2Cl2 (70 mL). The filtrate was washed with sat. aq. 
NH4Cl (30 mL) followed by brine (30 mL). The organic layer was dried (MgSO4) and 
concentrated. Purification by column chromatography (9:1 Hexane/EtOAc ! 4:1 
Hexane/EtOAc) yielded Fmoc-Asp(Mpe)-OBn S-5 as a white solid (1.457g, 48% 
yield). 1H and 13C NMR data matched that previously reported.47  
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 [α]D20.5 = -21.1o (c = 0.36, CHCl3) Lit. [α]D = +17o (c = 1.0, CHCl3) for Fmoc-L-
Asp(Mpe)-OBn 
 
Fmoc-Asp(Mpe)-OBn S-5: 1H NMR (600 MHz, CDCl3) 7.76 (d, J = 7.5 Hz, 2 H), 7.59 
(m, 2 H), 7.39 (app t, J = 7.5 Hz, 2 H), 7.28-7.34 (m, 7 H), 5.85 (d, J = 8.6 Hz, 1 H), 
5.21 (m, 2 H), 4.65 (m, 1 H), 4.41 (dd, J = 10.3, 7.5 Hz, 1 H), 4.32 (dd, J = 10.3, 7.5 
Hz, 1 H), 4.22 (app t, J = 7.2 Hz, 1 H), 3.00 (dd, J = 17.1, 4.3 Hz, 1 H), 2.81 (dd, J = 
17.1, 4.2 Hz, 1 H), 1.83 (m, 2 H), 1.72 (m, 2 H), 1.34 (s, 3 H), 0.82 (t, J = 7.5 Hz, 3 H). 
13C NMR (125 MHz, CDCl3) 171.0, 170.1, 156.2, 144.1, 143.9, 141.5, 135.4, 128.8, 
128.6, 128.5, 127.9, 127.2, 125.4, 125.3, 120.2, 87.5, 67.7, 67.5, 50.8, 47.3, 37.7, 30.5 
(2 C), 23.0, 8.2. LRMS: ESI(+)-MS for C32H35NO6 m/z: 552.32 [M+Na+]+. 
 
Fmoc-D-Asp(Mpe)-OBn S-5 (1.415g, 2.67 mmol) was dissolved in absolute EtOH (110 
mL), and degassed with argon sparge for 10 minutes. Palladium on carbon (10%, 212 
mg, 0.20 mmol) was added, and hydrogen gas was bubbled from a balloon into the 
reaction mixture for 20 minutes, at which point TLC analysis indicated consumption of 
starting material. The reaction was filtered through celite, which was further washed 
with EtOAc (75 mL), and the filtrate was concentrated. Purification by silica gel 
chromatography (9:1 Hexane:EtOAc +1% AcOH ! 4:1 Hexane:EtOAc +1% AcOH), 
followed by lyophilization twice from benzene afforded Fmoc-D-Asp(Mpe)-OH S-6 as 
a white solid (955 mg, 81% yield). 1H and 13C NMR data matched that previously 
reported.47  
[α]D22.5 = -30.8o (c = 0.45, CHCl3) Lit. [α]D = +31.0o (c = 1.0, CHCl3) for Fmoc-L-
Asp(Mpe)-OH 
Fmoc-D-Asp(Mpe)-OH S-6:  1H NMR (600 MHz, CDCl3) 7.76 (d, J = 7.6 Hz, 2H), 7.60 
(t, J = 6.8 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 5.84 (d, J = 8.5 Hz, 
1H), 4.65 (m, 1H), 4.43 (dd, J = 10.6, 7.2 Hz, 1H), 4.36 (dd, J = 10.6, 7.2 Hz, 1H), 4.24 
(t, J = 7.2 Hz, 1H), 3.04 (dd, J = 17.3, 4.1 Hz, 1H), 2.83 (dd, J = 17.3, 4.9 Hz, 1H), 1.88 
(m, 2H), 1.65 (m, 2H), 1.38 (s, 3H), 0.85 (t, J = 7.5 Hz, 6H). 13C NMR (150 MHz, 
CDCl3) 175.3, 170.5, 156.3, 144.0, 143.9, 141.5, 128.0, 127.3, 125.4, 125.3, 120.2, 
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88.1, 67.6, 50.5, 47.3, 37.6, 30.6, 30.5, 23.0, 8.2. LRMS: ESI(+)-MS for C25H29NO6 
m/z: 462.84 [M+Na+]+. 
 
General Procedure for Synthesis of all-D Pseudoproline Dipeptides:48,49 
 
 
 
 
Fmoc-D-Lys(Boc)-OH (S-7) (2.81 g, 6.00 mmol) and pentafluorophenol (1.14 g, 6.20 
mmol) were suspended in EtOAc (66 mL), and the mixture was cooled in a 0oC ice 
bath. To the rapidly stirred mixture was added N,N’-dicylohexylcarbodiimide (1.36 g, 
6.60 mmol), and the reaction was stirred at this temperature for 3 hours. The reaction 
mixture was then warmed to room temperature and filtered through a pad of celite. The 
solids were washed with additional EtOAc (20 mL), and the combined filtrate was 
washed with sat. aq. NaHCO3 (30 mL) followed by brine (30 mL). The organic layer 
was dried (MgSO4) and concentrated to afford a white solid residue, which was used in 
the next step without purification. 
The resulting crude pentafluorophenol ester (assumed 6.0 mmol) was dissolved in THF 
(30 mL), and D-Serine was added (1.26 g, 12.0 mmol, dissolved in 12 mL H2O). N,N-
Diisopropylethylamine was then added (2.09 mL, 12.0 mmol), and the reaction was 
stirred for 25 minutes, at which point UPLC/MS analysis indicated full conversion. 
After 10 minutes longer, the solvent was removed in vacuo, and the residue was taken 
FmocHN CO2H
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up in EtOAc (50 mL). The organic phase was washed with 1M HCl (30 mL), and the 
aqueous layer was further extracted with EtOAc (2 x 50 mL). The combined organic 
layers were washed with brine (30 mL), dried (MgSO4), and concentrated. Purification 
by silica gel chromatography (1!10% MeOH in CH2Cl2) afforded Fmoc-D-Lys(Boc)-
D-Ser-OH S-8 as a white solid (2.465 g, 74% yield over 2 steps).  
[α]D21.7 = -13.2 (c = 0.3, CHCl3) 
S-8: 1H NMR (600 MHz, MeOH-d4) 7.78 (d, J = 7.4 Hz, 2H), 7.65 (m, 2 H), 7.38 (t, J = 
7.4 Hz, 2H), 7.30 (J = 7.4 Hz, 2H), 4.47 (m, 1H), 4.37 (d, J = 6.9 Hz), 4.22 (m, 1H), 
4.15 (m, 1H), 3.90 (dd, J = 11.1, 4.4 Hz, 1H), 3.81 (dd, J = 11.0, 3.4 Hz, 1H), 3.02 (m, 
1H), 1.81 (m, 1H), 1.65 (m, 1H), 1.41-1.50 (m, 13 H). 13C NMR (150 MHz, MeOH-d4) 
174.9, 158.6, 145.4, 145.2, 142.6, 128.8, 128.2, 126.3, 126.2, 120.9, 79.9, 68.0, 62.9, 
56.4, 56.1, 41.1, 33.0, 30.6, 28.8, 24.1. LRMS: ESI-(+) for C29H37N3O8 m/z: 556.48  
[M+H+]+.  
 
Dipeptide S-8 (1.896 g, 3.41 mmol) was dissolved in anhydrous THF (69.0 mL), and 
pyridinium p-toluenesulfonate (171.0 mg, 0.68 mmol) was added, followed by 2,2-
dimethoxypropane (2.77 mL, 22.6 mmol). The resulting solution was heated to reflux 
for 9 hours, passing the condensate over 4Å molecular sieves. At this point the reaction 
was quenched by the addition of triethylamine (0.15 mL, 1.08 mmol), and the solvent 
was removed under reduced pressure. Purification by silica gel chromatography 
(1!10% MeOH in CH2Cl2) afforded the pseudoproline dipeptide S-9 as a white solid 
(1.290 g, 64% yield). Spectroscopic data closely matched that of the commercially 
available all L-residue form of this pseudoproline. 
[α]D21.5 = +33.3 (c = 0.40, CHCl3) 
FmocHN
O
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Fmoc-D-Lys(Boc)-D-Ser(ψMe,MePro)-OH S-9: 1H NMR (600 MHz, DMSO-d6) 
Rotameric mixture 7.89 (d, J = 7.5 Hz, 2 H), 7.74 (m, 2 H), 7.41 (t, J = 7.4 Hz, 2 H), 
7.32 (m, 2 H), 6.76 (m, 1 H), 4.62 (m, 1 H), 4.01-4.29 (m, 6 H), 2.89 (m, 2 H), 1.20-
1.58 (m, 21 H). 13C NMR (150 MHz, DMSO-d6) 171.7, 171.4, 169.6, 169.0, 156.0, 
155.6, 155.4, 155.3, 144.0, 143.7, 140.7, 140.6, 127.6, 127.0, 125.4, 120.0, 95.3, 77.3, 
66.9, 65.7, 58.5, 53.2, 46.6, 31.9, 29.2, 28.2, 27.7, 25.8, 25.3, 23.0, 22.5.  LRMS: ESI-
(+) for C32H41N3O8 m/z: 596.46 [M+H+]+. 
 
S-10: Prepared according to an analogous procedure for the synthesis of S-8, starting 
with Fmoc-D-Asp(tBu)-OH (2.46 g, 6.00 mmol). D-Serine was used for dipeptide 
formation. Obtained Fmoc-D-Asp(tBu)-D-Ser-OH S-10 as a white solid (2.63 g, 88% 
over 2 steps) 
[α]D22.0 = -33.5 (c = 0.705, CHCl3) 
Fmoc-D-Asp(tBu)-D-Ser-OH S-10: 1H NMR (600 MHz, CDCl3) Rotameric Mixture 
7.73 (d, J = 7.0 Hz, 2 H), 7.45-7.60 (m, 3 H), 7.36 (m, 2 H), 7.27 (t, J = 7.2 Hz, 2 H), 
6.07 (d, J = 6.4 Hz, 1 H), 4.62 (m, 2 H), 4.36 (m, 2 H), 4.18 (t, J = 6.9 Hz, 1 H), 4.04 
(m, 1 H), 3.92 (d, J = 11.2 Hz), 2.80 (dd, J = 15.4, 4.6 Hz, 1 H), 2.71 (dd, J = 15.4, 4.6 
Hz, 1 H), 1.41 (s, 9 H). 13C NMR (150 MHz, CDCl3) 172.9, 171.5, 171.2, 156.6, 144.0, 
143.7, 141.5, 128.0, 127.3, 125.3, 120.2, 82.7, 67.7, 62.5, 55.0, 51.7, 47.2, 38.2, 28.2. 
LRMS: ESI-(+) for C26H30N2O8 m/z: 521.34 [M+Na+]+. 
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S-11: Prepared according to an analogous procedure as S-8, starting with Fmoc-D-
Asp(OtBu)-OH (2.46 mmol, 6.0 mmol). D-Threonine was used for dipeptide formation. 
Obtained S-11 as a white solid (2.427 g, 79% yield over 2 steps).  
[α]D22.4 = -23.4 (c = 1.07, CHCl3) 
Fmoc-D-Asp(tBu)-D-Thr-OH S-11: 1H NMR (600 MHz, CDCl3) 7.72 (d, J = 7.4 Hz, 2 
H), 7.49-7.57 (m, 3 H), 7.36 (m, 2 H), 7.25 (m, 2 H), 6.10 (d, J = 9.0 Hz, 1 H), 4.68 (m, 
1 H), 4.62 (d, J = 8.5 Hz, 1 H), 4.43 (m, 2 H), 4.33 (dd, J = 10.4, 7.0 Hz, 1 H), 4.19 (app 
t, J = 7.0 Hz, 1 H), 2.79 (dd, J = 16.5, 6.5 Hz, 1 H), 2.68 (dd, J = 16.4, 4.7 Hz, 1 H), 
1.40 (s, 9 H), 1.19 (d, J = 6.3 Hz, 3 H). 13C NMR (150 MHz, CDCl3) 173.3, 171.6, 
171.2, 156.6, 144.0, 143.7, 141.5, 120.2, 82.4, 68.5, 67.7, 57.7, 51.7, 47.2, 38.1, 28.2, 
19.5. LRMS: ESI-(+) for C27H32N2O8 m/z: 535.34 [M+Na+]+. 
 
S-12: Prepared using an analogous procedure for the preparation of S-9, starting with S-
10 (2.00 g, 4.01 mmol). Obtained S-12 as a white solid (1.34 g, 62% yield).  
[α]D22.0 = +50.1 (c = 0.47, CHCl3) 
Fmoc-D-Asp(tBu)-D-Ser(ψMe,MePro)-OH S-12: 1H NMR (600 MHz, DMSO-d6) 
Rotameric Mixture 7.89 (d, J = 7.5 Hz, 2 H), 7.71 (m, 2 H), 7.60 (d, J = 9.1 Hz, 1 H), 
7.41 (app t, J = 7.5 Hz, 2 H), 7.31 (m, 2 H), 4.63 (m, 1 H), 4.56 (m, 1 H), 4.11-4.32 (m, 
5H), 2.74 (dd, J = 15.8, 6.4 Hz, 1H), 2.40 (dd, J = 15.8, 7.3 Hz), 1.59 (s, 3 H), 1.42 (s, 3 
H), 1.37 (m, 9 H). 13C NMR (150 MHz, DMSO-d6) 171.6, 169.3, 167.4, 155.2, 143.9, 
143.7, 140.7, 140.6, 127.6, 127.0, 125.4, 125.3, 120.1, 95.5, 80.2, 67.1, 65.9, 58.7, 50.5, 
49.2, 46.5, 38.3, 27.6, 25.2, 22.7. LRMS: ESI-(+)-MS for C29H34N2O8 m/z: 539.34  
[M+H+]+. 
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 S13: Synthesized using an analogous procedure for the preparation of S-9, starting with 
S-11 (1.20 g, 2.34 mmol). Obtained S-13 as a white solid (908 mg, 70% yield).  
[α]D21.2 = +22.3 (c = 0.22, CHCl3) 
Fmoc-D-Asp(tBu)-Thr(ψMe,MePro)-OH S-13: 1H NMR (600 MHz, DMSO-d6) Rotameric 
Mixture 7.90 (d, 7.5 Hz, 2 H), 7.30 (m, 2 H), 7.43 (app t, J = 7.5 Hz, 2 H), 7.33 (m, 2 
H), 4.48 (m, 1 H), 3.95-4.28 (m, 5 H), 2.65 (dd, J = 15.5, 6.1 Hz, 1H), 2.48 (dd, J = 
15.5, 7.1 Hz, 1 H), 1.54 (s, 3 H), 1.49 (s, 3 H), 1.39 (m, 12 H). 13C NMR (150 MHz, 
DMSO-d6) major peaks 169.1, 168.1, 155.7, 155.0, 143.9, 143.7, 142.5, 140.7, 140.6 (2 
C), 139.4, 137.4, 128.9, 127.6, 127.3, 127.1, 127.0, 125.4, 125.3, 124.2,121.4, 120.1, 
120.0, 109.7, 95.6, 94.0, 80.7, 80.3, 75.0, 72.4, 66.0, 65.7, 51.7, 50.6, 49.4, 46.5, 27.7, 
27.6, 27.5, 26.3, 25.9, 24.0, 20.3. LRMS: ESI-(+)-MS for C30H36N2O8 m/z: 575.40 
[M+Na+]+. 
Synthesis of Fmoc-Val-(Hmb)Gly-OH dipeptide (S-16): 
 
S-14 was synthesized as adapted from the procedure of Nicolás and co-workers:50 HCl-
Gly-OH (2.00 g, 17.9 mmol) was dissolved in H2O (32 mL), and the pH was adjusted to 
pH~9 (pH paper) using 5 M NaOH. To this stirred solution was added 2-hydroxy-4-
methoxybenzaldehyde (2.72 g, 17.9 mmol), and the reaction was stirred at room 
temperature until all solids had fully dissolved (~3 hours), with periodic addition of 5 M 
NaOH to maintain a pH ~9-10. The resulting fully homogeneous yellow solution was 
cooled in an ice bath, and NaBH4 (678 mg, 17.9 mmol, dissolved in 15 mL H2O) was 
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added slowly, followed by 10 drops of 5 M NaOH. The reaction was further stirred for 
1 hour at this temperature, at which point UPLC/MS analysis indicated full reduction of 
the intermediary imine and the bright yellow color had faded. The reaction was 
quenched upon the careful addition of 2M HCl until the solution reaches pH~6-7, 
whereupon a white precipitate formed. The solution was then left overnight in a fridge, 
and the solids were filtered, washed with H2O (20 mL), and dried under high vacuum to 
afford N-Hmb-Gly-OH S-14 (4.00 g, 90% yield) as an off-white solid, which required 
no additional purification. 
S-14: 1H NMR (600 MHz, AcOH-d4) 7.21 (d, J = 8.4 Hz, 1 H), 6.52 (d, J = 2.4 Hz, 1 
H), 6.48 (dd, J = 8.4 Hz, 2.4 Hz, 1 H), 4.30 (s, 2 H), 3.84 (s, 2 H), 3.76 (s, 3H). 13C 
NMR (150 MHz, AcOH-d4) 172.6, 164.0, 158.5, 134.3, 110.1, 107.4, 103.3, 56.4, 49.9, 
49.0. LRMS: ESI(+)-MS for C10H13NO4 m/z: 212.01 [M+H]+. 
To a 0oC solution of Fmoc-Val-OH (300.0 mg, 0.884 mmol) in EtOAc (8 mL) was 
added a solution of 2,3,4,5,6-pentafluorophenol (178.0 mg, 0.97 mmol) in EtOAc (2 
mL). To this solution was added N,N’-dicyclohexylcarbodiimide (199.7 mg, 0.97 
mmol), and the reaction was stirred for 4 hours at this temperature. The reaction mixture 
was then warmed to room temperature and filtered to remove solids. The solids were 
washed with EtOAc (15 mL), and the filtrate was sequentially washed with sat. aq. 
NaHCO3 (15 mL) and brine (15 mL). The organic layer was then dried (MgSO4) and 
concentrated. The resulting crude pentafluorophenol ester (S-15) was then dissolved in 
DMF (4 mL), and N-Hmb-Gly-OH S-14 (280 mg, 1.326 mmol) was added, followed by 
N,N-diisopropylethylamine (0.31 mmol, 1.76 mmol). The reaction was stirred at room 
temperature for 3.5 hours, and was then diluted with EtOAc (45 mL). The solution was 
then washed with 0.5 M HCl (15 mL), and the aqueous layer was further extracted with 
EtOAc (1 x 40 mL). The combined organic layers were washed with brine (2 x 10 mL), 
dried (MgSO4), and concentrated. Purification by silica gel chromatography (1:1 
EtOAc/Hexane +1% AcOH ! 2:1 EtOAc/Hexane +1% AcOH) and combination of 
purest fractions afforded S-16 as a white solid (229 mg, 49% yield).  
Starting from Fmoc-L-Valine: [α]D22 = -23.6o (c = 0.57, CHCl3) 
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Starting from Fmoc-D-Valine: [α]D22 = +23.5o (c = 0.64, CHCl3) 
 
S-16: 1H NMR (600 MHz, CDCl3, 3.6:1 Mixture of amide rotamers) 7.74 (d, J = 7.5 Hz, 
2 H), 7.53 (m, 2 H), 7.37 (m, 2 H), 7.29 (m, 2 H), 6.95 (d, J = 8.2 Hz, 1 H), 6.47 (d, J = 
2.5 Hz, 1 H), 6.35 (dd, J = 8.3, 2.5 Hz, 1 H), 5.56 (d, J = 9.5 Hz, 1 H), 4.56 (d, J = 15.0 
Hz, 1 H), 4.28-4.41 (m, 4 H), 4.15-4.22 (m, 2 H), 3.73 (s, 3 H), 1.98 (m, 1 H), 0.90 (d, J 
= 6.5 Hz, 6 H). 13C NMR (150 MHz, CDCl3) 174.9, 170.6, 162.0, 157.5, 156.8, 143.9, 
143.6, 141.5 (2 C), 132.3, 128.0, 127.4, 127.3, 125.4, 125.3, 125.2, 120.2, 113.3, 106.1, 
102.8, 67.7, 56.2, 55.5, 48.4, 47.8, 47.2, 32.0, 19.4, 17.7. UPLC/MS: ESI(+)-MS for 
C30H32N2O7 m/z: 533.32 [M+H]+. 
 
Synthesis of HCl.H-D-Leu-SAlkyl (S-18) and HCl.H-D-Lys(Alloc)-SAlkyl (S-19): 
 
 
HCl.H-D-Leu-SAlkyl (S-18) was synthesized according to a procedure adapted from 
Stuhr-Hansen et al.51 To a solution of Boc-D-Leu-OH (1.00 g, 4.32 mmol) in MeCN (13 
mL) was added N,N-diisopropylethylamine (1.88 mL, 10.8 mmol) followed by HBTU 
(1.64 g, 4.32 mmol). After 5 minutes, Ethyl 3-mercaptopropionate (1.09 mL, 8.64 
mmol) was added. The reaction was stirred until no starting material remained by TLC 
analysis (5 hours), at which point the mixture was concentrated and purified by silica 
gel chromatography (100% Hexane!20:1 Hexane/EtOAc!9:1 Hexane/EtOAc) to 
afford the corresponding thioester as a colorless oil (1.160 g, 77% yield). A portion of 
the resulting Boc-protected amino acid thioester (1.08 g, 3.11 mmol) was then dissolved 
in CH2Cl2 (3 mL) and treated with 4M HCl in dioxane (6.0 mL, 24.0 mmol) and stirred 
for 4.5 hours. The reaction was concentrated under reduced pressure, and the residue 
was dissolved in ca. 5 mL 1:1 MeCN/H2O (0.1% TFA), shell frozen, and lyophilized to 
afford HCl-H-D-Leu-SAlkyl S-18 as a white solid (764 mg, 87% yield).  
 
[α]D22 = -42.7o (c = 0.38, MeOH)  
H2NHCl.
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 S-18: 1H NMR (600 MHz, D2O) 4.33 (dd, J = 8.1, 6.3 Hz, 1 H), 4.20 (q, J = 7.1 Hz, 2 
H), 3.35 (dt, J = 13.8, 6.8 Hz, 1 H), 3.25 (dt, J = 13.8, 6.8 Hz, 1 H), 2.78 (app t, J = 6.8 
Hz, 2 H), 1.88 (m, 1 H), 1.77 (m, 2 H), 1.27 (t, J = 7.1 Hz, 3 H), 1.00 (d, J = 6.4 Hz, 3 
H), 0.99 (d, J = 6.4 Hz, 3 H).  13C NMR (125 MHz, MeOH-d4) 198.2, 173.1, 62.1, 59.0, 
42.1, 34.9, 25.8, 25.5, 23.0, 22.3, 14.7. LRMS: ESI(+)-MS for C11H21NO3S m/z: 247.75 
[M+H+]+. 
 
 
S-19: Synthesized analogously to S-18, starting with Boc-D-Lys(Alloc)-OH.52  
 
[α]D22 = -41.0o (c = 0.47, MeOH)  
 
S-19: 1H NMR (600 MHz, MeOH-d4) 5.93 (m, 1 H), 5.28 (dd, J = 17.2, 1.4 Hz, 1 H), 
5.18 (d, J = 10.5 Hz, 1 H), 4.52 (m, 2 H), 4.23 (dd, J = 6.8, 5.8 Hz, 1 H) 4.15 (q, J = 7.1 
Hz, 2 H), 3.26 (m, 2 H), 3.13 (m, 2 H), 2.69 (dt, J = 6.7, 1.4 Hz, 2 H), 2.00 (m, 1 H), 
1.88 (m, 1 H), 1.56 (m, 2 H), 1.45 (m, 2 H), 1.26 (t, J = 7.1 Hz, 3 H). 13C NMR (150 
MHz, MeOH-d4) 197.6, 172.9, 158.9, 134.55, 117.5, 66.3, 62.0, 60.3, 41.1, 34.8, 32.3, 
30.5, 25.3, 22.8, 14.5. LRMS: ESI(+)-MS for C15H26N2O5S m/z: 347.11 [M+H+]+. 
 
 
Synthesis of L-GppNHp: 
L-GppNHp was synthesized according to literature protocols, starting with L-ribose 
(Carbosynth). L-Guanosine was synthesized from L-ribose tetraacetate as described by 
Zou, et al.18 5’-L-Guanosine Monophosphate was then converted into the corresponding 
imidotriphosphate according to the procedure of Yount.20 
H2NHCl.
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Dowex 8X50W resin (H+ form, 200-400 mesh, 3.48 g, prewashed with anhydrous 
MeOH (3 x 10 mL)) was added to a flame-dried 200 mL round bottom flask, and 
suspended in anhydrous MeOH (70 mL). L-Ribose 29 (3.00 g, 20.0 mmol, purchased 
from Carbosynth) was added, and the reaction was stirred for 5 hours at room 
temperature until TLC analysis indicated full consumption of starting material. At this 
time, the reaction was filtered through a medium porosity frit, the resin washed with 
additional MeOH (20 mL), and the filtrate was concentrated to yield the crude methyl 
glycoside which was carried forward without further purification.  
The crude residue was dissolved in pyridine (60 mL) and cooled in an ice bath. Acetic 
anhydride (12.0 mL, 127 mmol) was added, and the reaction stirred for 30 minutes, at 
which point the ice bath was removed and reaction stirred overnight at room 
temperature. The reaction mixture was concentrated, taken up in EtOAc (80 mL), and 
washed successively with water (75 mL), sat. aqueous NaHCO3 (3 x 30 mL, carefully), 
and Brine (30 mL). The organic layer was dried (MgSO4) and concentrated to yield a 
residue, which was then coevaporated with dry toluene (3 x 20 mL) and carried forward 
without further purification.  
This crude material (assumed 20.0 mmol) was then dissolved in AcOH (18.0 mL) and 
Ac2O (4.5 mL) and cooled in an ice bath. H2SO4 (1.26 mL, 23.6 mmol) was added 
dropwise over 5 minutes, and the reaction stirred 45 minutes, at which point the reaction 
was warmed to room temperature for 1.5 hours. Additional Ac2O (3.0 mL) was added, 
and the reaction stirred 1 hour longer. The reaction mixture was the poured onto 60 mL 
crushed ice and stirred until all the ice had melted. The mixture was extracted with 
CHCl3 (3 x 70 mL), and the combined organic layers were washed with sat. aq. 
NaHCO3 (3 x 40 mL, carefully) and then Brine (40 mL). The combined organic layers 
were then dried (MgSO4) and concentrated. The resulting residue was coevaporated 
with toluene (3 x 20 mL) then CHCl3 (20 mL) to afford L-Ribose tetraacetate 31 as a 
colorless oil that solidified upon standing, and which was used without further 
O
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purification. (5.590 g, 2.6:1 dr, 87% over 3 steps). NMR data and LRMS were 
consistent with that previously reported.53  
 
Synthesis of L-Guanosine and L-Guanosine 5’-monophosphate: 
 
 
S-20 was synthesized according to the protocol of Zou:18 
To a suspension of guanine (6.00 g, 39.7 mmol) in anhydrous N,N-dimethylacetamide 
(50 mL) was added Ac2O (10.0 mL, 105.8 mmol). The flask was equipped with a reflux 
condenser, and stirred in a 160oC oil bath under an argon atmosphere for 6.5 hours. The 
reaction was cooled to room temperature, and solids were filtered through a Büchner 
funnel, washed with EtOH (100 mL), and dried under high vacuum to yield bis-
acetylated guanine (7.157 g, 77% yield) as a white solid, whose spectroscopic data was 
consistent with that previously reported.18  
1H NMR (600 MHz, DMSO-d6) 8.45 (s, 1 H), 2.81 (s, 3 H), 2.21 (s, 3 H). 
A portion of this material (3.06 g, 13.01 mmol) was suspended in pyridine (60 mL), and 
N,N-diisopropylethylamine was added (4.60 mL, 26.4 mmol), followed by solid N,N-
diphenylcarbamoyl chloride (3.316 g, 14.30 mmol). The reaction was stirred at room 
temperature for 1 hour, becoming a homogeneous red solution. The reaction was 
quenched by the addition of H2O (5.5 mL), and was stirred for a further 10 minutes, at 
which point solvent was removed under reduced pressure. The residue was 
coevaporated with toluene (2 x 30 mL) to remove most residual pyridine. To the crude 
residue was added 50% aqueous EtOH (160 mL), and the mixture was heated under a 
reflux condenser in a 95oC oil bath for 2 hours. The resulting fine suspension was 
cooled to room temperature, and solids were filtered and washed with EtOH (3 x 50 
mL). The obtained solid was dried overnight in a vacuum desiccator over P2O5 to afford 
pure S-20 as a white solid (4.166 g, 82% yield). Spectroscopic data matched that 
previously reported.18  
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S20: 1H NMR (600 MHz, DMSO-d6) 13.56 (s, 1 H), 10.6 (s, 1 H), 8.44 (s, 1 H), 7.45 
(m, 8 H), 7.31 (m, 2 H), 2.15 (s, 3 H).  
 
 
Protected guanine derivative S-20 (1.218 g, 3.14 mmol) was suspended in 1,2-
dichloroethane (30.0 mL), and N,O-bis(trimethylsilyl)acetamide (1.56 mL, 6.39 mmol) 
was added. The flask was equipped with a reflux condenser and heated in an 80oC oil 
bath for approximately 15 minutes, until the solution had become fully homogeneous. 
After cooling to room temperature, the solvent was removed in vacuo, and the residue 
was redissolved in anhydrous toluene (15.0 mL). To this solution was added TMSOTf 
(0.79 mL, 2.90 mmol), followed by a solution of L-Ribose tetraacetate 31 (1.199 g, 3.77 
mmol, dissolved in 15 mL toluene). The reaction was heated to 80 oC for 1 hour under 
argon, then cooled and diluted with 50 mL ethyl acetate. The organic layer was washed 
with sat. aq. NaHCO3 (30 mL), then brine (50 mL), dried (MgSO4) and concentrated. 
The residue was purified by silica gel chromatography (1:1 EtOAc/Hexane ! 5:1 
EtOAc/Hexanes) to yield protected L-guanosine 33 as a colorless foamy solid (1.799 g, 
73% yield).  
 
[α]D21.5 = +4.0o (c = 0.15, CHCl3) 
 
33: 1H NMR (600 MHz, MeOH-d4) 8.43 (s, 1 H), 7.47 (m, 4 H), 7.39 (m, 4 H), 7.28 (m, 
2 H), 6.30 (d, J = 4.4 Hz, 1H), 5.99 (dd, J = 5.8, 4.4 Hz, 1 H), 5.86 (app t, J = 5.4 Hz, 1 
H), 4.44 (m, 3 H), 2.27 (s, 3 H), 2.13 (s, 3 H), 2.06 (s, 3 H), 2.00 (s, 3H). 13C NMR (150 
MHz, MeOH-d4) 172.3, 171.8, 171.4, 171.3, 157.2, 155.6, 153.9, 152.1, 145.4, 143.2, 
130.4, 128.4, 127.7, 122.2, 88.8, 81.7, 74.7, 72.2, 64.6, 24.7, 20.6, 20.5, 20.3. LRMS: 
ESI(+)-MS for C31H30N6O10 m/z: 647.3 [M+H+]+, 669.4 [M+Na+]+ 
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33 (1.416 g, 2.19 mmol) was dissolved in methanolic ammonia (7N, 20.0 mL), and 
stirred at room temperature overnight. Addition 7N NH3 in methanol (10.0 mL) was 
then added, and the mixture stirred a total of 20 hours. The reaction was directly 
concentrated, suspended in 80 mL H2O, and washed with CHCl3 (3 x 50 mL). The 
combined organic layers were back extracted with 30 mL H2O to recover emulsified 
material. The cloudy white aqueous layer was heated in a 100 oC oil bath until it 
became homogeneous, and solids were allowed to precipitate in a refrigerator over 2 
days. The precipitated solids were filtered through a Büchner funnel, rinsed with 10 mL 
cold H2O, and air-dried to afford L-guanosine (S-21) as a white solid (350 mg, 57% 
yield).  
 
[α]D22 = +72.4o (c = 0.30, 0.1 N NaOH). Lit54: [α]D26 = -70o (c = 1.15, 0.1 N NaOH) for 
enantiomer 
 
S-21: 1H NMR (500 MHz, MeOH-d4) 7.95 (s, 1 H), 5.83 (d, J = 5.9 Hz, 1 H), 4.59 (app 
t, J = 5.5 Hz, 1 H), 4.28 (dd, J = 5.1, 3.4 Hz, 1 H), 4.09 (m, 1 H), 3.84 (dd, J = 12.3, 2.9 
Hz, 1 H), 3.73 (dd, J = 12.3, 3.2 Hz, 1 H). 13C NMR (125 MHz, MeOH-d4) 159.2, 
152.3, 152.5, 138.6, 118.4, 90.2, 87.4, 75.5, 72.3, 63.2. LRMS: ESI(+)-MS for 
C10H13N5O5 m/z: 284.28 [M+H+]+. 
 
 
Synthesized according to a previously reported method:17 S-24 (177 mg, 0.625 mmol, 
dried over P2O5 in a vacuum desiccator) was suspended in trimethyl phosphate (2.12 
mL, dried over 4Å molecular sieves), and heated to 50oC for 15 min. The mixture was 
O
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then cooled to 0oC, and H2O (5.6 uL, 0.31 mmol) was added followed by POCl3 (120 
uL, 1.29 mmol) dropwise. The resulting homogeneous light yellow reaction mixture 
was stirred for 3 hours, and was quenched by the addition of 3 mL H2O, stirred for 30 
minutes, and then adjusted to pH~4-5 with 3M NaOH, and the mixture was shell-frozen 
and lyophilized. The residue was dissolved in H2O (10 mL+ 1% TFA), and purified by 
RP-HPLC. Conditions: Microsorb 100-8 C18 column (250 x 21.4 mm), 0-30% MeCN 
(+0.05% TFA) against H2O (+0.05% TFA) over 30 minutes, 16 mL/min. The product 
elutes around 8 minutes. Collected purest fractions are shell-frozen and lyophilized, 
redissolved in 10 mL H2O, and a few drops of NH4OH are added until pH~10. 
Lyophilization then affords the corresponding ammonium salt S-25 (133 mg, 58% 
yield). Spectral data closely matched that reported.17 
[α]D21.3 = +37.7 (c = 0.12, H2O)  
S-25: 1H NMR (600 MHz, D2O) 8.10 (s, 1 H), 5.93 (d, J = 6.1 Hz, 1H), 4.74 (dd, J = 
5.8, 5.4 Hz, 1 H), 4.47 (dd, J = 5.1, 3.5 Hz, 1 H), 4.11 (m, 2 H). 13C NMR (150 MHz, 
D2O) 158.9, 153.9, 151.7, 137.5, 116.2, 86.8, 83.9 (d, JC-P = 8.7 Hz), 73.8, 70.4, 64.4 (d, 
JC-P = 4.9 Hz). 31P NMR (200 MHz, D2O) -2.74 (s, 1 P). LRMS: ESI(+)-MS for 
C10H14N5O8P m/z: 364.01 [M+H+]+; 727.18 [2M+H+]+. 
 
This nucleotide monophosphate was then converted to its corresponding 
tributylammonium salt according to the procedure of Yount:20 S-25 (133 mg) was added 
in a minimal volume of cold H2O to a column of pre-washed Dowex 50WX8 (H+ form, 
2 cm x 2 cm), eluting with cold deionized water. All fractions containing the desired 
compound (as judged by direct injection mass spectral analysis of individual fractions) 
were collected and stirred with excess NBu3 (2.0 mL), and the mixture was 
concentrated on a rotatory evaporator. This residue was dissolved in 1:1 MeCN/H2O 
and lyophilized to yield the corresponding mono-tributylammonium salt as a white solid 
(169 mg), which was further dried in a vacuum desiccator over solid KOH and CaSO4.  
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Synthesis of ditetrabutylammonium imidodiphosphate20 
Tetrasodium imidodiphosphate (158.4 mg, 0.6 mmol) was dissolved in 5 mL cold 
deionized H2O and eluted on a column of washed Dowex 50WX8 (50-100 mesh, ~30 
meq, ~17mL of wet resin), using cold deionized H2O as the eluent. All acidic fractions 
(pH paper) were combined in a rapidly stirring solution of excess NBu3 (1.45 mL) in 
~30mL H2O in an ice-bath. The resulting mixture was then concentrated on a rotatory 
evaporator with a water bath temperature <30 oC. The residual colorless gum was 
coevaporated with 3 x 15 mL CHCl3, and dissolved in 1.2 mL dry DMF (0.5 M 
solution, assuming quantitative conversion).  
Synthesis of L-GppNHp (35)20 
L-Guanosine 5’-Monophosphate tributylammonium salt 34 (60.0 mg, 0.109 mmol) was 
dissolved in anhydrous DMF (0.54 mL) in an oven-dried 1-dram vial, and NBu3 was 
added (54 uL, 0.22 mmol, dried over 4Å molecular sieves) followed by diphenyl 
chlorophosphate (43 uL, 0.123 mmol). The reaction was stirred at room temperature for 
2 hours, at which point cold diethyl ether (3 mL) was added, and the reaction flask was 
kept over a bed of dry ice for 5 minutes. The vial was placed inside a 50 mL plastic 
centrifuge tube and centrifuged (5 min, 5000 rpm, 10oC), and the solvent was carefully 
pipetted out of the vial. The residue was triturated once more with 2 mL ether, 
centrifuged and decanted to afford a white solid residue. The vial was briefly placed on 
high vacuum to remove residual ether, and the residue was redissolved in dry DMF 
(0.60 mL). Separately, ditetrabutylammonium imidodiphosphate (0.5 M solution in 
DMF, 0.44 mL, 0.22 mmol) was added to a flame-dried 10 mL round bottom flask 
under argon, and pyridine (1.50 mL) was added. The solution of activated intermediate 
was then added dropwise via syringe over a 10-minute period, and the reaction was 
stirred for 2 hours longer (the reaction mixture goes from homogeneous to cloudy over 
the course of the reaction). The reaction mixture was transferred in two equal portions 
into two 15 mL centrifuge tubes and precipitated upon the addition of cold diethyl ether 
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(26 mL total). The suspensions were cooled over a bed of dry ice for 5 minutes, and 
then centrifuged. The ether was decanted, and the residue triturated with 8 mL cold 
ether, and decanted again. The resulting white solid was dissolved in 0.1 M 
triethylammonium bicarbonate (TEAB) buffer (pH ~ 7.5) and purified by ion-pairing 
RP-HPLC. Conditions: xBridge Prep C18 5µm OBD column (19 x 150 mm), 0-10% 
MeCN against 0.1 M TEAB (pH ~7.5) over 45 min, 5 mL/min. Tr = 20 min. 1 mL 
fractions were collected around the eluting peak and analyzed by diluting small aliquots 
in 4:1 H2O/MeOH and analyzing by direct injection ESI-MS(-). Fractions containing 
the desired mass were combined and concentrated on a rotatory evaporator below 30oC, 
followed by coevaporation of the residue with MeOH (2 x 5 mL). 
 
The resulting triethylammonium salt was converted to the Na+ form through the 
following procedure: The above material was dissolved in MeOH (0.8 mL) and 
transferred via syringe into a 15 mL centrifuge tube. The nucleotide triphosphate was 
precipitated upon the addition of NaI (1M solution in acetone, 2.5 mL). Additional cold 
acetone (1.5 mL) was added, the mixture was cooled on a bed of dry ice for 5 minutes, 
and then centrifuged. The solvent was decanted, and the pellet was further triturated 
with NaI (1M in acetone) as before, and the mixture was centrifuged as before. The 
white solid residue was then sequentially triturated and centrifuged with cold acetone (3 
x 5 mL), then cold diethyl ether (2 x 5 mL), and finally dried in vacuo to yield a white 
free-flowing solid (14.8 mg, 23% yield). Redissolution and lyophilization from pure 
H2O should be avoided, as some hydrolysis of the imidotriphosphate was observed 
upon relyophilization or standing in water over time (1H, 13C, and 31P NMR data were 
consistent with a sample of commercially available GppNHp (Santa Cruz 
Biotechnology).  
1H NMR (600 MHz, D2O) 8.12 (s, 1H), 5.92 (d, J = 6.1 Hz, 1 H), 4.81 (app t, J = 5.8 
Hz, 1 H), 4.61 (dd, J = 5.0, 3.5 Hz, 1 H), 4.35 (m, 1 H), 4.26 (m, 1 H), 4.20 (m, 1 H). 
13C NMR (150 MHz, D2O) 159.9, 154.6, 151.8, 137.57, 116.4, 86.6, 83.8 (d, JC-P = 8.6 
Hz), 73.4, 70.1, 64.8 (d, JC-P = 4.3 Hz). 31P NMR (200 MHz, D2O) -4.20 (d, J = 4.0 Hz, 
1 P), -11.65 (br s, 1 P), -13.82 (dt, J = 21.0, 4.8 Hz, 1 P). LRMS ESI(-)-MS for 
C10H17N6O13P3 (Free acid) m/z: 521.31 [M-H+]-. 
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Part VI. Procedures for the preparation of mant-GppNHp and biological assays 
Synthesis of mant-GppNHp: 
Syntheses of mant-GppNHp and mant-L-GppNHp were performed as generally 
described for mant-GTP.55  GppNHp was dissolved to 20 mM in 500 uL ultrapure water, 
then the pH was adjusted to ~9.5 with 1 M NaOH. The solution was heated to 38 oC, 
and N-Methylisatoic anhydride (6 mg / 34 µmol / 3.4 equiv, technical grade, Aldrich) 
was added while stirring. The pH was maintained between 9 and 10 by periodic 
addition of 1 M NaOH. After 3 hours, 1 M HCl was added to lower the pH to ~7 and 
terminate the reaction. Undissolved N-Methylisatoic anhydride was removed by 
centrifugation and the product was purified by HPLC using a 30 minute 10-60% MeCN 
gradient on an Agilent Zorbax semi-preparative C18 column. The expected compound 
has a m9ss of 655.4 and a λmax at 252 nm with ε=21500 M-1cm-1 at pH 7. The observed 
M+H (ESI+) was 656.1 for mant-GppNHp and 656.1 for mant-L-GppNHp, and 
observed m/z (ESI-) was 654.1 for mant-GppNHp and 654.1 for mant-L-GppNHp. 
Ras Refolding and Purification. All steps were performed at 4 oC, using low-binding 
plastic consumables and taking care to minimize transfers. Lyophilized Ras proteins 
were dissolved to 500 uM in refolding buffer (50 mM Tris pH 8.0, 75 mM NaCl, 5 mM 
MgCl2) containing 5 M GdnHCl, 5 mM DTT, and 100 uM guanine nucleotide, then 10 
ul (5 nmol) was rapidly diluted 100-fold with 1000 ul of refolding buffer containing 1 
mM DTT and 100 uM guanine nucleotide. After 1 hour incubation, the sample was 
dialyzed (Pierce 66380) for 3+ hours against 250 ml of refolding buffer containing 1 
mM DTT, then concentrated to 25 ul (Pierce 88513) and purified by gel filtration using 
an 8-minute isocratic run in refolding buffer on an Agilent AdvanceBio SEC 300 Å, 2.7 
um column (4.6 x 150 mm) at 1.0 ml/min flow rate at 4 oC on an Agilent 1200 Series 
HPLC, collecting the monomer fraction. For CD measurements, the running buffer was 
20 mM sodium phosphate pH 7.5, 2 mM MgCl2. Proteins were quantified by 
absorbance at 280 nm using an extinction coefficient of 19,685 M-1cm-1 for nucleotide-
bound proteins and 11,920 M-1cm-1 for apoproteins. Purification of recombinant 
KRas(G12V) and loading with GppNHp nucleotides, purification of Raf RBD, and 
synthesis and purification of RDA peptides was performed as described24.  
The sequence of the RDA44 peptides is 
PRRPRCPGDAASIAALHAYWARLWNYLYRVS. 
Circular Dichroism (CD) Spectroscopy. CD measurements were carried out on a 
Jasco J-710 spectrophotometer equipped with a PTC-348W temperature controller. Ras 
proteins were placed in a 1 mm quartz cuvette at 0.5-1.0 µM in 20 mM sodium 
phosphate pH 7.5, 2 mM MgCl2, and the CD was scanned from 260 nm to 190 nm at 25 
oC. 
Nucleotide Dissociation Assays. mant-GppNHp-bound KRas proteins were prepared 
by the refolding procedure described above, performing all steps with protection from 
light. For the assay, the wells of a black 96-well plate (Costar 3915) were seeded with 
100 ul of assay buffer (50 mM Tris pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.1 mg/ml 
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BSA), containing 2.5 µM Raf or RDA miniprotein, followed by 100 ul of ~0.5 uM 
purified Ras protein. After 15 minutes incubation to allow binding, nucleotide was 
added to 10 uM final concentration and the dissociation of mant nucleotide from Ras 
was monitored by tracking the mant fluorescence (excitation 370 nm, emission 450 nm, 
cutoff 435 nm) with a SpectraMax M5 (Molecular Devices), recording six reads every 
30 seconds. 
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Part VII: Synthesis of HIV-1 Protease 
 
Synthesis of HIV[1-27] Thioacid (42) 
 
 
 
Synthesized on 0.075 mmol scale (starting with Fmoc-Gly-OH NovaSyn TGT resin, 
0.19 mmol/g, using 5.3 equiv amino acids, 5.3 equiv coupling agents, Deblock: 2% 
DBU, 2% Piperidine in DMF). Mild cleave using 8:1:1 CH2Cl2/TFE/AcOH according 
to the general procedure afforded the cruded protected peptide. 
 
To a suspension of crude peptide (298 mg, 58 µmol) in THF (8.5 mL) and CH2Cl2 (2.0 
mL) was added HBTU (110.0 mg, 0.29 mmol), DIEA (140 µL, 0.80 mmol), and 2,4,6-
trimethoxybenzylthiol7 (62.0 mg, 0.29 mmol). The reaction was stirred for 6 hours at 
room temperature under argon, at which point additional 2,4,6-trimethoxybenzylthiol 
(37.0 mg, 0.17 mmol) and HBTU (32.0 mg, 0.08 mmol) were added, and the reaction 
stirred overnight. The mixture was concentrated, and filtered by column 
chromatography (12 g SiO2, 0-5% MeOH in CH2Cl2, then 10% MeOH in CH2Cl2 wash). 
All fractions containing the desired peptide were concentrated and subjected to cocktail 
B deprotection (4.5 mL, argon). The peptide was directly precipitated with the addition 
of cold ether according to the general procedure to afford the crude deprotected peptide. 
Lyophilization from 1:1 MeCN/H2O (+0.1% TFA) afforded the crude thioacid as a 
QITLWQRPLVTIRIGGQLKEALLDTG
O
O
1. 8:1:1 CH2Cl2/TFE/AcOH
2. TmobSH, HBTU, DIEA
    THF/CH2Cl2
3. Cocktail B
*Fully protected 
(non-standard protecting groups shown)
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white solid (122.5 mg). Due to solubility issues, the residue could not be efficiently 
purified using RP-HPLC. The thioacid was further purified by reverse-phase column 
chromatography (12g C2 silica gel, 20 mg portions dissolved in 250 µL TFA). 
Conditions: 15% MeCN!50% MeCN!70% MeCN!90% MeCN against H2O over 
12 minutes. The product elutes around 6.5 min. Combination of the purest fractions and 
lyophilization afforded thioacid 42 as a white fluffy solid (19.8 mg). 
ESI-MS(+) for peptide 42. Chemical Formula = C156H244N38O41S. MW = 3339.95 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1670.97, found: 1670.99; [M+3H+]3+ m/z: 
1114.31, found: 1113.91. 
 
Synthesis of HIV[28-66] (43): 
 
 
Synthesized on a 0.1 mmol scale, starting with Fmoc-Glu(tBu)-OH NovaSyn TGT 
Resin. Non-standard amino acids (used at the indicated positions) were Fmoc-Gly-
(Dmb)-Gly-OH, Fmoc-Asp(Mpe)-OH, and Fmoc-Lys(Alloc)-OH. Cleavage with 8:1:1 
CH2Cl2/TFE/AcOH according to the general protocol yielded the desired protected 
peptide. 
 
To a suspension of the protected peptide (500 mg, 76.1 µmol) in CHCl3 (7.0 mL) at 0 
oC was added HOOBt (37.2 mg, 0.228 mmol) followed by HCl-H-Ala-Set (34.6 mg, 
0.204 mmol) and EDC (40.3 µL, 0.228 mmol). The reaction was stirred at this 
temperature for 2 hours, and was quenched upon the addition of 6 mL CHCl3 
(containing 5% AcOH). The mixture was washed with H2O (4 mL), which was 
reextracted once with 5 mL CHCl3 (containing 5% AcOH). The organic layers were 
O
O
*Fully protected (only non-standard amino acid protection shown)
Boc
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2. HCl.H-Ala-SEt
    EDC, HOOBt
    CHCl3 0 oC
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concentrated and subjected to cocktail B (10 mL, 2.5 hr, argon). The peptide was 
precipitated with cold diethyl ether according to the general protocol, and the pellet was 
redissolved in 28 mL 1:1 MeCN/H2O (+0.1% TFA). This solution was allowed to sit at 
room temperature overnight to allow for any CO2 adducts with Trp to be removed. 
Purification of ½ of this material by RP-HPLC afforded the desired peptide 43 as a 
white solid (31.5 mg, approx. 18% yield). 
HPLC Conditions: Microsorb 300-5 C4 (250 x 21.4 mm), 30-80% MeCN/H2O (0.05% 
TFA) over 30 minutes. Flow Rate: 20 mL/min. Tr = 15 minutes. 
ESI-MS(+) for peptide 43: Chemical Formula = C214H332N50O64S3. MW = 4725.48 
g/mol. ESI calculated for [M+3H+]3+ m/z: 1576.16, found: 1575.83; [M+4H+]4+ m/z: 
1182.37, found: 1182.82. 
 
Synthesis of HIV[67-94] Thioacid (44): 
 
 
Synthesized on a 0.1 mmol scale. Non-standard amino acids used were Fmoc-
Lys(Alloc)-OH, Fmoc-Val-(Dmb)Gly-OH, Fmoc-Gly-Thr(ΨMe,Mepro)-OH, and Fmoc-
Leu-Thr(ΨMe,Mepro)-OH. The peptide was cleave from the resin using 8:1:1 
CH2Cl2/TFE/AcOH according to the general procedure. 
 
Crude peptide (309 mg, 66 µmol) was dissolved in CHCl3 (6.0 mL) and TFE (0.7 mL). 
The mixture was cooled to 0 oC and HOOBt (32.2 mg, 0.198 mmol) was added 
followed by TFA.H-Gly-STmob7 (69.0 mg, 0.18 mmol) and EDC (35 µL, 0.198 mmol). 
O
O
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The reaction was stirred for 2.5 hours, at which point some unreacted starting material 
remained. Additional TFA.H-Gly-STmob (30 mg, 0.078 mmol) and EDC (15 µL, 0.085 
mmol) were added and the reaction stirred a further 2 hours. The reaction was quenched 
upon the addition of 15 mL CHCl3 (+5% AcOH), and the organic layer was washed 
with H2O (6 mL) and then concentrated. The peptide was deprotected using cocktail B 
(8 mL, 2.5 hr, argon) and was precipitated upon addition of diethyl ether according to 
the general procedure. Due to the insolubility and difficulty in handling of this crude 
peptide, only a portion was purified by RP-HPLC to afford 44 as a white solid (8.0 mg). 
HPLC conditions: C4 Microsorb column, 30-80% MeCN (+0.05% TFA) over 30 min. 
Flow rate: 20 mL/min. TR = 17 min. 
ESI-MS(+) for peptide 44. Chemical Formula = C149H239N37O38S3. MW = 3252.95 
g/mol. ESI calculated for [M+2H+]2+ m/z: 1627.48, found: 1627.09; [M+3H+]3+ m/z: 
1085.31, found: 1085.02; [M+4H+]4+ m/z: 814.24, found: 813.97. 
 
Synthesis of HIV[95-115] (45): 
	
Synthesized on a 0.05 mmol scale starting with amide Sieber resin (~0.21 mmol/g 
loading). Cleavage with cocktail B (5 mL, 5 hours) and precipitation of the peptide with 
diethyl ether according to the general procedure afforded the crude deprotected peptide. 
Purification by RP-HPLC afforded 45 as a white solid (11.1 mg, 9% yield). 
HPLC Conditions: C8 xBridge column 5 µm OBD, 20-65% MeCN (+0.05% TFA) 
over 30 min. Flow rate: 16 mL/min. TR = 8.5 min. 
ESI-MS(+) for peptide 45. Chemical Formula = C115H201N41O27S2. MW = 2654.25 
g/mol. ESI calculated for [M+3H+]3+ m/z: 885.75, found: 885.40; [M+4H+]4+ m/z: 
664.56, found: 664.46. 
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Synthesis of HIV-1 Protease [1-66] I66A (46): 
 
 
 
[Pro1-Gly27] thioacid 42 (3.20 mg, 0.958 umol) and [Ala28-Ala66] thioester 43 (8.14 
mg, 1.72 umol) were directly weighed into a 1.5 mL eppendorf tube with a stirbar. 
HOBt (1.46 mg, 9.58 umol, dissolved in 90uL anhydrous NMP) was added followed by 
tBuNC (0.24 mg, 2.89 umol, dissolved in 90uL anhydrous NMP). The solid fragments 
were solubilized with stirring, the vial centrifuged for 1 minute, and the headspace of 
the reaction flushed with argon for 1 minute. The reaction was then stirred at room 
temperature for 48 hours, at which point a solution containing 1% DBU/1% Piperidine 
in DMF (300 uL) was added. After 40 minutes, UPLC/MS analysis indicated complete 
Fmoc removal. The solution was then transferred via micropipette into a 15 mL 
centrifuge tube and transfer was quantitated with 100uL DMF to wash the reaction vial. 
Cold ether (10 mL) was added, and the suspension was cooled over dry ice for 5 
minutes and then centrifuged. Ether was decanted, and the crude precipitate was washed 
once more with ether, centrifuged and decanted. The residue was lyophilized from 1:1 
MeCN/H2O (+0.1% TFA). 
 
The crude lyophilized material in a 15mL conical centrifuge tube was then dissolved in 
anhydrous DMF (400 uL, degassed with argon sparge for 30 minutes) and a stirbar was 
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O
N
Fmoc
SEtDDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEA
O
H2N
AllocAllocAlloc
Alloc
Alloc
tBuNC, HOBt
NMP, RT 40 hours
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added. Argon was blown over the headspace of the reaction for 30 seconds, and the vial 
was centrifuged. PhSiH3 (12.8 uL, 103.8 umol) was added followed by PdCl2(dppf) 
(0.34 mg, 0.47 umol, freshly prepared as a stock solution in 106 uL degassed DMF). 
The reaction was stirred for 35 minutes at room temperature (as Alloc deprotection 
proceeds, the reaction mixture goes from homogeneous to cloudy), at which point 
UPLC/MS analysis indicated complete deprotection. The reaction was cooled over dry 
ice for 5 minutes, and cold ether (10 mL) was added to precipitate the crude product. 
The suspension was centrifuged and ether was decanted. The crude solid was again 
washed with ether (5 mL), centrifuged, and ether was decanted. The crude peptide was 
redissolved in 2mL 1:1 MeCN/H2O (+0.1% TFA) and purified by RP-HPLC. Pure 
fractions were combined and lyophilized to afford 46 as a white fluffy solid (1.55 mg, 
21% overall yield). 
HPLC Conditions: C8 xBridge column OBD 5 µm, 20-60% MeCN (0.05% TFA) 
against H2O (0.05% TFA) over 30 minutes. Flow rate: 16mL/min. Tr = 15 min. 
ESI-MS(+) for peptide 46: Chemical Formula = C335H544N88O93S3. MW = 7388.74 
g/mol. ESI calculated for [M+4H+]4+ m/z: 1848.18, found: 1847.93; [M+5H+]5+ m/z: 
1478.75, found: 1478.64; [M+6H+]6+ m/z: 1232.45, found: 1232.34; [M+7H+]7+ m/z: 
1056.53, found: 1056.43; [M+8H+]8+ m/z: 924.59, found: 924.43; [M+9H+]9+ m/z: 
821.97, found: 821.55; [M+10H+]10+ m/z: 739.87, found: 739.37. 
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Synthesis of HIV-1 Protease [67-115] (47): 
 
Thioacid 44 (1.78 mg, 0.547 umol) and 45 (2.17 mg, 0.82 umol) were weighed directly 
into a 1.5 mL eppendorf tube. HOBt (0.84 mg, 5.47 umol, prepared as a stock solution 
in 55uL anhydrous DMA) was added followed by tBuNC (0.13 mg, 1.64 umol, prepared 
as a stock solution in 55 uL anhydrous DMA). Argon was blown over the headspace of 
the reaction for 30 seconds, and the reaction was sealed and stirred for 48 hours at room 
temperature. At this time, piperidine (15 uL) was added, and the reaction stirred a 
further 20 minutes, at which point UPLC/MS analysis showed complete Fmoc 
deprotection. Cold ether (1 mL) was added to precipitate the crude peptides, the 
reaction vessel was centrifuged and ether was decanted. The precipitate was washed 
once more with ether (1 mL), centrifuged and decanted as before. The pellet was 
dissolved in 0.7 mL 1:1 MeCN/H2O (+0.1% TFA) and lyophilized. 
The crude lyophilized peptide was then suspended in anhydrous DMF (150 uL, 
degassed with argon sparge for 30 minutes). PhSiH3 (1.4 uL, 10.9 umol) was added 
followed by PdCl2(dppf) (0.08 mg, 0.11 umol, freshly prepared as a stock solution in 20 
uL degassed DMF). The mixture was stirred for 30 minutes, at which point cold ether (1 
mL) was added to precipitate the crude peptide. The suspension was centrifuged, and 
the ether was decanted. The residue was then redissolved in 0.7 mL 1:1 MeCN/H2O 
(+0.1% TFA) and purified by RP-HPLC. Combined pure fractions were lyophilized to 
afford 47 as a white solid (1.20 mg, 39% yield). 
HPLC Conditions: C8 X-Bridge Column 5 µm OBD, 20-65% MeCN (+0.05% TFA) 
against H2O (+0.05% TFA). Flow rate: 15mL/min. Tr = 16 min. 
GHKAIGTVLVGPTPVNIIGRNLLTQIG
O
S
FmocHN SH TLNFPISPIETVPVRRRRRR
O
S
H2N NH2
StBu
1. tBuNC (3 eq), HOBt (10 eq)
    DMA, rt
2. Piperidine added
3. PdCl2(dppf), PhSiH3, DMF
(39% yield overall)
Gly68 - Arg112
O
S
H2N NH2
StBu
Alloc
HIV[67-94] (44) HIV[95-115] (45)
HIV[67-115] (47)
StBu
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ESI-MS(+) for peptide 47: Chemical Formula = C245H424N78O61S4. MW = 5566.81 
g/mol. ESI calculated for [M+3TFA+3H+]3+ m/z: 1970.62, found: 1970.39; 
[M+2TFA+4H+]4+ m/z: 1449.71, found: 1449.40; [M+1TFA+4H+]4+ m/z: 1421.21, 
found: 1421.08; [M+4H+]4+ m/z: 1392.70, found: 1392.56; [M+5H+]5+ m/z: 1114.36, 
found: 1114.33; [M+6H+]6+ m/z: 928.80, found: 928.92; [M+7H+]7+ m/z: 796.26, found: 
796.42. 
 
Native Chemical Ligation for HIV-1 Protease I66A [1-115] (48) 
 
 
HIV[67-115] 47 (1.20 mg, 0.21 µmol) was dissolved in 100 µL NCL buffer (6M 
Gn.HCl, 200 mM Na2HPO4, 200 mM MPAA, 40 mM TCEP.HCl, pH = 7.2, degassed 
30 minutes with argon sparge and sonication) in a 1.5 mL eppendorf tube. The tube was 
vortexed and centrifuged for 1 minute, and the solution transferred via micropipette into 
a 1.5 mL eppendorf tube containing HIV[1-66] 46 (1.55 mg, 0.21 umol). Transfer was 
quantitated with 20 uL NCL buffer to wash the initial vial, with vortexing and 
centrifugation as before. Additional TCEP (4 uL 0.5M aqueous solution, 2 umol, pH = 
7.0) was added, argon was blown over the headspace of the reaction for 30 seconds, and 
the reaction was stirred at room temperature for 17 hours. The reaction was quenched 
by the addition of TCEP (6 µL, 0.5M aqueous solution, 3 µmol, pH = 7.0) and 500 µL 
1:1 MeCN/H2O (+0.1% TFA). The solution was then purified by RP-HPLC. Pure 
Gly68 - Arg115
O
S
H2N NH2Pro1 - Ala66H2N SEt
6 M Gn.HCl, 200 mM Na2HPO4
40 mM TCEP.HCl, 200 mM MPAA
pH = 7.2
(52% yield)
PQITLWQRPLVTIRIGGQLKEALLDTGH2N NHDDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEA
O
N
H
O
SH
FNLTCGIQTLLNRGIINVPTPGVLVTGIAKHGRRRRRRVPVTEIPSIPH2N
StBu
HIV[1-66] (46) HIV[67-115] (47)
HIV[1-115] (48)
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fractions were combined and lyophilized to afford 48 as a white solid (1.38 mg, 52% 
yield). 
HPLC Conditions: C8 X-Bridge column 5 µm OBD, 20-55% MeCN (+0.05% TFA) 
against H2O (+0.05% TFA) over 30 min. Flow rate: 15 mL/min. Tr = 17.4 min. 
ESI-MS(+) for peptide 48: Chemical Formula = C570H946N166O154S4. MW = 12717.09 
g/mol. ESI calculated for [M+7H+]7+ m/z: 1817.72, found: 1817.48; [M+8H+]8+ m/z: 
1590.65, found: 1590.47; [M+9H+]9+ m/z: 1414.01, found: 1413.88; [M+10H+]10+ m/z: 
1272.70, found: 1272.67; [M+11H+]11+ m/z: 1157.10, found: 1157.11; [M+12H+]12+ m/z: 
1060.76, found: 1060.75; [M+13H+]13+ m/z: 979.24, found: 979.30; [M+14H+]14+ m/z: 
909.36, found: 909.39; [M+15H+]15+ m/z: 848.80, found: 848.94. 
 
Folding of HIV-1 Protease I66A: 
 
HIV[1-115] 48 (1.38 mg, 0.11 µmol) was dissolved in denaturing buffer (1.5 mL, 6M 
Gn.HCl, 200 mM Na2HPO4, 40 mM TCEP.HCl, pH ~ 7.4). A portion of this solution 
(100 µL) was diluted with 100 µL folding buffer (100 mM NaOAc, containing 10% 
glycerol, pH = 5.5). This solution was loaded into a 2 mL Slide-A-Lyzer® MINI dialysis 
unit (3500 MW cutoff). The solution was dialyzed in a 50 mL centrifuge tube against 50 
mL folding buffer submerged in an ice water bath for 2 hours. Buffer was replaced and 
the sample was dialyzed for a further 1.5 hours. The sample was further dialyzed at this 
temperature against 50 mL diluted folding buffer (25 mM NaOAc, 10% glycerol, pH = 
5.5) for one hour, and the buffer was replaced once more and the sample was dialyzed 1 
hour longer. The resulting sample was then removed, centrifuged, and allowed to sit on 
ice for a further 2 hours. At this point, only a trace amount of unfolded starting material 
remained by UPLC/MS analysis, with the major peak corresponding to the 99-residue 
folded protein (49).  
ESI-MS(+) for peptide 49: Chemical Formula = C485H793N131O135S4. MW = 10747.70 
g/mol. ESI calculated for [M+6H+]6+ m/z: 1792.27, found: 1792.28; [M+7H+]7+ m/z: 
1536.39, found: 1536.21; [M+8H+]8+ m/z: 1344.46, found: 1344.38; [M+9H+]9+ m/z: 
1195.19, found: 1195.11; [M+10H+]10+ m/z: 1075.77, found: 1075.64; [M+11H+]11+ m/z: 
210
978.06, found: 978.08; [M+12H+]12+ m/z: 896.64, found: 896.66; [M+13H+]13+ m/z: 
827.75, found: 828.15. 
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Appendix	I	:		
Selected	NMR	Spectra	for	Chapter	2	
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Selected	UPLC/MS	Spectra	for	Chapter	4	
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